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Abstract Metastasis	  causes	  most	  late	  relapses	  and	  fatalities	  from	  cancer.	  	  Investigating	  mechanisms	  of	  metastasis	  and	  designing	  therapies	  to	  limit	  metastatic	  disease	  are	  challenging	  due	  to	  difficulties	  studying	  key	  events	  that	  occur	  before	  clinical	  detection,	  frequently	  involving	  small	  numbers	  of	  cells	  and	  intercellular	  interactions	  within	  three	  metastatic	  compartments	  (primary	  tumor,	  intravascular,	  and	  metastatic	  sites).	  	  By	  combining	  microfluidic,	  tissue	  engineering,	  and	  molecular	  imaging	  tools	  to	  screen	  therapies	  and	  analyze	  individual	  steps	  of	  metastasis,	  we	  further	  bridge	  the	  physiological	  gap	  between	  standard	  in	  vitro	  models,	  animal	  models,	  and	  human	  disease.	  Firstly,	  we	  model	  how	  multiple	  cell	  types	  form	  and	  respond	  to	  chemotactic	  gradients	  that	  drive	  cell	  migration	  in	  a	  primary	  tumor.	  	  Using	  microfluidic	  tools	  to	  robustly	  pattern	  chemokine	  CXCL12	  secreting	  cells,	  CXCR7+	  cells	  that	  scavenge	  this	  chemokine,	  and	  CXCR4+	  cells	  that	  migrate	  towards	  resulting	  gradients,	  we	  performed	  sensitivity	  analysis	  to	  identify	  functional	  combinations	  that	  are	  refractory	  to	  therapeutic	  inhibition.	  	  We	  found	  one	  high-­‐matrix	  binding	  isoform	  (CXCL12-­‐γ)	  to	  robustly	  promote	  chemotaxis	  even	  at	  low	  chemokine	  levels	  in	  the	  absence	  of	  scavenging	  cells	  and	  in	  the	  presence	  of	  a	  clinically	  approved	  inhibitor.	  	  Linking	  these	  findings	  to	  clinical	  physiology,	  we	  found	  this	  high-­‐matrix-­‐binding	  isoform	  to	  only	  be	  expressed	  in	  late	  stage	  breast	  cancer.	  Secondly,	  we	  combine	  tissue	  engineering	  and	  molecular	  imaging	  tools	  to	  study	  the	  response	  of	  cancer	  cells	  in	  3D	  tissue	  spheroids.	  	  We	  designed	  a	  platform	  to	  facilitate	  
xv	  	  
handling	  and	  high	  resolution	  imaging	  of	  384	  well	  spheroids.	  	  Using	  this	  platform	  we	  developed	  a	  bone	  marrow	  spheroid	  model	  to	  recreate	  breast	  cancer	  quiescence	  and	  resistance	  to	  therapies.	  	  Using	  dual-­‐colored	  bioluminescence	  imaging	  we	  simultaneously	  measured	  response	  of	  quiescent	  cancer	  and	  bone	  stromal	  cells	  to	  standard	  cytotoxic	  and	  targeted	  therapies.	  	  Using	  this	  strategy	  we	  identified	  therapeutic	  combinations	  that	  selectively	  eliminated	  quiescent	  cancer	  cells	  in	  vitro	  and	  entirely	  eliminated	  bone	  marrow	  metastases	  in	  mice.	  	  We	  also	  used	  this	  system	  to	  visualize	  metabolic	  gradients	  in	  bone	  marrow	  spheroids	  and	  measure	  cancer	  and	  stromal	  response	  to	  metabolic	  perturbations.	  Combining	  microfluidic,	  tissue	  engineering,	  and	  molecular	  imaging	  tools	  as	  described	  herein	  can	  improve	  development	  of	  better	  models	  that	  recreate	  in	  vivo	  physiology	  and	  allow	  development	  of	  patient-­‐specific	  therapies	  that	  prevent	  or	  eliminate	  metastatic	  disease.	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1 Chapter One: Systems to Study Cancer Metastasis 
1.1 Introduction	  and	  Challenges	  to	  Studying	  Metastasis	  Cancer	  is	  the	  second	  leading	  killer	  in	  developed	  countries,	  accounting	  for	  nearly	  1	  in	  4	  deaths	  in	  the	  US	  (1).	  	  The	  yearly	  incidence	  rate	  of	  cancer	  has	  declined	  for	  men	  (0.6%)	  but	  was	  stable	  for	  women.	  	  Mortality	  rates	  have	  decreased	  more	  rapidly	  than	  yearly	  incidence	  (1.8%	  and	  1.6%	  for	  men	  and	  women,	  respectively)	  in	  part	  due	  to	  earlier	  detection	  and	  improved	  therapies.	  Mismatched	  decrease	  in	  incidence	  and	  mortality	  shows	  that	  more	  people	  are	  living	  as	  cancer	  survivors,	  which	  puts	  the	  onus	  on	  limiting	  cancer	  relapse	  and	  limiting	  treatment	  toxicity.	  	  Although	  these	  factors	  are	  critical	  to	  most	  cancers,	  we	  focus	  on	  breast	  cancer.	  	  To	  reduce	  recurrence	  of	  cancer	  and	  limit	  treatment	  toxicity,	  we	  highlight	  three	  challenges,	  including	  1)	  personalized	  therapy,	  2)	  elimination/prevention	  of	  metastasis	  and	  relapse,	  and	  3)	  development	  of	  therapies	  that	  eliminate	  cancer	  but	  spare	  normal	  cells.	  	  In	  this	  dissertation	  we	  aim	  to	  develop	  engineering	  systems	  that	  begin	  to	  address	  these	  challenges	  via	  drug	  development	  and	  mechanistic	  understanding.	  Firstly,	  treatment	  must	  move	  towards	  personalized	  therapies	  that	  consider	  factors	  including	  genetic	  diversity	  and	  unique	  microenvironments	  that	  house	  each	  cancer	  cell.	  	  Towards	  personalized	  therapy,	  successful	  effort	  has	  been	  dedicated	  to	  defining	  phenotypic	  sub-­‐types,	  their	  associated	  risk,	  and	  optimized	  treatment	  regimens	  (2,	  3).	  	  However,	  recent	  studies	  show	  that	  even	  within	  a	  single	  tumor,	  plurality	  and	  plasticity	  of	  these	  classifications	  may	  complicate	  clinical	  usefulness	  of	  these	  markers	  (3,	  4).	  	  Heterogeneous	  tumor	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microenvironments	  complicate	  understanding	  of	  these	  phenotypes	  but	  also	  offer	  novel	  opportunities	  for	  therapy	  (5).	  	  	  Engineering	  models	  of	  tumor	  and	  metastatic	  microenvironments	  must	  capture	  such	  biological	  heterogeneity	  to	  better	  screen	  for	  drugs	  targeting	  patient-­‐specific	  disease.	  Secondly,	  we	  must	  understand	  how	  to	  entirely	  prevent	  and/or	  eliminate	  metastatic	  disease.	  	  In	  breast	  cancer,	  distinct	  relapse	  peaks	  occur	  at	  roughly	  1,	  5,	  and	  10	  years	  after	  diagnosis,	  and	  adjuvant	  therapy	  substantially	  diminishes	  the	  first	  of	  these	  peaks	  (Fig.	  1.1)	  (6,	  7).	  	  These	  findings	  suggest	  metastatic	  quiescent/dormant	  cells	  are	  refractory	  to	  standard	  cytotoxic	  therapies,	  persist	  for	  many	  years,	  and	  return	  to	  growth	  after	  years.	  	  Mathematical	  modeling	  of	  a	  subset	  of	  these	  data	  suggest	  prior	  to	  clinically	  detectable	  relapse	  at	  primary	  sites,	  tumor	  cells	  grow	  rapidly	  for	  ~30	  weeks,	  despite	  average	  regression	  free	  survival	  of	  ~65	  weeks	  (range	  19-­‐316	  weeks)	  (8).	  	  This	  model	  indicates	  a	  period	  of	  tumor	  dormancy	  followed	  by	  return	  to	  rapid	  growth.	  	  Difficulty	  monitoring	  single	  or	  clusters	  of	  metastatic	  cells,	  their	  quiescent	  microenvironment,	  and	  triggers	  of	  their	  regrowth	  necessitates	  experimental	  models	  that	  capture	  these	  phenotypes.	  	  	  Thirdly,	  we	  must	  therapeutically	  approach	  the	  first	  two	  challenges	  in	  a	  way	  that	  targets	  cancer	  cells	  but	  spares	  normal	  organ	  function,	  limits	  off-­‐target	  toxicities,	  and	  minimizes	  long-­‐term	  treatment	  effects.	  	  Treatment	  of	  cancers	  is	  often	  terminated	  due	  to	  cardiovascular,	  renal,	  and	  other	  systemic	  cytotoxicities.	  	  In	  part	  these	  challenges	  are	  being	  met	  by	  development	  of	  less	  cytotoxic	  therapies	  that	  are	  specific	  to	  cancer	  cells	  and	  spare	  normal	  tissues.	  	  The	  objective	  of	  selectively	  targeting	  cancer	  cells	  necessitates	  experimental	  models	  that	  include	  “normal”	  cells	  as	  a	  therapeutic	  reference	  to	  benchmark	  “patient”	  health.	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From	  a	  practical	  standpoint	  meeting	  these	  challenges	  require	  more	  comprehensive	  understanding	  of	  the	  processes	  of	  cancer	  metastasis	  from	  primary	  disease	  to	  metastatic	  outgrowth	  and	  how	  to	  therapeutically	  limit	  them.	  	  Progress	  in	  such	  understanding	  has	  been	  hindered	  due	  to	  a	  paucity	  of	  experimental	  systems	  that	  recreate	  the	  physiology	  of	  cancer	  metastasis,	  allow	  monitoring	  of	  rare	  metastatic	  events,	  and/or	  allow	  screening	  of	  therapies	  against	  metastatic	  steps.	  	  The	  aim	  of	  this	  dissertation	  is	  to	  engineer	  systems	  that	  model	  steps	  of	  metastatic	  disease	  that	  are	  clinically	  and	  experimentally	  difficult	  to	  observe.	  	  These	  systems	  must	  better	  replicate	  in	  vivo	  physiology/complexity,	  allow	  analysis	  of	  very	  rare	  cellular	  events,	  and	  facilitate	  screening	  for	  drugs	  that	  selectively	  eliminate	  cancer	  cells	  but	  spare	  normal	  cells.	  	  In	  order	  to	  meet	  these	  challenges,	  we	  utilize	  tissue	  engineering	  tools	  to	  bridge	  the	  dimensionality	  gap	  between	  in	  vitro	  assays	  and	  in	  vivo	  physiology,	  as	  summarized	  in	  Fig.	  1.2.	  	  Increasing	  dimensionality	  refers	  to	  the	  following	  characteristics:	  physical	  (2D	  vs	  3D	  environments),	  temporal	  (endpoint,	  time	  point,	  and	  continuous	  observation;	  short-­‐	  and	  long-­‐scale),	  and	  biological	  complexity	  (multiple	  cell	  types,	  secreted	  factors,	  receptor	  status,	  etc).	  	  We	  employ	  diverse	  tools	  including:	  genetic	  engineering,	  tissue	  engineering,	  multi-­‐modal	  molecular	  imaging,	  microfluidics,	  and	  manufacturing	  of	  tissue	  culture	  tools,	  amongst	  others.	  These	  tools	  span	  multi-­‐scale	  interactions,	  from	  intracellular	  dynamics,	  to	  single	  cells,	  small	  metastases,	  larger	  tumors,	  and	  animal	  models.	  	  Using	  these	  systems	  we	  seek	  to	  understand	  how	  biological	  systems	  operate	  as	  a	  whole	  to	  create	  metastatic	  phenotypes	  and	  how	  we	  can	  intervene	  within	  these	  processes.	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1.2 Compartments	  of	  the	  Metastatic	  Cascade	  	  To	  inform	  design	  of	  systems	  to	  study	  cancer	  metastasis,	  we	  have	  to	  first	  understand	  the	  metastatic	  cascade	  and	  challenges	  associated	  with	  each	  step.	  	  Generally	  speaking,	  there	  are	  three	  major	  compartments	  in	  which	  cancer	  cells	  exist:	  the	  primary	  site,	  intravascular	  compartment,	  and	  metastatic	  sites	  at	  multiple	  organs	  (Fig.	  1.3)	  (9,	  10).	  	  Drivers	  of	  the	  metastatic	  cascade	  have	  been	  verbalized	  as	  the	  “seed	  and	  soil”	  hypothesis,	  which	  reflects	  the	  characteristics	  of	  robust	  cancer	  cells	  exiting	  a	  primary	  tumor,	  surviving	  the	  “elements”	  throughout	  the	  blood	  stream,	  and	  cultivating	  fertile	  organ	  environments	  for	  persistence/growth	  (11).	  	  This	  hypothesis	  suggests	  organ-­‐specific	  metastasis	  to	  be	  an	  active	  process,	  rather	  than	  due	  to	  circulation-­‐based	  probability.	  This	  simplification	  considers	  unidirectional	  flow	  of	  cancer	  cells	  (primary	  to	  secondary	  sites),	  but	  the	  order	  of	  metastatic	  steps	  and	  the	  directionality	  is	  widely	  debated.	  	  One	  recent	  study	  provided	  evidence	  that	  metastasis	  is	  a	  process	  in	  flux,	  where	  cancer	  cells	  flow	  to-­‐and-­‐from	  primary	  and	  secondary	  sites	  starting	  at	  early	  stages	  of	  carcinogenesis	  (12).	  	  This	  finding	  suggests	  the	  need	  for	  experimental	  models	  that	  reproduce	  primary,	  intravascular,	  and	  secondary	  steps	  in	  metastasis	  to	  analyze	  early,	  rare	  cell	  events	  that	  govern	  metastasis.	  	  The	  engineering	  challenge	  is	  to	  develop	  tissue-­‐engineering	  models	  to	  analyze	  and	  target	  few	  cells	  operating	  within	  multi-­‐cellular	  microenvironments	  of	  these	  three	  metastatic	  compartments.	  	  Here	  we	  break	  down	  a	  simplified	  view	  of	  the	  steps	  within	  each	  compartment.	  	  	  
1.2.1 Primary	  Tumor	  Microenvironment	  Despite	  seemingly	  localized	  disease,	  upwards	  of	  60%	  of	  patients	  have	  disseminated	  tumor	  cells	  in	  other	  organs,	  suggesting	  cancer	  cells	  exit	  the	  primary	  tumor	  early	  in	  tumor	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formation	  (13).	  	  The	  primary	  tumor	  microenvironment	  involves	  multiple	  cytokine	  and	  nutrient	  gradients	  that	  evolve	  from	  interactions	  between	  cancer	  cells	  and	  associated	  support	  cells.	  	  As	  a	  tumor	  outgrows	  it’s	  infrastructure,	  gradients	  of	  nutrients	  and	  waste	  form	  (14,	  15)	  (Fig.	  1.3A).	  	  Nutrient	  limitations	  (oxygen,	  carbon,	  nitrogen	  sources)	  and	  increased	  waste	  (lactate,	  etc)	  cause	  many	  changes	  in	  the	  tumor	  microenvironment,	  including:	  modifying	  the	  expression	  patterns	  at	  the	  core	  of	  these	  tumors,	  increased	  reactive	  oxygen	  species	  and	  sensing	  thereof,	  up-­‐regulation/stabilization	  of	  hypoxia	  inducible	  factor	  (HIF1α)	  (16),	  increased	  secretion	  of	  cytokines	  (CXCL12,	  VEGF,	  etc)	  (17),	  and	  recruitment	  of	  immune	  and	  vascular	  endothelial	  cells,	  via	  cytokines/chemokines	  (18-­‐20).	  Together	  these	  compensatory	  effects	  and	  resultant	  gradients	  aid	  the	  growth	  and	  exit	  of	  cancer	  cells	  from	  the	  primary	  tumor.	  Although	  many	  studies	  focus	  on	  the	  primary	  tumor	  microenvironment,	  model	  systems	  are	  lacking	  to	  consider	  how	  multi-­‐cell	  type	  interactions	  evolve	  gradient	  formation	  and	  eventual	  tumor	  dissemination.	  	  Instead,	  most	  studies	  of	  nutrient	  and	  cytokine	  gradients	  apply	  non-­‐physiological,	  fixed,	  exogenous	  gradients.	  However,	  systems	  are	  needed	  to	  study	  what	  multi-­‐cellular	  phenotypes	  cause	  gradient	  formation	  and	  sensing.	  Here	  we	  use	  microfluidics	  and	  spheroid	  systems	  to	  recreate	  aspects	  of	  gradient	  formation	  in	  a	  primary	  tumor	  and	  use	  these	  findings	  to	  study	  system-­‐level	  impact	  of	  therapies.	  	  Firstly	  in	  Chapter	  2,	  we	  utilize	  a	  microfluidic	  device	  to	  initialize	  and	  observe	  interactions	  between	  multiple	  cells	  types	  that	  participate	  in	  gradient	  formation	  of	  the	  chemokine	  (chemotactic	  sub-­‐class	  of	  cytokine)	  CXCL12	  (21).	  	  Utilizing	  this	  device	  we	  perform	  sensitivity	  analysis	  to	  understand	  interdependence	  of	  chemokine	  production,	  scavenging,	  sensing,	  and	  inhibition.	  	  In	  Chapter	  3	  we	  leverage	  a	  hanging	  drop	  3D	  spheroid	  culture	  system	  to	  develop	  an	  advanced	  handling/imaging	  system	  for	  spheroids	  (22).	  	  Using	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this	  spheroid	  analysis	  system	  in	  Chapters	  4	  and	  5,	  we	  extend	  our	  ability	  to	  perform	  relatively	  high	  throughput	  two-­‐photon	  microscopy	  imaging	  of	  cancer	  cells	  in	  3D	  bone	  marrow	  spheroids.	  	  In	  the	  latter	  chapter,	  we	  use	  optical	  metabolic	  imaging	  to	  monitor	  metabolic	  gradients	  in	  3D	  bone	  marrow	  spheroids.	  	  	  	  
1.2.2 Intravascular	  Compartment	  As	  with	  detecting	  onset	  of	  primary	  disease	  due	  to	  small	  tumor	  size,	  it	  is	  more	  difficult	  to	  monitor	  even	  fewer	  cells	  that	  follow	  gradients	  in	  the	  primary	  tumor	  and	  intravasate	  into	  the	  vascular	  compartment	  (Fig.	  1.3A-­‐C).	  	  For	  example,	  reports	  of	  number	  of	  circulating	  tumor	  cells	  in	  blood	  show	  enormous	  variability	  (0	  to	  23,618,	  with	  average	  and	  SD	  =	  84	  ±	  885),	  where	  such	  rarity	  and	  diversity	  complicates	  our	  ability	  to	  monitor	  the	  intravascular	  compartment	  even	  in	  animals	  (23).	  	  More	  so,	  cancer	  cells	  account	  for	  less	  than	  1	  cell	  per	  105-­‐106	  mononuclear	  cells,	  and	  only	  a	  fraction	  are	  viable	  and	  capable	  of	  metastatic	  outgrowth	  (24).	  	  Recent	  work	  has	  improved	  our	  ability	  to	  study	  these	  intravascular	  steps	  via	  capture	  of	  circulating	  tumor	  cells	  (23,	  25).	  	  However,	  the	  link	  between	  disease	  progression,	  response	  to	  therapy,	  and	  the	  existence	  of	  circulating	  tumor	  cells	  is	  improving,	  but	  still	  unclear	  (26,	  27).	  	  In	  part,	  difficulties	  with	  capturing	  circulating	  tumor	  cells	  may	  be	  attributed	  to	  plasticity	  and	  heterogeneity	  of	  cell-­‐surface	  expression	  for	  antibody-­‐	  or	  size/stiffness-­‐based	  capture.	  Additionally,	  it	  is	  difficult	  to	  decouple	  circulating	  tumor	  cells	  flowing	  from	  the	  primary	  tumor	  cells,	  secondary	  sites,	  and	  their	  longevity	  in	  the	  bloodstream.	  	  Therefore,	  recreating	  the	  physiology	  of	  intravascular	  interactions	  of	  cancer	  cells	  may	  provide	  insight	  towards	  capturing,	  eliminating,	  and/or	  decreasing	  metastatic	  capacity	  of	  circulating	  tumor	  cells.	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In	  order	  to	  properly	  study	  the	  intravascular	  steps	  of	  cancer	  metastasis,	  several	  biochemical	  factors,	  biomechanical	  flow	  factors,	  and	  multi-­‐cellular	  interactions	  must	  be	  considered	  (28,	  29).	  	  Firstly,	  cancer	  cells	  may	  exit	  the	  primary	  tumor	  in	  isolation,	  in	  cancer	  cell	  clusters,	  and/or	  with	  associated	  fibroblasts	  or	  platelets	  (30-­‐32).	  	  Once	  in	  the	  circulation,	  tumor	  cells	  must	  associate	  with	  platelets	  and	  other	  blood	  factors	  to	  improve	  viability,	  deform	  through	  small	  blood	  vessels,	  sense	  supportive	  organ	  environments,	  and	  maintain	  adhesion-­‐independent	  viability	  (33-­‐35).	  	  Finally,	  cancer	  cells	  must	  sense	  supportive	  organ	  environments,	  contact	  vascular	  walls,	  decelerate,	  firmly	  adhere,	  and	  extravasate.	  	  These	  processes	  occur	  under	  shear	  forces	  and	  biochemical	  stimuli	  within	  the	  blood	  stream,	  which	  complicates	  development	  of	  physiolocigal	  models.	  	  Therefore,	  physiological	  models	  of	  the	  intravascular	  compartment	  must	  include	  these	  multi-­‐cellular	  interactions,	  biomechanical	  factors,	  biochemical	  factors,	  and	  collectively	  recreate	  diverse	  cancer	  functions.	  Although	  not	  the	  focus	  of	  this	  dissertation,	  we	  have	  previously	  have	  advanced	  tissue-­‐engineering	  tools	  to	  study	  the	  intravascular	  compartment	  of	  cancer	  metastasis	  (36).	  	  Using	  this	  microfluidic	  system	  we	  interfaced	  shear	  flow	  of	  breast	  cancer	  cells	  with	  organ-­‐specific	  endothelial	  compartments	  and	  measured	  intravascular	  adhesion	  of	  cancer	  cells	  (36).	  	  We	  found	  basolateral	  activation	  of	  endothelial	  cells	  was	  more	  important	  than	  receptor-­‐ligand	  interactions	  on	  the	  circulating	  tumor	  cells	  for	  promoting	  firm	  adhesion.	  	  Further	  studies	  have	  extended	  this	  model	  to	  consider	  perfusable	  3D	  vascular	  models	  and	  the	  extravasation	  of	  cancer	  cells	  into	  various	  organ	  environments	  (37-­‐40).	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1.2.3 Metastatic	  Sites	  Up	  to	  60%	  patients	  with	  locally	  contained	  breast	  tumors	  harbor	  disseminated	  tumor	  cells	  in	  their	  bone	  marrow	  (13)	  and	  these	  cells	  may	  contribute	  to	  late	  relapse	  that	  is	  largely	  unaffected	  by	  adjuvant	  chemotherapy	  (6,	  7).	  These	  results	  suggest	  that	  early	  in	  tumor	  formation,	  cancer	  cells	  successfully	  follow	  gradients	  out	  of	  the	  primary	  tumor,	  survive	  the	  circulatory	  compartment,	  and	  colonize	  secondary	  sites	  early	  in	  the	  tumor	  formation	  process.	  	  Bias	  towards	  particular	  organs	  (lung,	  liver,	  brain,	  and	  bone	  marrow)	  suggests	  that	  within	  a	  particular	  organ	  environment	  more	  cancer	  cells	  arrive,	  have	  supported	  growth	  once	  there,	  and/or	  are	  protected	  from	  therapy.	  	  Here	  we	  focus	  on	  the	  microenvironment	  that	  supports	  cancer	  cell	  growth,	  protection	  from	  cytotoxic	  therapies,	  and/or	  quiescence	  in	  metastatic	  sites.	  	  	  The	  organ	  microenvironment	  and	  the	  molecular	  subtype	  of	  cancer	  dictate	  the	  aggressiveness	  of	  malignant	  cells	  in	  metastatic	  sites,	  which	  vary	  from	  indefinitely	  quiescent	  to	  immediately	  proliferating.	  	  There	  are	  two	  definitions	  for	  quiescence,	  either	  cellular	  quiescence	  or	  balanced	  proliferation	  and	  death	  of	  a	  micro-­‐metastases.	  	  Single	  cells	  enter	  cellular	  quiescence	  and	  stop	  dividing	  by	  locking	  in	  G1	  and/or	  exiting	  into	  G0	  states	  of	  the	  cell	  cycle.	  	  Unlike	  rapidly	  growing	  metastases	  that	  are	  more	  susceptible	  to	  existing	  cytotoxic	  therapies,	  quiescent	  metastases	  are	  often	  protected	  from	  standard	  chemotherapeutic	  drugs.	  	  In	  part	  the	  lack	  of	  therapies	  that	  successfully	  target	  quiescent	  cancer	  cells	  is	  due	  to	  our	  model	  bias	  towards	  studying	  rapidly	  dividing	  cancer	  cells	  in	  a	  dish.	  	  Few	  systems	  reproduce	  the	  quiescent	  phenotypes	  of	  cancer	  cells	  in	  metastatic	  bone	  marrow	  sites	  (37,	  41).	  	  Capturing	  the	  complex	  interactions	  that	  govern	  metastatic	  growth	  and/or	  quiescence	  is	  critical	  to	  developing	  therapies	  to	  limit	  cancer	  fatalities	  and	  relapse.	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There	  is	  no	  one-­‐size-­‐fits-­‐all	  model	  for	  metastatic	  sites	  in	  cancers,	  as	  organ-­‐to-­‐organ	  and	  within-­‐organ	  variability	  create	  enumerable	  combinations	  of	  cells,	  structures,	  etc.	  	  As	  a	  starting	  point	  we	  highlight	  the	  metastatic	  diversity	  of	  bone	  marrow,	  particularly	  due	  to	  the	  commonality	  of	  this	  site	  for	  metastasis	  of	  multiple	  cancers	  (breast,	  prostate,	  pancreas,	  non-­‐small	  cell	  lung,	  and	  melanoma)	  (13,	  42),	  and	  heterogeneity	  of	  this	  organ	  in	  support	  of	  cancer	  cell	  growth	  versus	  quiescence.	  Generally	  there	  are	  two	  critical	  niches	  within	  the	  bone	  marrow	  that	  differently	  support	  expansion	  or	  maintenance	  of	  hematopoietic	  stem	  and	  cancer	  cells:	  the	  endosteal	  niche	  and	  the	  perivascular	  niche.	  	  These	  two	  niches	  contain	  many	  mesenchymal	  stromal,	  vascular,	  and	  immune	  cells	  (43).	  	  Several	  recent	  models	  begin	  to	  capture	  the	  3D	  structure	  and/or	  cellular	  heterogeneity	  of	  the	  bone	  marrow	  (44-­‐46).	  	  However,	  these	  studies	  are	  lacking	  in	  throughput	  and/or	  are	  limited	  in	  the	  ability	  to	  monitor	  viability	  of	  stromal	  cells,	  cancer	  cells,	  and	  their	  underlying	  cellular	  status	  (45,	  46).	  Here	  we	  leverage	  long-­‐term	  bone	  marrow	  spheroid	  cultures	  to	  recreate	  quiescent	  and	  growing	  populations	  of	  metastatic	  cancer	  cells	  in	  vitro.	  	  In	  Chapter	  4	  we	  develop	  these	  growing	  and	  quiescence	  co-­‐culture	  models,	  validate	  a	  dual-­‐colored	  luciferase	  imaging	  strategy	  to	  capture	  relative	  viability	  of	  cancer	  and	  stromal	  cells	  and	  utilize	  fluorescence	  imaging	  to	  observe	  cell	  cycle	  status	  of	  cancer	  cells.	  	  Using	  this	  strategy	  we	  identified	  a	  drug	  combination	  that	  selectively	  eliminated	  quiescent	  cancer	  cells	  in	  vitro	  and	  completely	  eliminated	  bone	  marrow	  metastases	  in	  mice.	  	  In	  Chapter	  5,	  we	  extend	  this	  bone	  marrow	  model	  in	  order	  to	  study	  metabolic	  interactions	  that	  support	  a	  quiescent	  cancer	  phenotype.	  	  We	  use	  multiple	  strategies	  to	  image	  and	  perturb	  the	  metabolic	  environment	  produced	  by	  different	  bone	  marrow	  stroma	  types,	  including	  frequency-­‐domain	  fluorescence	  lifetime	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imaging	  of	  endogenous	  metabolic	  fluorophores,	  molecular	  intervention,	  extracellular	  flux	  assays,	  and	  bioluminescence	  imaging.	  	  	  	  
1.3 Engineering	  Extracellular,	  Biomechanical,	  and	  Metabolic	  Sensing	  Within	  each	  of	  the	  three	  metastatic	  compartments,	  cancer	  cells	  rely	  on	  integration	  of	  extracellular	  signals,	  biomechanical	  signaling,	  and	  metabolic	  sensing	  that	  are	  often	  poorly	  replicated	  in	  vitro.	  	  Standard	  tissue	  culture	  often	  employ	  2D	  mono-­‐cultures,	  a	  surplus	  of	  growth	  factors	  (serum),	  non-­‐physiological	  rigid	  plastic	  substrates	  (47),	  and	  a	  pathologic	  surplus	  of	  metabolic	  intermediates	  (glucose,	  glutamine,	  etc).	  	  However,	  in	  vivo	  situations	  are	  uniquely	  3D,	  involving	  numerous	  interacting	  cell	  types,	  non-­‐rigid	  biological	  substrates,	  and	  dynamic	  levels/gradients	  of	  cytokines	  and	  metabolic	  intermediates.	  	  In	  order	  to	  better	  capture	  the	  integration	  of	  these	  three	  factors	  and	  improve	  dimensionality	  (physical	  and	  biological,	  Fig.	  1.2),	  we	  use	  a	  combination	  of	  microfluidic	  and	  3D	  tissue	  engineering	  technologies	  to	  model	  metastatic	  steps.	  	  Successfully	  engineered	  model	  systems	  will	  integrate	  extracellular	  signals,	  biomechanical	  signaling,	  and	  metabolic	  sensing	  to	  capture	  rare	  cellular	  events	  and	  predict	  in	  vivo	  responses,	  including	  metastatic	  tendencies,	  expression	  profiles,	  and	  drug	  sensitivities.	  	  Here	  we	  examine	  advantageous	  and	  opportunities	  using	  both	  microfluidic	  and	  3D	  tissue	  engineering	  technologies	  to	  model	  metastasis.	  
1.3.1 Microfluidic	  Technologies	  Microfluidic	  technologies	  facilitate	  precise	  fluidic	  delivery	  of	  reagents	  (growth	  factors,	  metabolites,	  cells)	  in	  order	  to	  finely	  tune	  control	  and	  surveillance	  of	  multi-­‐scale	  cellular	  events.	  	  In	  particular,	  microfluidic	  devices	  produce	  highly	  defined	  and	  predictable	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extracellular	  gradients	  to	  study	  chemotaxis	  of	  cells	  towards	  varying	  shapes,	  magnitudes,	  and	  combinations	  of	  gradients	  (48,	  49).	  	  Although	  highly	  defined,	  microfluidic	  gradients	  often	  do	  not	  recreate	  the	  cellular	  and	  physical	  heterogeneity	  of	  in	  vivo	  physiology.	  	  In	  vivo	  gradients	  occurs	  in	  endocrine,	  paracrine,	  and	  autocrine	  fashions,	  which	  reflect	  systemic-­‐,	  local-­‐,	  and	  auto-­‐signaling	  environments	  (50).	  	  Additionally,	  chemokines	  often	  are	  scavenged	  by	  receptors	  and	  sequestered	  on	  extracellular	  surfaces	  by	  proteoglycans,	  both	  of	  which	  change	  the	  kinetics,	  dynamics,	  and	  magnitudes	  of	  gradients	  (51-­‐53).	  	  These	  complex	  interactions	  collectively	  regulate	  gradient	  formation,	  movement	  of	  cells	  in	  vivo,	  and	  must	  be	  considered	  in	  developing	  experimental	  systems.	  Improved	  microfluidic	  manufacturing	  techniques	  are	  beginning	  to	  better	  recreate	  these	  complexities	  by	  including	  multiple	  cell	  types,	  structural	  arrangements	  of	  tissues,	  and	  interfaces	  between	  molecules,	  cells,	  and	  different	  organ	  environments.	  	  For	  example,	  incorporating	  flexible,	  porous	  membranes	  within	  a	  PDMS	  device	  recreates	  the	  aveolar	  interface	  and	  mechanics	  of	  lungs	  (54).	  	  Additionally,	  continuous	  flow	  between	  multiple	  separate	  organ	  compartments	  provided	  a	  pharmacokinetic-­‐pharmacodynamic	  model	  for	  drug	  development	  (55).	  	  In	  this	  dissertation	  we	  build	  upon	  a	  previously	  developed	  microfluidic	  device	  (56)	  to	  understand	  how	  three	  populations	  of	  cells	  interact	  with	  each	  other	  and	  their	  environment	  to	  form	  and	  respond	  to	  a	  gradient	  (21).	  
1.3.2 3D	  Tissue	  Engineering	  Technologies	  Improvements	  to	  3D	  culture	  techniques	  facilitate	  modeling	  the	  biomechanics	  and	  mass-­‐transfer	  limitations	  of	  in	  vivo	  tissues.	  	  Integration	  of	  biomechanical	  and	  biochemical	  sensing	  is	  improved	  in	  3D	  culture	  systems	  (57).	  	  For	  example,	  gradients	  of	  glucose,	  lactate,	  and	  hypoxic	  factors	  have	  been	  recreated	  using	  3D	  spheroid	  systems	  (15).	  	  Additionally,	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using	  3D	  systems	  better	  recreates	  in	  vivo-­‐like	  growth	  rates	  (58)	  and	  drug	  sensitivity	  of	  tumor	  cells	  	  (59).	  	  Four	  main	  strategies	  are	  used	  for	  3D	  cell	  culture	  techniques,	  including	  matrix-­‐independent	  cultures	  (spheroids)	  (60),	  hydrogel-­‐based	  cultures	  (61-­‐63),	  rigid	  scaffold-­‐based	  structures	  (64),	  and	  ex	  vivo	  organoid	  cultures	  (65).	  	  While	  improved	  synthetic	  chemistry	  and	  manufacturing	  techniques	  have	  aided	  development	  of	  hydrogel	  and	  scaffold-­‐based	  cultures,	  their	  wide	  adoption	  for	  high	  throughput	  analysis	  has	  been	  hindered	  by	  cost,	  complexity,	  and	  assay	  robustness.	  	  Spheroids	  have	  gained	  popularity	  with	  recent	  studies	  describing	  simple,	  high	  throughput	  formation	  of	  uniform	  spheroids	  using	  hanging	  drop	  and	  low	  attachment	  tissue	  culture	  plates	  (66,	  67).	  	  As	  these	  culture	  systems	  improve	  to	  increase	  throughput,	  diversity	  of	  cell	  types,	  and	  amenability	  to	  standard	  assays,	  their	  popularity	  will	  grow	  for	  studying	  tumor	  and	  metastasis	  microenvironments.	  	  	  In	  Chapter	  3	  we	  build	  upon	  development	  of	  the	  384	  hanging	  drop	  spheroid	  array	  (66,	  67)	  to	  enable	  improved	  analysis	  and	  imaging	  of	  spheroids	  (22).	  	  Additionally,	  in	  Chapters	  4	  and	  5	  we	  capture	  biochemical,	  biomechanical,	  and	  metabolic	  effects	  within	  multiple	  co-­‐culture	  models	  of	  quiescent	  cancer	  and	  bone	  marrow	  stromal	  cells.	  	  We	  found	  different	  microenvironments	  to	  promote	  cancer	  cell	  quiescence	  or	  growth,	  differences	  in	  drug	  susceptibility,	  and	  to	  reflect	  in	  vivo	  responses	  of	  bone	  metastases	  to	  combination	  therapies.	  	  
1.3.3 Combined	  Microfluidic	  and	  3D	  Approaches	  Combinations	  of	  microfluidic	  technologies	  and	  3D	  tissue	  technologies	  allow	  integrated	  control	  and	  surveillance	  of	  extracellular	  signaling,	  biomechanical	  stimuli,	  and	  metabolic	  pathways.	  	  For	  instance,	  within	  microfluidic	  cell-­‐laden	  hydrogels,	  VEGF	  gradients	  and	  interstitial	  flow	  have	  been	  shown	  to	  govern	  formation	  of	  perfusable	  vessels	  in	  vitro	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(68,	  69).	  	  Building	  on	  these	  studies,	  similar	  systems	  have	  incorporated	  different	  underlying	  organ	  systems	  and	  observed	  cancer	  cell	  adhesion,	  extravasation,	  and	  growth	  (37,	  38).	  	  The	  progression	  towards	  “human-­‐on-­‐a-­‐chip”	  will	  continue	  with	  improvements	  to	  microfluidic	  and	  3D	  technologies,	  including	  physiological	  arrangement	  of	  cells,	  inclusion	  of	  additional	  organ	  environments,	  and	  adaptation	  to	  primary	  cells.	  	  The	  goal	  of	  such	  combined	  approaches	  is	  to	  replicate	  normal	  and	  pathologic	  interactions	  between	  multiple	  organ	  compartments	  and	  to	  screen	  for	  drugs	  that	  spare	  the	  former	  but	  eliminate	  the	  latter.	  	  
1.4 Molecular	  Imaging	  Tools	  to	  Study	  Multi-­‐scale	  Cell	  Interactions	  To	  observe	  interactions	  between	  multiple	  receptor-­‐ligand	  pairs	  and	  cell	  combinations	  across	  multiple	  time-­‐scales	  and	  physical	  dimensions,	  we	  employ	  multi-­‐modal	  imaging	  techniques.	  	  Each	  imaging	  modality	  has	  advantages	  and	  disadvantages	  in	  terms	  of	  ease	  of	  use,	  observation	  timing	  and	  scale,	  and	  interpretation.	  	  These	  techniques	  involve	  two-­‐photon	  microscopy	  of	  fluorescent	  proteins	  and	  endogenous	  fluorescence	  (70,	  71)	  and	  bioluminescence	  flux	  (72),	  which	  rely	  on	  radiant	  and	  chemical	  excitation,	  respectively.	  	  Together	  bioluminescence	  and	  fluorescence	  imaging	  provide	  complementary	  information	  about	  the	  location,	  abundance,	  and	  status	  of	  cells	  in	  vitro	  and	  in	  vivo.	  
1.4.1 Fluorescence	  Imaging	  We	  use	  two-­‐photon	  microscopy	  for	  optical	  metabolic	  imaging	  and	  imaging	  engineered	  fluorophores.	  	  	  The	  balance	  between	  energy-­‐efficient	  oxidative	  metabolism	  and	  less	  efficient	  (often	  hypoxic)	  glycolytic	  metabolism	  is	  important	  to	  growth	  and	  quiescence	  of	  both	  cancer	  cells	  and	  hematopoietic	  stem	  cells.	  	  Label-­‐free	  optical	  metabolic	  imaging	  utilizes	  both	  intensity-­‐based	  and	  frequency-­‐domain	  lifetime	  imaging	  of	  spectrally	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separated	  fluorescent	  NADH	  and	  FAD	  metabolites	  (73,	  74).	  	  Intensity	  provides	  information	  about	  abundance	  and	  lifetime	  describes	  the	  local	  environment	  of	  the	  fluorophore.	  	  Shifts	  of	  levels	  and	  lifetimes	  of	  these	  molecules	  indicate	  relative	  glycolytic	  and	  oxidative	  metabolism.	  Intensity-­‐independent	  lifetime	  analysis	  allows	  for	  analysis	  of	  metabolic	  gradients	  at	  depth	  in	  both	  3D	  tissue	  cultures	  and	  in	  vivo.	  	  We	  also	  use	  two-­‐photon	  microscopy	  to	  image	  the	  abundance	  and	  location	  of	  engineered	  fluorescent	  receptor	  fusions	  (75),	  cell	  cycle	  protein	  fusions	  (76),	  and	  cytoplasmic	  fluorophores	  for	  cell	  tracking.	  	  Two-­‐photon	  microscopy	  allows	  capture	  of	  subcellular	  and	  population-­‐scale	  measures	  both	  
in	  vitro	  and	  cancer	  foci	  in	  vivo.	  	  Microscopy	  throughput	  and	  time	  scales	  are	  limited	  by	  the	  acquisition	  times,	  frame	  stability,	  and	  difficulties	  with	  photo	  bleaching.	  	  Engineered	  fluorophores	  are	  also	  amenable	  to	  flow	  cytometry	  analysis	  of	  population-­‐based	  variability.	  	  	  
1.4.2 Bioluminescence	  Imaging	  We	  use	  multiple	  bioluminescence	  reporters	  to	  study	  ligand-­‐receptor	  kinetics,	  in	  vivo	  location	  and	  abundance	  of	  metastatic	  foci,	  in	  vitro	  abundance	  of	  cells.	  	  Using	  complementary	  luciferase	  fragments	  fused	  to	  extracellular	  or	  intracellular	  ligands,	  we	  can	  measure	  receptor-­‐receptor	  interactions	  (77)	  and	  ligand-­‐receptor	  signaling	  events	  in	  vivo	  and	  in	  vitro	  (77-­‐81).	  Using	  bioluminescence	  fusions	  of	  Gaussia	  luciferase,	  we	  sensitively	  measure	  the	  secretion	  and	  uptake	  of	  chemokines	  (82).	  	  We	  also	  use	  dual-­‐colored	  luciferase	  imaging	  to	  spectrally	  separate	  competing	  receptor-­‐based	  interactions	  and/or	  multiple	  cell	  types	  (83-­‐85).	  	  Using	  bioluminescence	  we	  also	  track	  the	  metastatic	  location	  of	  cancer	  cells	  
in	  vivo	  and	  the	  relative	  abundance	  of	  cancer	  and	  stromal	  cells	  in	  vitro.	  	  	  We	  use	  complementary	  bioluminescence	  and	  fluorescent	  imaging	  to	  qualitatively	  and	  quantitatively	  assess	  abundance,	  location,	  and	  status	  of	  both	  cells	  and	  molecular	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species.	  	  For	  instance,	  we	  use	  bioluminescence	  to	  measure	  growth	  versus	  quiescence	  and	  viability	  in	  response	  to	  drugs	  for	  cancer	  cells	  in	  bone	  marrow	  spheroid	  cultures	  and	  in	  vivo.	  	  Subsequent	  fluorescence	  imaging	  reveals	  microscopic	  location	  and	  cell	  cycle	  status	  cancer	  cells	  in	  vitro	  and	  in	  vivo.	  	  	  	  Since	  fluorescence	  and	  bioluminescence	  are	  non-­‐overlapping	  imaging	  modalities	  they	  facilitate	  multiplexing	  and	  imaging	  of	  multiple	  sub-­‐cellular,	  cellular,	  population,	  and	  whole	  animal	  imaging	  scales.	  	  We	  use	  both	  imaging	  modalities	  throughout	  this	  dissertation.	  
1.5 Figures	  
	  








Figure	  1.3.	  Overview	  of	  the	  metastatic	  cascade.	  	  Metastatic	  cancer	  cells	  follow	  a	  progression	  through	  primary	  tumor,	  intravascular,	  and	  metastatic	  compartments.	  	  Throughout	  growth	  of	  the	  (A)	  primary	  tumor,	  metabolic	  and	  cytokine	  gradients	  are	  formed	  towards	  and	  away	  from	  the	  vascular	  compartment	  (represented	  by	  the	  graded	  gray	  triangle).	  	  Transformed	  cancer	  cells	  follow	  gradients	  to	  (B)	  degrade	  the	  basement	  membrane,	  invade	  the	  interstitial	  space,	  and	  migrate	  towards	  the	  vascular	  compartment.	  	  After	  (C)	  intravasating	  into	  the	  intravascular	  compartment,	  cancer	  cells	  must	  survive	  (D)	  circulation,	  evade	  immune	  response,	  and	  survive	  non-­‐adhesive	  stimuli.	  	  Note	  immune	  response	  is	  critical	  in	  primary,	  circulatory,	  and	  metastatic	  compartments	  despite	  being	  depicted	  only	  at	  metastatic	  sites.	  Circulating	  cancer	  cells	  subsequently	  may	  (E)	  adhere	  to	  the	  endothelium	  and	  extravasate	  into	  underlying	  organ	  environment.	  	  Within	  a	  metastatic	  site,	  cancer	  cells	  (F)	  find	  or	  create	  a	  microenvironment	  that	  supports	  proliferation	  or	  survival	  in	  a	  quiescent	  state.	  	  Cancer	  cells	  in	  metastatic	  sites	  may	  remain	  quiescent	  indefinitely	  	  (F)	  or	  (G)	  grow	  into	  large	  metastatic	  foci.	  	  For	  both	  (F)	  quiescent	  cancer	  cells	  housed	  with	  organ-­‐specific	  stroma	  or	  in	  (G)	  growing	  metastatic	  foci,	  gradients	  of	  metabolites	  and	  cytokines	  are	  also	  critical	  to	  regulating	  movement,	  quiescence,	  drug	  resistance,	  and/or	  growth.	  This	  figure	  is	  modified	  from	  work	  by	  Chaffer	  and	  Weinberg	  (9).	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2 Chapter Two: Microfluidic source-sink model reveals effects of 
biophysically distinct CXCL12-isoforms in breast cancer chemotaxis 
2.1 Summary	  Chemokines	  critically	  regulate	  chemotaxis	  in	  normal	  and	  pathologic	  states,	  but	  there	  is	  limited	  understanding	  of	  how	  multicellular	  interactions	  generate	  gradients	  needed	  for	  cell	  migration.	  	  Previous	  studies	  of	  chemotaxis	  of	  CXCR4+	  cells	  toward	  chemokine	  CXCL12	  suggest	  the	  requirement	  of	  cells	  expressing	  scavenger	  receptor	  CXCR7	  in	  a	  source-­‐sink	  system.	  	  We	  leveraged	  an	  established	  microfluidic	  device	  to	  discover	  that	  chemotaxis	  of	  CXCR4	  cells	  toward	  distinct	  isoforms	  of	  CXCL12	  required	  CXCR7	  scavenging	  only	  under	  conditions	  with	  higher	  than	  optimal	  levels	  of	  CXCL12.	  	  Chemotaxis	  toward	  CXCL12-­‐β	  and	  -­‐γ	  isoforms,	  which	  have	  greater	  binding	  to	  extracellular	  molecules	  and	  have	  been	  largely	  overlooked,	  was	  less	  dependent	  on	  CXCR7	  than	  the	  more	  commonly	  studied	  CXCL12-­‐α.	  	  Chemotaxis	  of	  CXCR4+	  cells	  toward	  even	  low	  levels	  of	  CXCL12-­‐γ	  and	  CXCL12-­‐β	  still	  occurred	  during	  treatment	  with	  a	  FDA-­‐approved	  inhibitor	  of	  CXCR4.	  	  We	  also	  detected	  CXCL12-­‐γ	  only	  in	  breast	  cancers	  from	  patients	  with	  advanced	  disease.	  	  Physiological	  gradient	  formation	  within	  the	  device	  facilitated	  interrogation	  of	  key	  differences	  in	  chemotaxis	  among	  CXCL12	  isoforms	  and	  suggests	  CXCL12-­‐γ	  as	  a	  biomarker	  for	  metastatic	  cancer.	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2.2 Introduction	  Chemotaxis	  of	  cells	  along	  a	  concentration	  gradient	  is	  essential	  for	  normal	  development,	  tissue	  homeostasis,	  and	  pathogenesis	  of	  diseases	  including	  metastatic	  cancer,	  atherosclerosis,	  and	  multiple	  sclerosis	  (1-­‐6).	  	  Chemotaxis	  controls	  trafficking	  of	  normal	  stem	  cells,	  and	  there	  are	  ongoing	  efforts	  to	  enhance	  homing	  of	  stem	  cells	  to	  injured	  tissues	  for	  regenerative	  medicine	  (7,	  8).	  	  The	  source-­‐sink	  model	  of	  chemotaxis	  is	  one	  common	  process	  to	  generate	  gradients	  and	  drive	  cell	  migration	  in	  vitro	  and	  in	  vivo	  (9-­‐11).	  	  The	  balance	  between	  chemotactic	  molecule	  secretion	  (source)	  and	  degradation	  (sink)	  critically	  determines	  gradient	  profiles	  and	  responsiveness	  of	  migrating	  cells	  (10-­‐19).	  	  Recent	  studies	  also	  demonstrate	  that	  gradients	  of	  chemokine	  bound	  to	  the	  extracellular	  matrix,	  rather	  than	  soluble	  molecules,	  drive	  chemotaxis	  (20)	  by	  increasing	  local	  concentrations	  of	  chemokine,	  limiting	  degradation,	  and	  enhancing	  presentation	  to	  receptors	  (21).	  	  Therapeutic	  targeting	  of	  source-­‐sink	  chemotaxis	  as	  an	  emergent	  phenotype	  of	  multiple	  cells,	  receptors,	  and	  microenvironmental	  factors	  rather	  than	  a	  singular	  molecular	  event	  provides	  flexibility	  in	  drug	  targets	  but	  requires	  evaluation	  of	  the	  entire	  integrated	  system.	  	  	  Chemokine	  CXCL12-­‐α	  and	  its	  receptors	  CXCR4	  and	  CXCR7	  are	  a	  prominent	  example	  of	  source-­‐sink	  chemotaxis	  in	  normal	  physiology	  and	  pathologic	  conditions	  (22-­‐24).	  	  CXCR7	  functions	  as	  a	  scavenger	  receptor,	  controlling	  availability	  of	  CXCL12	  by	  removing	  it	  from	  the	  extracellular	  space	  and	  degrading	  it	  (10-­‐19).	  	  Two	  recent	  studies	  highlight	  that	  CXCL12	  secretion	  and	  CXCR7	  scavenging	  are	  obligate	  partners	  in	  generating	  sustained,	  local	  gradients	  of	  CXCL12-­‐α	  in	  vivo,	  allowing	  cells	  with	  CXCR4	  to	  migrate	  toward	  CXCL12	  source	  cells	  (25,	  26).	  	  Loss	  of	  CXCR7	  in	  both	  zebrafish	  and	  an	  in	  vitro	  device	  we	  developed	  prevented	  normal	  migration	  of	  CXCR4+	  cells	  due	  to	  loss	  of	  chemokine	  gradients	  and/or	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desensitization	  of	  CXCR4	  from	  elevated	  levels	  of	  CXCL12-­‐α	  (10,	  11).	  	  While	  prior	  studies	  show	  that	  CXCR7	  is	  required	  for	  CXCR4-­‐dependent	  migration	  toward	  CXCL12-­‐α,	  these	  studies	  overlook	  the	  importance	  of	  variable	  interactions	  of	  CXCL12	  isoforms	  with	  receptors	  and	  the	  extracellular	  space.	  	  Studies	  of	  CXCL12	  isoforms	  in	  chemotaxis	  have	  been	  particularly	  challenging	  because	  only	  the	  α-­‐isoform	  efficiently	  stimulates	  chemotaxis	  in	  conventional	  transwell	  assays,	  while	  other	  isoforms	  require	  supraphysiologic	  concentrations	  to	  drive	  cell	  migration	  (27).	  To	  investigate	  interrelationships	  between	  a	  source-­‐sink	  model	  and	  binding	  of	  chemotactic	  molecules	  to	  extracellular	  surfaces,	  we	  used	  our	  established	  microfluidic	  source-­‐sink	  model	  of	  CXCL12,	  CXCR4,	  and	  CXCR7	  (Fig.	  2.1).	  	  We	  tested	  three	  of	  the	  six	  naturally	  expressed	  CXCL12-­‐isoforms	  (α,	  β,	  and	  γ,	  common	  to	  humans,	  mice,	  and	  rats)	  that	  span	  low-­‐to-­‐high	  affinities	  for	  receptors	  CXCR4,	  CXCR7,	  and	  the	  extracellular	  environment	  (28-­‐30).	  	  Secreted	  forms	  of	  these	  CXCL12	  isoforms	  share	  a	  common	  N-­‐terminal	  68	  amino	  acid	  core	  that	  comprises	  the	  entirety	  of	  CXCL12-­‐α.	  	  CXCL12-­‐β	  and	  -­‐γ	  have	  four	  and	  30	  additional	  amino	  acids	  at	  the	  C-­‐termini,	  respectively.	  	  C-­‐termini	  of	  CXCL12-­‐β	  and	  -­‐γ	  are	  enriched	  with	  basic	  amino	  acids	  that	  enhance	  interactions	  with	  negatively-­‐charged	  extracellular	  molecules	  and	  surfaces	  (27,	  29,	  31).	  	  In	  particular,	  CXCL12-­‐γ	  binds	  to	  major	  components	  of	  the	  extracellular	  matrix,	  such	  as	  the	  glycosaminoglycan	  heparan	  sulfate,	  with	  more	  than	  two	  orders	  of	  magnitude	  greater	  affinity	  than	  the	  most	  commonly	  studied	  isoform,	  CXCL12-­‐α.	  	  However,	  CXCL12-­‐γ	  binds	  with	  lower	  affinity	  to	  receptor	  CXCR4,	  and	  scavenging	  by	  CXCR7	  is	  also	  less	  efficient.	  	  Association	  of	  chemotactic	  molecules	  with	  extracellular	  components	  also	  may	  enhance	  chemotaxis	  by	  increasing	  local	  concentrations	  of	  chemokine,	  favoring	  oligomerization	  that	  may	  be	  necessary	  for	  chemokine	  activity,	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limiting	  proteolytic	  degradation,	  and	  enhancing	  presentation	  to	  receptors	  (21).	  	  These	  opposing	  interactions	  between	  CXCL12-­‐isoforms	  and	  extracellular	  surfaces	  or	  receptors	  produce	  marked	  disparities	  in	  bound	  versus	  soluble	  concentrations	  of	  each	  isoform	  (27,	  29).	  	  Effects	  of	  different	  isoforms	  of	  CXCL12	  on	  gradient	  formation	  and	  chemotaxis	  within	  physiological	  source-­‐sink	  environments	  are	  unknown.	  	  	  Using	  unique	  capabilities	  of	  our	  microfluidic	  device,	  we	  discover	  that	  levels	  of	  secreted	  CXCL12	  isoforms	  dictate	  the	  requirement	  for	  CXCR7-­‐dependent	  scavenging	  in	  chemotaxis	  of	  CXCR4+	  cells.	  	  CXCR7-­‐scavenging	  is	  necessary	  for	  chemotaxis	  of	  CXCR4	  cells	  under	  conditions	  with	  higher	  levels	  of	  CXCL12,	  while	  reducing	  amounts	  of	  CXCL12	  partially	  rescues	  chemotaxis	  without	  functional	  scavenging	  by	  CXCR7.	  	  Even	  at	  concentrations	  10	  to	  20-­‐fold	  lower,	  we	  also	  show	  for	  the	  first	  time	  in	  vitro	  that	  CXCL12-­‐γ,	  an	  isoform	  with	  highest	  binding	  to	  the	  extracellular	  environment,	  drives	  chemotaxis	  of	  CXCR4	  cells	  to	  an	  extent	  similar	  to	  CXCL12-­‐β	  and	  greater	  than	  CXCL12-­‐α.	  	  Exploiting	  capabilities	  of	  this	  device	  for	  drug	  testing,	  we	  demonstrate	  that	  AMD3100,	  the	  only	  FDA-­‐approved	  inhibitor	  of	  CXCR4,	  fails	  to	  entirely	  block	  migration	  of	  CXCR4+	  cells	  toward	  CXCL12-­‐β	  or	  -­‐γ.	  	  Moreover,	  we	  show	  for	  the	  first	  time	  expression	  of	  CXCL12-­‐γ	  in	  primary	  human	  breast	  cancers	  and	  suggest	  that	  this	  isoform	  is	  associated	  with	  metastatic	  disease.	  	  These	  results	  demonstrate	  that	  intrinsic	  biophysical	  and	  biochemical	  differences	  among	  chemokine	  isoforms	  regulate	  cell	  migration	  and	  emphasize	  the	  need	  for	  drugs	  that	  more	  effectively	  target	  CXCL12-­‐β	  and	  -­‐γ.	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2.3 Experimental	  Methods	  
2.3.1 Plasmid	  construction	  	  	  The	  CXCL12	  fusions	  to	  Gaussia	  luciferase	  (GLuc)	  were	  generated	  by	  PCR	  or	  gene	  synthesis	  (supplied	  in	  pIDTSMART-­‐Kan	  blunt,	  Integrated	  DNA	  Technologies)	  as	  indicated	  in	  Supplemental	  Table	  S1,	  products	  1,3-­‐5.	  	  These	  were	  constructed	  in	  pEGFP-­‐N1	  digested	  with	  XhoI	  and	  NotI	  to	  remove	  the	  EGFP	  open	  reading	  frame.	  	  A	  Gly/Ser	  linker	  and	  EcoRI	  site	  were	  included	  between	  the	  CXCL12	  and	  GL	  open	  reading	  frames.	  	  	  The	  CXCL12-­‐GL	  fusions	  were	  amplified	  by	  PCR	  with	  appropriate	  primers	  shown	  in	  Table	  S1,	  products	  9,10,	  and	  inserted	  into	  the	  PacI	  sites	  of	  FU650W	  (constructed	  from	  FUGW	  as	  described	  (32))	  for	  product	  9	  or	  the	  XbaI	  and	  NotI	  sites	  of	  pLVX-­‐EF1α-­‐IRES-­‐mCherry	  (Clontech)	  for	  product	  10.	  	  Unfused	  versions	  of	  CXCL12	  isoforms	  and	  secreted	  Gaussia	  luciferase	  were	  amplified	  with	  primers	  as	  indicated	  in	  Table	  S1,	  products	  2,	  6-­‐8	  and	  cloned	  into	  the	  XbaI	  and	  NotI	  sites	  of	  pLVX-­‐EF1α-­‐IRES-­‐mCherry	  (note	  that	  NheI	  and	  XbaI	  have	  compatible	  cohesive	  ends).	  	  Vector	  FUAcGFP-­‐nucW	  was	  generated	  by	  amplifying	  nuclear-­‐targeted	  AcGFP	  from	  pAcGFP1-­‐Nuc	  (Clontech)	  as	  indicated	  in	  Table	  S1,	  product	  11,	  and	  cloned	  into	  the	  PacI	  site	  of	  FUGW.	  
2.3.2 Stable	  cell	  lines	  	  We	  transduced	  MDA-­‐MB-­‐231	  cells	  with	  lentiviral	  vectors	  described	  above	  to	  generate	  populations	  of	  cells	  expressing	  fusions	  of	  CXCL12-­‐α,	  β,	  or	  γ	  to	  GL	  with	  co-­‐expressed	  fluorescent	  protein	  FP650	  (33).	  	  Expression	  of	  FP650	  and	  the	  IRES-­‐linked	  mCherry	  enabled	  flow	  cytometry	  sorting	  and	  identification	  of	  cells	  within	  the	  microfluidic	  device.	  	  We	  previously	  described	  MDA-­‐MB-­‐231	  cells	  stably	  transduced	  with	  CXCR4-­‐GFP	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(231-­‐CXCR4)	  (34).	  	  To	  facilitate	  imaging	  and	  image	  analysis,	  we	  transduced	  231	  CXCR4	  cells	  with	  FUAcGFP-­‐nucW.	  	  We	  previously	  reported	  MDA-­‐MB-­‐231	  cells	  stably	  transduced	  with	  CXCR7-­‐GFP	  (231-­‐CXCR7)	  or	  CXCR7-­‐Δ322-­‐GFP	  (231-­‐	  CXCR7-­‐Δ322)	  (16).	  	  We	  used	  MDA-­‐MB-­‐231	  cells	  stably	  expressing	  click	  beetle	  green	  and	  red	  luciferase	  complementation	  reporters	  for	  association	  of	  β-­‐arrestin	  2	  and	  CXCR7	  or	  CXCR4,	  respectively	  (35).	  	  These	  reporter	  cell	  lines	  are	  comparable	  to	  the	  firefly	  luciferase	  complementation	  systems	  we	  previously	  have	  described	  for	  these	  protein	  interactions	  (36,	  37).	  
2.3.3 Murine	  tumor	  models	  	  	  We	  implanted	  2	  x	  105	  E0771	  mouse	  breast	  cancer	  cells	  stably	  expressing	  firefly	  luciferase	  and	  GFP	  along	  with	  1	  x	  105	  immortalized	  mouse	  mammary	  fibroblasts	  (gift	  of	  Harold	  Moses,	  Vanderbilt)	  orthotopically	  into	  4th	  inguinal	  mammary	  fat	  pads	  of	  syngeneic	  C57Bl/6	  mice	  (Taconic).	  	  We	  harvested	  8-­‐10	  mm	  diameter	  tumors	  and	  extracted	  RNA	  using	  Trizol	  (Life	  Technologies)	  according	  the	  manufacturer’s	  directions.	  	  We	  also	  generated	  human	  breast	  cancer	  xenografts	  by	  implanting	  5	  x	  105	  231-­‐CXCR4	  cells	  co-­‐expressing	  firefly	  luciferase	  into	  4th	  inguinal	  mammary	  fat	  pads	  of	  NSG	  mice	  (15).	  	  We	  extracted	  RNA	  from	  these	  tumors	  as	  described	  above.	  	  	  	  	  	  	  	  	  
2.3.4 Western	  blot	  analysis	  We	  measured	  phosphorylation	  of	  AKT	  as	  we	  have	  previously	  described	  (38).	  	  Synthetic	  CXCL12	  isoforms	  for	  this	  assay	  were	  purchased	  from	  R&D	  Systems.	  
2.3.5 Secreted	  CXCL12	  ELISA	  analysis	  We	  contracted	  the	  University	  of	  Michigan	  Cancer	  Center	  Immunology	  Core	  to	  perform	  CXCL12	  ELISA	  per	  specifications	  for	  R&D	  Systems	  CXCL12-­‐α	  ELISA.	  	  We	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previously	  demonstrated	  complementary	  ELISA-­‐	  and	  bioluminescence-­‐based	  CXCL12	  measurement	  (38).	  	  	  
2.3.6 Quantitative	  RT-­‐PCR	  for	  CXCL12-­‐isoforms	  	  	  We	  measured	  mRNA	  levels	  of	  CXCL12-­‐α,	  β,	  or	  γ	  fusions	  to	  Gaussia	  luciferase	  in	  stably	  transduced	  MDA-­‐MB-­‐231	  cells	  by	  qRT-­‐PCR	  using	  PCR	  primers	  common	  to	  all	  isoforms	  and	  SYBR	  Green	  detection:	  5’	  tgcccttcagattgttgcacg	  3’	  and	  5’	  ctccaggtactcttggatccac	  3’,	  based	  on	  our	  prior	  protocol	  (32).	  	  To	  analyze	  expression	  of	  CXCL12	  isoforms	  in	  mouse	  tumors	  and	  bone	  marrow,	  we	  extracted	  RNA	  with	  Trizol	  reagent	  (Life	  Technologies)	  and	  further	  purified	  RNA	  with	  a	  column-­‐based	  kit	  and	  on-­‐column	  treatment	  with	  DNaseI	  (Qiagen).	  	  We	  performed	  qRT-­‐PCR	  as	  described	  above	  with	  isoform-­‐specific	  primers:	  common	  forward	  primer	  5’-­‐tgcccttcagattgttgcacg-­‐3’,	  α-­‐reverse	  primer	  5’-­‐ggctgttgtgcttacttgtttaaagc-­‐3’,	  mouse	  β-­‐reverse	  primer	  5’-­‐ctgactcacacctctcacatcttg-­‐3’,	  human	  β-­‐reverse	  primer	  5’-­‐ggcgtctgaccctctcacatcttg-­‐3’,	  and	  γ-­‐reverse	  primer	  5’-­‐gaactagtttttccttttctgggcagcc-­‐3’.	  	  The	  primers	  are	  the	  same	  for	  human	  and	  mouse	  except	  for	  the	  reverse	  primer	  for	  CXCL12-­‐β.	  	  We	  used	  a	  cDNA	  array	  of	  normal	  human	  breast	  tissue	  and	  breast	  cancers	  (Origene,	  Breast	  Cancer	  cDNA	  Array	  II).	  	  Human	  primers	  were	  used	  for	  xenograft	  tumors	  and	  the	  human	  cDNA	  array.	  	  For	  both	  cells	  and	  tissues,	  we	  amplified	  GADPH	  as	  a	  control	  and	  quantified	  data	  as	  ΔCt	  values.	  	  We	  defined	  tissues	  as	  positive	  for	  an	  isoform	  of	  CXCL12	  based	  on	  amplification	  at	  <40	  qRT-­‐PCR	  cycles	  and	  appropriate	  size	  PCR	  product	  identified	  by	  gel	  electrophoresis.	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2.3.7 Microfluidic	  device	  fabrication	  and	  preparation	  We	  fabricated	  the	  microfluidic	  migration	  device	  as	  described	  previously	  (11).	  	  We	  used	  a	  top	  channel	  with	  100μm	  depth	  instead	  of	  200	  μm.	  	  We	  patterned	  cells	  in	  three	  200μm	  wide	  strips	  spaced	  200	  μm	  apart.	  	  For	  time	  course	  confocal	  imaging	  and	  for	  imaging	  of	  receptor	  localization	  within	  the	  device,	  we	  fabricated	  the	  microfluidic	  device	  with	  the	  total	  top	  layer	  thickness	  of	  ~2mm	  to	  allow	  imaging.	  	  
2.3.8 Microfluidic	  device	  experimental	  setup	  	   	  We	  seeded	  cells	  as	  described	  previously	  (11).	  	  For	  treatment	  with	  AMD3100,	  we	  supplemented	  both	  the	  final	  batch	  of	  cells	  and	  parallel	  medium	  with	  1	  μM	  AMD3100	  (Tocris)	  in	  DMEM	  with	  10%	  FBS.	  	  Within	  an	  hour	  of	  seeding	  the	  final	  batch	  of	  cells	  (CXCR4-­‐GFP),	  we	  imaged	  each	  device	  to	  match	  corresponding	  phase	  contrast	  and	  epifluorescence	  images.	  	  We	  matched	  parallel	  device	  conditions	  among	  isoforms,	  dilutions	  of	  secreting	  cells,	  and	  treatments	  for	  each	  run.	  	  
2.3.9 Bioluminescence	  imaging	  	  	  We	  imaged	  fusions	  of	  CXCL12-­‐isoforms	  to	  Gaussia	  luciferase	  and	  luciferase	  complementation	  between	  CXCR4	  or	  CXCR7	  and	  β-­‐arrestin	  2	  as	  described	  previously	  (36-­‐38).	  	  	  
2.3.10 Image	  acquisition	  and	  analysis	  	  	  For	  time	  point	  analyses	  of	  cells	  in	  the	  microfluidic	  device,	  we	  acquired	  phase	  contrast	  and	  fluorescence	  images	  at	  4	  and	  6	  locations	  along	  the	  length	  of	  the	  device	  channel	  for	  t=0	  and	  24	  hours,	  respectively	  (n=4-­‐11	  device	  setups	  per	  condition).	  	  We	  captured	  images	  using	  an	  inverted	  Olympus	  IX70	  microscope	  with	  a	  10X	  objective.	  	  We	  
	  31	  
developed	  a	  semi-­‐automated	  NIH	  ImageJ	  (64bit)	  script	  to	  measure	  location	  of	  NLS-­‐AcGFP	  tagged	  CXCR4+	  cells	  relative	  to	  the	  channel	  boundaries	  (Supplemental	  Info).	  	  The	  script	  returned	  coordinates	  of	  each	  CXCR4+	  cell	  based	  on	  NLS-­‐GFP	  (fluorescence)	  relative	  to	  the	  matched	  channel	  boundaries	  (phase	  contrast).	  	  We	  measured	  the	  average	  position	  for	  each	  view	  field	  in	  the	  direction	  of	  the	  source	  cells.	  	  For	  time-­‐lapse	  microscopy,	  we	  used	  a	  custom	  CO2	  and	  temperature	  controlled	  stage	  for	  live-­‐cell	  imaging	  with	  a	  10X,	  0.3	  NA	  objective	  and	  upright	  confocal	  microscope	  (Olympus	  MPE	  Twin).	  	  For	  each	  CXCL12-­‐isoform,	  we	  imaged	  a	  single	  view	  field	  of	  three	  separate	  device	  setups	  at	  15-­‐minute	  increments	  for	  20	  hours	  total.	  	  Using	  a	  modified	  ImageJ	  script,	  we	  measured	  position	  of	  cells	  over	  time.	  	  We	  imaged	  CXCR4-­‐GFP	  localization	  in	  the	  microfluidic	  channel	  by	  confocal	  microscopy	  using	  a	  60X,	  1.0NA	  objective.	  	  We	  captured	  z-­‐stack	  images	  (2.5μm	  increments)	  at	  5	  positions	  along	  the	  channel	  length	  and	  displayed	  representative	  z-­‐compressions	  that	  were	  adjusted	  identically	  in	  parallel	  for	  demonstration	  (n	  =	  2	  devices	  per	  condition).	  
2.3.11 Transwell	  migration	  experiments	  	  	  We	  performed	  transwell	  migration	  assays	  as	  reported	  previously(39).	  	  Briefly,	  we	  incubated	  231-­‐cells	  overexpressing	  CXCR4+	  in	  transwells	  with	  equal	  levels	  of	  CXCL12-­‐isoforms,	  based	  on	  Gaussia	  luciferase	  activity.	  	  We	  observed	  migrated	  cells	  based	  on	  crystal	  violet	  staining.	  	  	  
2.3.12 Statistical	  analysis	   	  We	  made	  all	  plots	  and	  statistical	  comparisons	  using	  GraphPad	  Prism.	  	  We	  plotted	  time	  point	  data	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (S.E.M.).	  	  For	  time	  course	  data,	  we	  plotted	  the	  mean	  ±	  standard	  deviation	  (S.D.)	  of	  percentile	  lines,	  which	  we	  created	  in	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Microsoft	  Excel.	  	  For	  all	  statistical	  comparisons	  of	  migration	  data	  we	  performed	  paired,	  two-­‐sided	  statistical	  comparisons	  using	  the	  Mann-­‐Whitney	  U-­‐test	  (non-­‐parametric)	  with	  exact	  p-­‐values.	  	  For	  analysis	  of	  CXCL12-­‐uptake	  we	  performed	  simple	  two-­‐sided	  t-­‐test.	  	  For	  analyses	  of	  	  bioluminescence	  complementation	  (Figs.	  2.1,	  2.3,	  A.6,	  and	  A.7)	  and	  CXCR4-­‐GFP	  internalization	  over	  time	  (Fig.	  2.4	  E)	  we	  performed	  two-­‐way	  ANOVA	  and	  post	  hoc	  Tukey	  multiple	  comparisons	  test	  within	  rows.	  	  For	  two-­‐way	  ANOVA	  we	  used	  time	  as	  the	  row	  effect	  versus	  CXCL12-­‐isoform	  or	  concentration	  for	  the	  column	  effect.	  	  	  
2.4 Results	  
2.4.1 Microfluidic	  source-­‐sink-­‐migration	  system	  	  Using	  a	  multi-­‐layered	  device	  (Fig.	  2.1A),	  we	  patterned	  cells	  that	  secrete	  individual	  CXCL12	  isoforms	  (source)	  in	  a	  geometrically	  defined	  location	  relative	  to	  MDA-­‐MB-­‐231	  breast	  cancer	  cells	  expressing	  CXCR7	  (CXCR7+,	  sink)	  or	  CXCR4	  (CXCR4+,	  migrating	  cells)	  (Fig.	  2.1B-­‐D).	  	  In	  this	  device,	  intercellular	  interactions	  between	  source	  and	  sink	  cells	  generate	  chemotactic	  gradients	  in	  situ	  in	  the	  context	  of	  serum-­‐containing	  medium	  and	  other	  molecules	  secreted	  by	  cells.	  	  We	  also	  emphasize	  that	  the	  only	  difference	  among	  source	  cells	  is	  the	  isoform	  of	  secreted	  CXCL12,	  so	  differences	  in	  chemotaxis	  of	  CXCR4	  cells	  arise	  from	  distinct	  biologic	  effects	  of	  each	  isoform.	  	  The	  device	  allows	  us	  to	  quantify	  changes	  in	  position	  of	  all	  CXCR4+	  cells	  through	  time	  lapse	  imaging	  (Fig.	  A.1)	  or	  endpoint	  analyses	  to	  give	  chemotaxis	  data	  as	  a	  pooled	  frequency	  distribution	  or	  mean	  position	  per	  view	  field	  (see	  Fig	  A.2	  A-­‐D	  or	  2.1E-­‐G,	  respectively,	  as	  examples).	  	  By	  changing	  the	  percentage	  of	  secreting	  cells	  mixed	  in	  with	  non-­‐secreting	  cells,	  the	  system	  also	  tests	  the	  effect	  of	  changing	  the	  amount	  of	  source	  CXCL12	  produced.	  	  We	  also	  analyzed	  the	  role	  of	  the	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sink	  cells	  by	  either	  eliminating	  CXCR7	  cells	  or	  by	  patterning	  cells	  expressing	  non-­‐functional	  forms	  of	  CXCR7.	  	  CXCL12	  conditions	  did	  not	  cause	  differences	  in	  growth	  in	  these	  settings	  based	  on	  the	  number	  of	  231-­‐CXCR4	  cells	  uniformly	  doubling	  over	  24	  hours	  (data	  not	  shown).	  	  	  	  	  
2.4.2 Characterization	  of	  secreted	  Gaussia	  luciferase	  CXCL12-­‐isoform-­‐fusions	  	  	  	  For	  the	  CXCL12-­‐isoform	  secreting	  (source)	  cells	  we	  stably	  transduced	  MDA-­‐MB-­‐231	  breast	  cancer	  cells	  with	  an	  isoform	  of	  CXCL12	  fused	  to	  Gaussia	  luciferase	  (GLuc).	  	  We	  previously	  described	  that	  fusion	  of	  CXCL12-­‐α	  to	  GLuc	  provides	  a	  sensitive,	  quantitative	  measure	  of	  chemokine	  levels	  without	  affecting	  ligand	  activity	  (38).	  	  We	  focused	  on	  CXCL12-­‐α,	  -­‐β,	  and	  -­‐γ,	  the	  most	  common	  human	  isoforms	  and	  those	  shared	  with	  mice	  and	  rats	  (28).	  	  While	  we	  emphasized	  CXCL12	  secretion	  by	  cancer	  cells,	  previous	  studies	  show	  that	  both	  malignant	  and	  stromal	  cells	  may	  secrete	  this	  chemokine	  (40,	  41).	  	  We	  expressed	  CXCL12-­‐isoforms	  using	  two	  different	  vectors	  (Fig.	  A.3),	  allowing	  us	  to	  create	  GLuc-­‐fused	  and	  -­‐unfused	  chemokines	  to	  demonstrate	  that	  fusion	  to	  GLuc	  retains	  biological	  activity	  of	  each	  isoform	  (Supplemental	  Results	  and	  Fig.	  A.3-­‐5).	  	  We	  note	  that,	  despite	  only	  modest	  differences	  in	  mRNA	  levels,	  amounts	  of	  secreted	  CXCL12-­‐γ	  were	  10-­‐fold	  lower	  than	  CXCL12-­‐α	  and	  -­‐β	  by	  GLuc	  activity	  and	  ELISA	  reactivity	  (Fig.	  A.2E-­‐F).	  	  Although	  the	  polyclonal	  ELISA	  antibodies	  were	  developed	  against	  CXCL12-­‐α,	  the	  assay	  detects	  the	  N-­‐terminal	  core,	  which	  is	  common	  to	  all	  isoforms.	  	  	  Relatively	  lower	  amounts	  of	  secreted	  CXCL12-­‐γ	  protein	  as	  compared	  with	  mRNA	  may	  reflect	  previously	  reported	  differences	  in	  intracellular	  trafficking	  of	  CXCL12-­‐γ	  (42),	  and	  we	  have	  observed	  this	  effect	  with	  multiple	  vectors	  and	  cell	  types.	  	  GLuc-­‐fused	  CXCL12-­‐isoforms	  also	  signalled	  via	  AKT	  at	  comparable	  levels	  as	  synthetic	  isoforms	  based	  on	  our	  ELISA	  and	  GLuc	  concentration	  estimates	  (Fig.	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A.5).	  	  Overall,	  these	  data	  allow	  us	  to	  quantitatively	  compare	  levels	  of	  CXCL12	  isoforms	  secreted	  by	  source	  cells.	  	  	  
2.4.3 CXCL12-­‐β	  and	  -­‐γ	  have	  surprisingly	  high	  chemotaxis	  potency	  in	  an	  in	  vitro	  source-­‐sink	  
model	  	  	  	  Chemotaxis	  of	  CXCR4+	  cells	  toward	  CXCL12-­‐γ	  was	  slightly	  more	  than	  CXCL12-­‐β	  (p<0.05)	  and	  significantly	  more	  than	  CXCL12-­‐α	  (p	  =	  0.0001)	  after	  24	  hours	  (Fig	  2.1E-­‐G,	  comparison	  among	  100%	  secreting	  conditions	  for	  each	  isoform	  with	  statistics	  not	  marked	  on	  plots).	  	  These	  results	  differ	  notably	  from	  transwell	  assays	  in	  which	  CXCR4+	  cells	  show	  higher	  sensitivity	  migration	  toward	  cell-­‐secreted	  or	  recombinant	  CXCL12-­‐α	  (Fig.	  A.2G)	  (27,	  43,	  44).	  	  Rueda	  and	  colleagues	  previously	  showed	  a	  ten-­‐fold	  higher	  concentration	  of	  CXCL12-­‐γ	  was	  required	  to	  drive	  chemotaxis	  of	  CXCR4	  cells	  to	  the	  same	  extent	  as	  CXCL12-­‐α	  in	  transwells.	  	  However,	  their	  study	  required	  100nM	  CXCL12-­‐γ	  to	  promote	  chemotaxis,	  substantially	  higher	  than	  amounts	  expected	  in	  vivo	  or	  produced	  in	  our	  system.	  	  Using	  time-­‐lapse	  microscopy	  we	  also	  show	  that	  CXCL12-­‐γ	  induced	  more	  immediate	  and	  rapid	  migration	  of	  both	  leading	  and	  trailing	  edges,	  followed	  by	  continued	  migration	  comparable	  to	  sustained	  effects	  of	  CXCL12-­‐α	  and	  -­‐β	  (Fig.	  A.1B-­‐D).	  	  	  Chemotactic	  responses	  of	  CXCR4+	  cells	  toward	  CXCL12	  can	  show	  a	  bell-­‐shaped	  curve	  with	  reduced	  effects	  at	  both	  high	  and	  low	  concentrations	  of	  chemokine	  (27).	  	  To	  evaluate	  such	  effects,	  we	  progressively	  reduced	  concentrations	  of	  CXCL12	  by	  patterning	  lower	  percentages	  of	  CXCL12-­‐secreting	  cells	  mixed	  with	  non-­‐secreting	  parental	  cells	  while	  keeping	  the	  total	  number	  of	  cells	  in	  the	  source	  region	  constant	  (p<0.0001;	  Fig	  2.2A-­‐C).	  	  Chemotaxis	  toward	  CXCL12-­‐α	  showed	  no	  significant	  peak	  before	  dropping	  off	  at	  1%	  relative	  concentration.	  	  CXCL12-­‐β	  elicited	  a	  clear	  bell-­‐shaped	  response	  with	  peak	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chemotaxis	  at	  50%	  and	  10%	  relative	  concentrations	  (p<0.05	  and	  p<0.0001,	  respectively)	  (Fig	  2.2B),	  indicating	  that	  100%	  source	  cells	  produce	  a	  higher	  than	  optimal	  concentration	  of	  chemokine.	  	  Chemotaxis	  towards	  CXCL12-­‐γ	  also	  showed	  no	  significant	  peak	  before	  dropping	  off	  at	  1%	  (p<0.0001).	  To	  investigate	  mechanisms	  underlying	  greater	  responsiveness	  of	  CXCR4+	  cells	  toward	  CXCL12-­‐γ,	  we	  quantified	  activation	  of	  CXCR4	  by	  recruitment	  of	  the	  cytosolic	  adapter	  protein	  β-­‐arrestin	  2,	  which	  is	  implicated	  in	  chemotaxis	  (45,	  46).	  	  We	  treated	  cells	  expressing	  a	  luciferase	  complementation	  reporter	  for	  association	  of	  CXCR4	  and	  β-­‐arrestin	  2	  with	  increasing	  concentrations	  of	  recombinant	  CXCL12-­‐α,	  -­‐β,	  or	  -­‐γ	  (36,	  47).	  	  CXCL12-­‐γ	  stimulated	  greater	  recruitment	  of	  β-­‐arrestin	  2	  to	  CXCR4	  than	  the	  other	  isoforms,	  potentially	  contributing	  to	  enhanced	  chemotaxis	  toward	  the	  γ-­‐isoform	  (Fig	  2.1H-­‐J,	  A.6)	  (45,	  46).	  	  	  
2.4.4 Inhibiting	  CXCL12-­‐CXCR4	  dependent	  chemotaxis	   	  AMD3100	  is	  a	  small-­‐molecule	  competitive	  inhibitor	  of	  CXCL12-­‐CXCR4	  binding	  used	  clinically	  to	  mobilize	  hematopoietic	  stem	  cells	  (44,	  48).	  	  Little	  is	  known	  about	  effects	  of	  AMD3100	  against	  different	  isoforms	  of	  CXCL12.	  	  Using	  the	  microfluidic	  source-­‐sink	  model,	  we	  found	  AMD3100	  to	  be	  less	  effective	  than	  may	  be	  expected	  from	  transwell	  studies	  against	  just	  the	  α-­‐isoform	  (Fig.	  2.2A-­‐C).	  	  While	  AMD3100	  effectively	  eliminated	  chemotaxis	  in	  transwell	  assays	  with	  CXCL12-­‐α	  (Fig	  A.2G),	  in	  the	  source-­‐sink	  device	  CXCL12-­‐β	  or	  -­‐γ	  secreting	  cells	  still	  drove	  migration	  in	  the	  presence	  of	  AMD3100	  (p<0.0001	  and	  p<0.01,	  respectively	  for	  β-­‐	  and	  γ-­‐isoforms).	  	  These	  data	  indicate	  that	  even	  very	  low,	  physiologic	  levels	  of	  CXCL12-­‐β	  or	  -­‐γ	  may	  continue	  to	  drive	  detectable	  chemotaxis	  in	  the	  presence	  of	  a	  validated	  CXCR4	  inhibitor.	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2.4.5 Limited	  CXCR7-­‐dependent	  scavenging	  of	  CXCL12-­‐γ	  	  	  Cells	  expressing	  wild-­‐type	  CXCR7	  internalized	  more	  CXCL12-­‐α	  and	  -­‐β	  than	  cells	  with	  either	  CXCR7-­‐Δ322	  (p<0.005	  and	  p<0.0001	  for	  α	  and	  β,	  respectively)	  or	  no	  CXCR7	  (p<0.0001	  for	  both	  α	  and	  β)	  (Fig.	  2.3A).	  	  In	  cells	  with	  wild-­‐type	  (WT)	  CXCR7,	  intracellular	  accumulation	  of	  CXCL12-­‐α	  was	  highest	  and	  followed	  by	  -­‐β,	  with	  only	  minimal	  CXCR7-­‐dependent	  accumulation	  of	  CXCL12-­‐γ	  relative	  to	  CXCR7-­‐Δ322	  or	  control	  cells	  without	  CXCR7	  (Fig.	  2.3A).	  	  This	  order	  was	  reversed	  for	  cells	  without	  CXCR7,	  suggesting	  that	  higher	  binding	  affinity	  of	  CXCL12-­‐γ	  to	  glycosaminoglycans	  on	  cell	  membranes	  confers	  CXCR7-­‐independent	  accumulation	  (Fig	  2.3A	  inset).	  	  Likewise,	  a	  small	  molecule	  inhibitor	  of	  CXCL12	  binding	  to	  CXCR7	  (CCX771)	  decreased	  CXCR7-­‐dependent	  internalization	  for	  CXCL12-­‐α	  and	  -­‐β,	  but	  not	  -­‐γ	  (Fig.	  2.3B).	  	  Accordingly,	  lower	  amounts	  of	  CXCL12-­‐α	  and	  -­‐β	  than	  -­‐γ	  induced	  CXCR7-­‐dependent	  recruitment	  of	  β-­‐arrestin	  2,	  which	  is	  involved	  in	  CXCR7	  internalization,	  as	  determined	  by	  luciferase	  complementation	  (Fig.	  2.3C-­‐E,	  A.7)	  (16,	  37).	  	  These	  data	  show	  inefficient	  scavenging	  of	  CXCL12-­‐γ	  by	  CXCR7.	  
2.4.6 Levels	  of	  CXCL12	  determine	  requirement	  for	  CXCR7	  scavenging	  in	  chemotaxis	  	  	  We	  previously	  demonstrated	  that	  CXCR7	  functions	  as	  a	  sink	  to	  determine	  the	  magnitude	  and	  shape	  of	  a	  CXCL12-­‐α	  gradient	  in	  our	  microfluidic	  device	  (11).	  	  To	  investigate	  to	  what	  extent	  CXCR7	  scavenging	  is	  required	  for	  chemotaxis	  of	  CXCR4	  cells,	  we	  used	  sink	  cells	  that	  does	  not	  internalize	  CXCL12	  (16).	  	  When	  using	  high	  numbers	  of	  CXCL12	  source	  cells,	  chemotaxis	  of	  CXCR4+	  cells	  toward	  all	  CXCL12-­‐isoforms	  decreased	  when	  CXCR7-­‐Δ322	  sink	  cells	  replaced	  WT-­‐CXCR7	  cells	  (p<0.0001)	  	  (Fig	  2.4A-­‐C).	  	  However,	  differences	  in	  chemotaxis	  between	  CXCR7-­‐Δ322	  and	  CXCR7-­‐WT	  were	  substantially	  less	  with	  only	  10%	  of	  the	  source	  cells	  producing	  CXCL12.	  	  For	  devices	  with	  CXCR7-­‐Δ322	  sink	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cells,	  we	  observed	  greater	  chemotaxis	  when	  the	  relative	  concentration	  was	  10%	  rather	  than	  100%	  (p<0.0001).	  	  These	  data	  emphasize	  the	  dynamic	  balance	  between	  levels	  of	  CXCL12	  secretion	  and	  CXCR7-­‐dependent	  scavenging	  in	  CXCR4-­‐dependent	  chemotaxis.	  	  CXCL12	  scavenging	  by	  CXCR7	  is	  required	  for	  chemotaxis	  of	  CXCR4+	  cells	  at	  higher	  levels	  of	  chemokine,	  while	  functioning	  CXCR7	  is	  less	  important	  for	  chemotaxis	  with	  lower	  levels	  of	  CXCL12.	  	  	  	  Upon	  prolonged	  stimulation	  with	  CXCL12,	  CXCR4	  internalizes	  and	  is	  degraded	  (15,	  44).	  	  In	  our	  experiments,	  localization	  and	  fluorescence	  intensity	  of	  a	  CXCR4-­‐GFP	  fusion	  protein	  in	  migrating	  cells	  could	  be	  used	  as	  metrics	  of	  CXCR4	  signaling	  and	  desensitization	  (Fig	  2.4D-­‐E).	  	  Using	  CXCL12-­‐β	  secreting	  cells	  as	  the	  source,	  we	  found	  significantly	  higher	  CXCR4-­‐GFP	  internalization	  when	  the	  WT	  CXCR7	  scavenging	  cells	  were	  replaced	  with	  the	  scavenging-­‐deficient	  CXCR7-­‐Δ322	  cells	  (p	  <	  0.05).	  	  Such	  CXCR4	  internalization	  effects,	  however,	  were	  significantly	  mitigated	  when	  using	  a	  lower	  10%	  relative	  concentration	  of	  CXCL12-­‐β	  cells	  independent	  of	  WT	  or	  mutant	  CXCR7	  sink	  cells	  (Fig.	  2.4E).	  	  These	  results	  show	  that	  CXCR7-­‐scavenging	  prevents	  degradation	  of	  CXCR4	  and	  loss	  of	  chemotaxis	  under	  conditions	  with	  relatively	  higher	  levels	  of	  CXCL12.	  	  Conversely,	  by	  lowering	  the	  amount	  of	  CXCL12,	  migrating	  cells	  retain	  a	  signaling	  pool	  of	  CXCR4-­‐GFP	  at	  the	  cell	  membrane	  and	  overall	  levels	  of	  receptor	  sufficient	  for	  chemotaxis	  even	  with	  CXCR7-­‐Δ322	  cells.	  
2.4.7 CXCL12-­‐γ	  in	  primary	  breast	  tumors	  	  	  To	  link	  our	  data	  to	  breast	  cancer	  biology	  in	  vivo,	  we	  analyzed	  expression	  of	  CXCL12-­‐α,	  -­‐β,	  and	  -­‐γ	  in	  orthotopic	  breast	  tumor	  implants	  from	  syngeneic	  and	  human	  xenograft	  mouse	  models	  and	  a	  cDNA	  array	  from	  bulk	  tissues	  derived	  from	  normal	  breast	  and	  primary	  human	  breast	  cancers.	  	  We	  detected	  CXCL12-­‐α,	  -­‐β,	  and	  -­‐γ	  in	  mouse	  tumors	  and	  with	  rank	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order	  of	  frequency	  of	  expression	  being	  α	  >	  β	  >	  γ	  (Fig.	  A.8),	  based	  on	  the	  number	  of	  samples	  amplifying	  at	  <40	  qRTPCR	  cycles.	  	  Despite	  quantitatively	  lower	  levels	  of	  CXCL12-­‐β	  and	  γ-­‐isoforms,	  nearly	  all	  samples	  had	  detectable	  signal.	  	  In	  human	  tissues,	  we	  detected	  transcripts	  for	  CXCL12-­‐α	  and	  -­‐β	  more	  consistently	  in	  human	  tissues	  (normal	  and	  tumor)	  as	  compared	  with	  the	  γ-­‐isoform.	  	  CXCL12-­‐β	  was	  expressed	  slightly	  more	  frequently	  in	  cancers.	  	  Remarkably,	  we	  detected	  CXCL12-­‐γ	  only	  in	  primary	  tumors	  from	  patients	  with	  advanced	  disease	  (Table	  2.1).	  	  We	  note	  that	  these	  data	  do	  not	  assign	  the	  cell	  type(s)	  in	  tumors	  that	  produce	  CXCL12	  isoforms.	  	  While	  our	  microfluidic	  device	  emphasized	  secretion	  of	  CXCL12	  by	  cancer	  cells,	  stromal	  cells	  in	  tumors	  also	  are	  sources	  of	  this	  chemokine	  (15,	  40,	  49).	  
2.5 Discussion	  CXCL12	  is	  a	  homeostatic	  chemokine	  that	  drives	  many	  finely	  tuned,	  dynamic	  physiologic	  and	  pathologic	  processes,	  necessitating	  multiple	  levels	  of	  regulation.	  Our	  study	  focuses	  on	  chemotaxis	  as	  a	  dynamic	  balance	  among	  chemokine	  secretion,	  endocytosis	  by	  sink	  cells,	  binding	  to	  extracellular	  surfaces,	  and	  regulating	  chemokine-­‐sensing	  receptor	  numbers.	  	  These	  factors	  must	  all	  be	  included	  in	  models	  for	  screening	  therapeutic	  agents,	  as	  changing	  one	  has	  concerted	  effects	  on	  the	  entire	  system.	  In	  the	  simplest	  conceptual	  model,	  secreted	  ligands	  freely	  diffuse	  from	  their	  source	  and	  create	  a	  concentration-­‐dependent	  gradient	  according	  to	  Fick’s	  law	  of	  diffusion.	  	  We	  highlight	  mechanisms	  that	  modify	  the	  shape	  and	  magnitude	  of	  this	  gradient	  in	  the	  extracellular	  space.	  	  CXCR7	  removes	  and	  degrades	  CXCL12,	  which	  decreases	  local	  concentrations	  of	  chemokine	  and	  sharpens	  the	  chemokine	  gradient	  to	  facilitate	  migration	  (10,	  13-­‐16).	  	  The	  requirement	  for	  CXCR7	  scavenging	  in	  chemotaxis	  of	  CXCR4	  cells	  is	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contingent	  upon	  levels	  of	  CXCL12.	  	  CXCR7	  scavenging	  is	  particularly	  critical	  for	  chemotaxis	  of	  CXCR4	  cells	  under	  conditions	  with	  relatively	  high	  levels	  of	  CXCL12.	  	  However,	  when	  source	  cells	  secrete	  only	  low	  levels	  of	  CXCL12,	  CXCR4	  cells	  still	  migrate	  in	  the	  absence	  of	  CXCR7	  scavenging,	  albeit	  at	  somewhat	  reduced	  efficiency.	  	  In	  devices	  with	  reduced	  numbers	  of	  source	  cells,	  cells	  retained	  sufficient	  CXCR4	  at	  the	  cell	  surface	  to	  migrate	  in	  response	  to	  the	  CXCL12	  gradient.	  	  These	  results	  highlight	  an	  essential	  balance	  in	  gradient	  formation	  between	  relative	  capacities	  of	  the	  source	  and	  sink	  to	  produce	  and	  scavenge	  ligand,	  respectively.	  	  Our	  data	  also,	  suggest	  that	  therapeutic	  targeting	  of	  CXCR7	  in	  chemotaxis	  will	  be	  contingent	  on	  relative	  CXCL12	  levels	  locally.	  Although	  CXCR7	  has	  been	  highlighted	  (25,	  26)	  as	  a	  critical	  mediator	  of	  CXCL12	  gradient	  formation	  and	  chemotaxis	  (25,	  26),	  we	  emphasize	  CXCL12	  isoforms	  as	  another	  largely	  overlooked	  mechanism	  for	  controlling	  gradient	  shape,	  local	  chemokine	  levels,	  and	  chemotaxis.	  	  CXCL12	  exists	  as	  six	  human	  (α,	  β,	  γ,	  δ,	  ε,	  and	  φ)	  and	  three	  mouse	  and	  rat	  (α,	  β,	  and	  γ)	  isoforms,	  which	  are	  expressed	  in	  time	  and	  tissue-­‐specific	  distributions	  during	  development	  and	  post-­‐natal	  life	  (28-­‐30).	  	  CXCL12	  isoforms	  share	  68	  common	  amino-­‐terminal	  amino	  acids,	  which	  comprise	  all	  of	  the	  most	  studied	  CXCL12-­‐α	  isoform	  and	  contain	  one	  glycosaminoglycan-­‐binding	  BBXB	  domain	  (B	  denotes	  basic	  and	  X	  denotes	  any	  amino	  acid,	  respectively).	  	  Other	  isoforms	  differ	  by	  addition	  of	  1-­‐41	  largely	  basic	  amino	  acids	  to	  the	  carboxy-­‐terminus,	  accounting	  for	  one	  and	  four	  additional	  BBXB	  motifs	  in	  CXCL12-­‐β	  and	  -­‐γ,	  respectively.	  	  Differences	  in	  carboxy-­‐termini	  among	  isoforms	  alter	  biologic	  and	  biophysical	  properties	  of	  CXCL12,	  including	  binding	  affinities	  for	  receptors	  and	  extracellular	  matrix	  molecules	  and	  activation	  of	  downstream	  signaling	  (27,	  29).	  In	  our	  model,	  despite	  adjusting	  the	  fraction	  of	  secreting	  cells	  to	  produce	  comparable	  levels	  of	  each	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isoform,	  we	  established	  for	  the	  first	  time	  in	  vitro	  that	  CXCL12-­‐γ	  maintains	  CXCR4	  sensitization	  and	  chemotaxis	  despite	  low	  chemokine	  levels	  and	  in	  the	  presence	  of	  AMD3100.	  	  Interestingly,	  CXCL12-­‐γ	  binds	  directly	  to	  CXCR4	  with	  lower	  affinity	  than	  CXCL12-­‐α	  or	  -­‐β,	  and	  yet	  our	  results	  show	  it	  functions	  as	  a	  high	  “effective”	  or	  multivalent	  affinity	  ligand	  for	  both	  CXCR4	  and	  cell	  surface	  proteoglycans	  in	  chemotaxis	  (27,	  29).	  	  We	  posit	  two	  mechanisms	  for	  this	  observation.	  	  One	  is	  that	  that	  CXCL12-­‐β	  and	  -­‐γ	  form	  sharper	  gradients	  due	  to	  relatively	  increased	  surface	  adhesion,	  both	  to	  cell	  and	  device	  surfaces.	  	  This	  notion	  is	  supported	  by	  the	  lack	  of	  absolute	  requirement	  for	  CXCR7	  scavenging	  cells	  to	  elicit	  chemotaxis.	  	  Another	  mechanism	  is	  that	  high	  affinity	  interactions	  between	  the	  more	  positively	  charged	  CXCL12-­‐β	  and	  -­‐γ	  and	  negatively	  charged	  cell	  surface	  proteoglycans	  increase	  local	  concentrations	  of	  chemokine	  to	  bind	  to	  CXCR4	  and	  drive	  migration	  (50).	  	  As	  a	  result,	  these	  isoforms	  promote	  chemotaxis	  at	  low	  total	  abundance	  and	  effectively	  compete	  with	  inhibitor	  AMD3100	  (See	  Appendix	  A	  Supplemental	  Discussion	  and	  Table	  A.2).	  	  By	  concentrating	  CXCL12	  isoforms	  on	  cell	  surfaces,	  we	  propose	  that	  heparan	  sulfates	  function	  as	  stable	  co-­‐receptors	  for	  CXCL12-­‐isoforms	  and	  CXCR4,	  enhancing	  activation	  of	  CXCR4-­‐β-­‐arrestin	  2	  signaling	  and	  chemotaxis	  relative	  to	  other	  isoforms	  (29,	  45,	  46,	  51-­‐53).	  	  	  While	  interactions	  between	  CXCL12	  and	  glycosaminoglycans	  are	  necessary	  for	  optimal	  chemotactic	  responses	  to	  this	  chemokine,	  interrelationships	  among	  glycosaminoglycan	  binding,	  chemokine	  oligomers,	  and	  chemotaxis	  remain	  uncertain	  (50,	  54).	  	  CXCL12	  bound	  to	  heparan	  sulfates	  may	  form	  dimers	  at	  physiologic	  concentrations	  of	  chemokine	  (39,	  55).	  	  CXCL12	  monomers	  have	  been	  reported	  to	  preferentially	  stimulate	  chemotaxis	  in	  some	  studies,	  while	  others	  have	  determined	  that	  CXCL12	  dimers	  comprise	  the	  more	  active	  species	  (39,	  54,	  56).	  	  Disparate	  results	  about	  potency	  of	  CXCL12	  monomers	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versus	  dimers	  in	  chemotaxis	  may	  be	  due	  to	  variable	  concentrations	  and	  presentations	  of	  chemokine	  and/or	  glycosaminoglycans	  in	  assays.	  	  Future	  studies	  adding	  heparan	  sulfates	  and	  other	  glycosaminoglycans	  to	  our	  device,	  combined	  with	  imaging	  reporters	  of	  dimers,	  may	  resolve	  this	  uncertainty	  (39).	  	  	  	  	  	  	  	  	  With	  the	  caveat	  of	  small	  sample	  size,	  a	  provocative	  observation	  of	  our	  study	  is	  detection	  of	  CXCL12-­‐α,	  -­‐β,	  and	  -­‐γ	  in	  human	  breast	  cancer	  with	  CXCL12-­‐γ	  only	  present	  in	  primary	  tumors	  from	  patients	  with	  metastases	  to	  lymph	  nodes	  or	  other	  organs.	  	  This	  result	  underscores	  previous	  descriptions	  of	  alternative	  splicing	  as	  transformative	  mechanism	  in	  cancer	  (57)	  and	  supports	  further	  studies	  of	  CXCL12-­‐γ	  as	  a	  biomarker	  for	  tumor	  microenvironments	  that	  promote	  metastasis.	  	  Similar	  to	  CXCL12,	  alternative	  splicing	  of	  vascular	  endothelial	  growth	  factor	  produces	  a	  functional	  range	  of	  short	  to	  long	  isoforms,	  with	  the	  longest	  and	  shortest	  having	  the	  highest	  and	  lowest	  heparan	  sulfate	  binding,	  respectively	  (58).	  	  However,	  in	  malignant	  transformation,	  alternative	  splicing	  switches	  towards	  expression	  of	  the	  more	  diffusible,	  short	  isoforms	  of	  VEGF	  in	  lung	  and	  colon	  cancers.	  	  Indeed,	  limited	  in	  vivo	  studies	  suggest	  that	  CXCL12-­‐γ	  drives	  chemotaxis	  to	  a	  much	  greater	  extent	  than	  CXCL12-­‐α	  or	  -­‐β,	  but	  standard	  in	  vitro	  assays	  fail	  to	  capture	  this	  phenotype	  and	  instead	  show	  CXCL12-­‐γ	  to	  be	  comparatively	  ineffective	  (27,	  59).	  	  One	  study	  in	  mice	  with	  mutated	  carboxy-­‐terminal	  BBXB	  domains	  showed	  exogenous	  delivery	  of	  CXCL12-­‐γ	  better	  recruited	  endothelial	  progenitor	  cells	  and	  restored	  vascular	  repair	  after	  acute	  ischemia	  as	  compared	  with	  exogenous	  CXCL12-­‐α	  (59).	  	  We	  further	  implicate	  CXCL12-­‐γ	  beyond	  post-­‐ischemic	  repair	  as	  a	  potential	  marker	  of	  advanced	  human	  breast	  cancer.	  	  	  We	  identified	  interdependence	  between	  levels	  of	  CXCL12	  isoforms	  and	  inhibition	  of	  chemotaxis	  with	  AMD3100.	  	  AMD3100	  only	  partially	  inhibited	  chemotaxis	  toward	  all	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isoforms	  with	  high	  levels	  of	  CXCL12,	  but	  the	  drug	  more	  effectively	  limited	  migration	  toward	  relatively	  lower	  amounts	  of	  CXCL12.	  	  However,	  even	  low	  levels	  of	  CXCL12-­‐β	  or	  -­‐γ	  drove	  CXCR4-­‐dependent	  chemotaxis	  in	  the	  presence	  of	  AMD3100,	  suggesting	  that	  the	  drug	  may	  be	  less	  effective	  against	  isoforms	  other	  than	  α.	  	  Our	  results	  are	  consistent	  with	  prior	  work	  showing	  that	  10-­‐fold	  more	  AMD3100	  is	  needed	  to	  block	  binding	  of	  CXCL12-­‐γ	  to	  CXCR4	  relative	  to	  CXCL12-­‐α	  (44).	  As	  CXCL12-­‐isoforms	  ostensibly	  confer	  signaling	  through	  the	  same	  CXCR4	  binding	  site,	  AMD3100	  should	  exhibit	  equal	  competitive	  inhibition	  of	  all	  isoforms.	  	  This	  point	  suggests	  that	  higher	  local	  concentrations	  of	  CXCL12-­‐β	  and	  -­‐γ	  effectively	  compete	  with	  AMD3100	  for	  binding	  to	  CXCR4.	  	  Although	  we	  detected	  modest	  amounts	  of	  mRNA	  for	  CXCL12	  isoforms	  in	  human	  cancers,	  these	  results	  suggest	  relatively	  few	  CXCL12-­‐β	  and	  -­‐β	  producing	  cells	  are	  required	  to	  drive	  migration.	  	  Shift	  of	  alternative	  splicing	  programs	  towards	  high	  potency	  CXCL12-­‐β	  and	  -­‐γ	  may	  enhance	  metastasis	  and	  drug	  resistance	  in	  advanced	  disease.	  	  Our	  results	  indicate	  the	  need	  for	  more	  potent	  agents	  to	  block	  chemotaxis	  in	  response	  to	  all	  isoforms	  of	  CXCL12.	  	  	  Our	  device	  facilitates	  gradient	  formation	  in	  a	  dynamic	  and	  cell-­‐autonomous	  way,	  unlike	  systems	  in	  which	  users	  introduce	  external	  gradients.	  	  The	  low,	  rising	  gradients	  in	  our	  device	  are	  less	  defined	  but	  more	  physiological	  than	  bolus	  doses	  in	  Boyden	  chambers	  and	  linear	  gradients	  generated	  in	  microfluidic	  systems.	  	  Nonetheless,	  we	  used	  several	  methods	  to	  quantify	  and	  perturb	  chemokine	  levels	  to	  understand	  their	  activities	  relative	  to	  reported	  dissociation	  constants	  for	  CXCL12-­‐isoforms	  to	  their	  receptors.	  	  First,	  we	  quantified	  the	  maximal	  soluble	  level	  of	  chemokine	  with	  a	  combination	  of	  ELISA,	  Gaussia	  luciferase	  assays,	  and	  signaling/uptake	  assays.	  	  Second,	  we	  varied	  isoform	  levels,	  numbers	  of	  cells	  secreting	  an	  isoform,	  efficiency	  of	  CXCR7-­‐dependent	  scavenging,	  and	  specific	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inhibitor	  AMD3100.	  	  Using	  these	  strategies	  we	  defined	  different	  qualitative	  functional	  regimes	  of	  the	  source-­‐sink	  components.	  	  Without	  improved	  real-­‐time	  chemokine	  measurement	  techniques	  and	  substantial	  computational	  modeling	  of	  this	  complex	  system,	  it	  is	  difficult	  to	  dynamically	  quantitate	  the	  soluble	  and	  more	  importantly	  bound	  levels	  of	  chemokine.	  	  Nonetheless,	  our	  device	  offers	  middle	  ground	  between	  migration	  assays	  of	  varying	  complexity:	  standard	  Boyden	  chambers,	  three-­‐dimensional	  hydrogel	  systems	  conditions	  (60),	  and	  in	  vivo	  physiology	  (61,	  62).	  	  	  Our	  device	  provides	  the	  first	  in	  vitro	  system	  that	  recapitulates	  observations	  in	  mouse	  models	  of	  enhanced	  chemotactic	  effects	  of	  CXCL12-­‐β	  and	  -­‐γ	  relative	  to	  α-­‐isoforms	  (27,	  63).	  	  Importantly,	  we	  emphasize	  that	  this	  device	  detects	  differences	  in	  chemotaxis	  among	  CXCL12	  isoforms	  secreted	  in	  the	  context	  of	  other	  molecules	  secreted	  by	  source	  cells.	  	  Our	  results	  differ	  markedly	  from	  standard	  Boyden	  chamber	  migration	  assays	  in	  which	  CXCL12-­‐α	  is	  most	  effective	  and	  cells	  migrate	  only	  in	  response	  to	  CXCL12-­‐γ	  lacking	  cationic	  BBXB	  domains	  or	  very	  high	  concentrations	  of	  wild-­‐type	  CXCL12-­‐γ	  (27).	  	  We	  propose	  several	  differences	  between	  our	  device	  and	  Boyden	  chambers	  allow	  us	  to	  replicate	  CXCL12-­‐β	  and	  -­‐γ	  in	  physiological	  conditions.	  	  Boyden	  chamber	  assays	  expose	  cells	  acutely	  to	  high	  levels	  of	  CXCL12,	  which	  may	  cause	  rapid	  CXCR4	  internalization	  and	  desensitization	  (44).	  	  We	  have	  shown	  that	  our	  device	  generates	  low,	  sustained	  gradients	  of	  CXCL12	  that	  may	  prevent	  CXCR4	  desensitization	  (11).	  	  Several	  studies	  suggest	  that	  low	  levels	  of	  CXCL12	  “prime”	  cells	  for	  signaling	  by	  recruiting	  additional	  cell-­‐surface	  CXCR4,	  as	  evidenced	  by	  increased	  HIV	  infection	  or	  β-­‐arrestin	  2	  recruitment	  after	  pre-­‐treatment	  with	  low	  amounts	  of	  CXCL12	  (36,	  43).	  	  The	  highly	  cationic	  C-­‐terminus	  of	  CXCL12-­‐β	  and	  -­‐γ	  also	  confers	  greater	  non-­‐specific	  binding	  to	  negatively-­‐charged	  tissue	  culture	  plastic,	  which	  may	  remove	  these	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chemokines	  from	  solution	  in	  standard	  Boyden	  chamber	  systems,	  altering	  the	  gradient	  profile	  and	  directionality.	  	  Binding	  of	  CXCL12	  to	  the	  migration	  surface	  of	  our	  microfluidic	  device	  may	  contribute	  to	  gradient	  formation	  in	  the	  direction	  of	  CXCR4+	  cell	  migration.	  	  Finally,	  observing	  migration	  along	  a	  longer	  distance	  in	  our	  device	  may	  be	  more	  representative	  of	  in	  vivo	  processes	  as	  compared	  to	  having	  cells	  squeeze	  through	  small	  pore	  over	  a	  very	  short	  distance	  in	  Boyden	  chambers	  (20).	  	  These	  and	  likely	  other	  factors	  allow	  our	  device	  to	  accurately	  reproduce	  in	  vivo	  chemotactic	  effects	  of	  CXCL12	  isoforms,	  providing	  a	  facile	  system	  to	  investigate	  functions	  and	  therapeutic	  targeting	  of	  various	  isoforms	  in	  chemotaxis.	  	  	  On	  the	  other	  end	  of	  assay	  complexity,	  extension	  of	  our	  cell-­‐based	  source-­‐sink	  model	  into	  three	  dimensions	  would	  better	  facilitate	  incorporation	  of	  glycosaminoglycans	  within	  a	  three	  dimensional	  hydrogel,	  and	  provide	  more	  in	  vivo-­‐like	  invasion/chemotaxis	  (60).	  	  We	  expect	  that	  incorporating	  heparan	  sulphate	  proteoglycan	  chemistry	  within	  a	  hydrogel	  matrix	  will	  sharpen	  gradients	  and	  limit	  gradient	  length	  scales,	  particularly	  for	  ligands	  with	  high	  matrix	  affinity.	  	  However,	  our	  device	  highlights	  the	  cell-­‐autonomous	  role	  in	  gradient	  formation	  due	  to	  ligand	  interactions	  with	  receptors,	  cell-­‐surface	  proteoglycans,	  and	  the	  device	  surface.	  	  In	  three	  dimensional	  hydrogel	  systems	  ligand-­‐matrix	  interactions	  dominate	  gradient	  formation.	  	  Nonetheless,	  understanding	  how	  source-­‐sink	  interactions	  facilitate	  gradient	  and	  chemotaxis	  dynamics	  in	  the	  context	  of	  three-­‐dimensional	  matrices	  and	  proteoglycans	  is	  an	  important	  next	  step	  to	  understanding	  in	  vivo	  physiology.	  
2.6 Conclusions	  Our	  study	  provides	  new	  insights	  into	  the	  chemotactic	  microenvironment	  and	  interdependencies	  between	  CXCL12-­‐secretion	  and	  bioavailability	  within	  the	  extracellular	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Figure	  2.1.	  Microfluidic	  source-­‐sink-­‐migration	  device.	  	  (A,	  B)	  Schematic	  multi-­‐layered	  microfluidic	  device	  fabrication	  and	  representation	  of	  patterned	  cell	  seeding.	  	  Controlled	  flow	  through	  bottom	  channels	  results	  in	  200	  µm	  wide	  cell	  patterns	  with	  200	  µm	  gaps.	  	  Parts	  i,	  ii,	  and	  iii	  depict	  stepwise	  addition	  of	  CXCL12-­‐secreting	  cells,	  CXCR7+	  cells,	  and	  CXCR4+	  cells,	  respectively.	  Parts	  iv	  and	  v	  represent	  conditions	  before	  and	  after	  migration.	  (C,	  D)	  Representative	  confocal	  images	  of	  patterned	  cells	  in	  the	  device	  at	  t=0	  (C	  corresponds	  to	  B	  iv)	  and	  after	  24	  hours	  (D	  corresponds	  to	  B	  v).	  	  The	  CXCL12	  secreting	  cells	  co-­‐express	  FP650	  (red);	  CXCR4+	  cells	  express	  NLS-­‐AcGFP	  (green);	  and	  CXCR7+	  cells	  are	  stained	  with	  Hoescht	  33342	  (blue).	  	  The	  dashed	  white	  line	  denotes	  channel	  boundaries	  that	  define	  the	  starting	  position.	  	  The	  graded	  red	  triangle	  below	  (D)	  denotes	  the	  gradient	  direction.	  (E-­‐G)	  Average	  position	  of	  CXCR4+	  cells	  after	  24	  hours	  of	  migration	  toward	  CXCL12-­‐α,	  -­‐β,	  or	  -­‐γ.	  	  Each	  point	  represents	  the	  mean	  position	  of	  ~300±50	  cells	  from	  1	  of	  6	  view	  fields	  from	  10-­‐11	  devices.	  	  Fraction	  of	  secreting	  cells	  denotes	  the	  relative	  dilution	  of	  CXCL12-­‐isoform	  secreting	  cells	  patterned	  with	  non-­‐secreting	  cells.	  Data	  are	  shown	  as	  mean	  values	  ±	  S.E.M.	  (n=6	  view	  fields	  for	  4-­‐11	  devices	  per	  condition).	  	  The	  bars	  represent	  statistical	  comparison	  between	  pairs	  of	  conditions.	  	  The	  arrow	  denotes	  multiple	  paired	  comparisons	  to	  the	  same	  condition	  (*p<0.05,	  ***p<0.005,	  ****p<0.0001).	  	  Data	  for	  100%	  and	  0%	  secreting	  cells	  are	  marked	  (#)	  to	  designate	  the	  same	  data	  plotted	  for	  comparison	  in	  multiple	  figures.	  	  Matched	  conditions	  were	  performed	  in	  parallel.	  	  (H-­‐J)	  	  Cells	  expressing	  a	  luciferase	  complementation	  reporter	  for	  association	  of	  CXCR4	  and	  β-­‐arrestin	  2	  were	  incubated	  with	  increasing	  equimolar	  concentrations	  of	  synthetic	  CXCL12-­‐α,	  β,	  or	  γ.	  	  Data	  were	  graphed	  as	  mean	  values	  ±	  S.E.M.	  (n=4	  measurements)	  from	  one	  of	  two	  representative	  experiments.	  	  Fold	  change	  in	  bioluminescence	  is	  relative	  to	  untreated	  cells	  at	  corresponding	  time	  points.	  	  The	  symbol	  §	  demarcates	  statistical	  differences	  by	  Tukey	  post	  hoc	  test	  between	  concentrations	  for	  the	  final	  time	  point.	  	  For	  CXCL12-­‐α,	  1nM	  is	  different	  from	  6nM	  (p<0.01)	  and	  10	  nM	  (p<0.01).	  	  For	  CXCL12-­‐β,	  1nM	  is	  different	  from	  6nM	  (p<0.05)	  and	  10	  nM	  (p<0.01).	  	  For	  CXCL12-­‐γ,	  1nM	  is	  different	  from	  all	  other	  concentrations	  (p<0.0001).	  	  Comparisons	  between	  isoforms	  are	  in	  supplemental	  information	  (Fig.	  A.6).	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Figure	  2.4.	  	  CXCR7	  scavenging	  is	  necessary	  for	  chemotaxis	  of	  CXCR4+	  cells	  in	  response	  to	  higher	  levels	  
of	  CXCL12.	  (A-­‐C)	  Migration	  of	  CXCR4+	  cells	  toward	  various	  fractions	  of	  cells	  secreting	  different	  isoforms	  of	  CXCL12	  in	  the	  presence	  of	  cells	  expressing	  either	  CXCR7-­‐WT	  or	  a	  mutant	  lacking	  the	  carboxy	  terminus	  of	  the	  receptor	  (CXCR7-­‐Δ322).	  Data	  are	  graphed	  as	  average	  position	  ±	  S.E.M.	  of	  migrating	  CXCR4+	  cells	  after	  24	  hours	  (n=6	  view	  fields	  each	  for	  4-­‐11	  devices	  per	  condition,	  similar	  to	  previous	  figures).	  Fraction	  of	  secreting	  cells	  denotes	  the	  relative	  dilution	  of	  CXCL12-­‐isoform	  secreting	  cells.	  	  The	  bar	  represents	  the	  statistical	  comparison	  between	  pairs	  of	  conditions.	  	  The	  arrow	  denotes	  multiple	  paired	  comparisons	  to	  the	  same	  condition	  (*p<0.05,	  **p<0.01,	  ****p<0.0001).	  	  Data	  for	  100%,	  10%,	  and	  0%	  secreting	  cells	  are	  marked	  (#)	  to	  designate	  the	  same	  data	  plotted	  for	  comparison	  in	  multiple	  figures.	  	  Matched	  conditions	  were	  performed	  in	  parallel.	  	  (D)	  Representative	  Z-­‐stack	  compressions	  of	  confocal	  images	  of	  CXCR4-­‐GFP+	  cells	  after	  24	  hours	  patterned	  in	  the	  context	  of	  dilutions	  of	  CXCL12-­‐β	  (0,	  10,	  and	  100%)	  and	  with	  WT	  and	  CXCR7-­‐Δ322	  cells.	  	  Red	  arrows	  highlight	  intracellular	  CXCR4-­‐GFP	  vesicles.	  	  White	  arrows	  denote	  cell	  membrane	  CXCR4-­‐GFP.	  	  (E)	  Time	  course	  quantification	  of	  CXCR4-­‐GFP	  intensity	  in	  devices	  patterned	  in	  the	  context	  of	  dilutions	  of	  CXCL12-­‐β	  source	  cells	  (0,	  10,	  and	  100%).	  	  The	  plot	  depicts	  the	  mean	  ±	  SEM	  of	  the	  ratio	  between	  average	  CXCR4-­‐GFP	  fluorescence	  intensity	  for	  devices	  with	  Δ322-­‐CXCR7	  relative	  to	  WT-­‐CXCR7	  (n=5	  images	  from	  one	  of	  two	  representative	  experiments).	  	  Two-­‐way	  ANOVA	  reveals	  significant	  time	  and	  source	  effects	  without	  significant	  interactions.	  	  The	  bars	  represent	  statistical	  significance	  by	  the	  Tukey	  post	  hoc	  test	  only	  for	  the	  100%	  source	  at	  the	  24	  hour	  time	  point	  (**	  p<0.01,	  ***,	  p<0.005).	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Table	  2.1	  CXCL12	  isoforms	  in	  human	  breast	  cancer.	  Numbers	  of	  samples	  positive	  for	  each	  isoform	  of	  CXCL12	  as	  determined	  by	  QRT-­‐PCR	  and	  total	  number	  of	  samples	  for	  normal	  breast	  tissue	  and	  various	  stages	  of	  primary	  human	  breast	  cancers.	  	  Transcripts	  amplified	  below	  40	  qRT-­‐PCR	  cycles	  and	  confirmed	  by	  gel	  electrophoresis	  were	   denoted	  as	  positive.	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3 Chapter Three: Systems for Three Dimensional Spheroid Imaging 
3.1 Summary	  Three-­‐dimensional	  culture	  systems	  bridge	  the	  experimental	  gap	  between	  in	  vivo	  and	  in	  vitro	  physiology.	  	  However,	  non-­‐standardized	  formation	  and	  limited	  downstream	  adaptability	  of	  three-­‐dimensional	  cultures	  have	  hindered	  mainstream	  adoption	  of	  these	  systems	  for	  biological	  applications,	  especially	  for	  low-­‐	  and	  moderate-­‐throughput	  assays	  commonly	  used	  in	  biomedical	  research.	  	  Here	  we	  build	  upon	  our	  recent	  development	  of	  a	  384	  well	  hanging	  drop	  plate	  for	  spheroid	  culture	  to	  design	  a	  complementary	  spheroid	  transfer	  and	  imaging	  (TRIM)	  plate.	  	  The	  low	  aspect	  ratio	  wells	  of	  the	  TRIM	  plate	  facilitated	  high	  fidelity,	  user-­‐independent,	  contact-­‐based	  collection	  of	  hanging	  drop	  spheroids.	  	  Using	  the	  TRIM	  plate,	  we	  demonstrated	  several	  downstream	  analyses	  including	  bulk	  tissue	  collection	  for	  flow	  cytometry,	  high-­‐resolution	  low	  working-­‐distance	  immersion	  imaging,	  and	  timely	  reagent	  delivery	  for	  enzymatic	  studies.	  	  Low	  working	  distance	  multi-­‐photon	  imaging	  of	  spheroids	  revealed	  cell-­‐type	  dependent,	  macroscopic	  spheroid	  structure.	  	  Unlike	  ovarian	  cancer	  spheroids,	  which	  formed	  loose,	  disc-­‐shaped	  spheroids,	  human	  mammary	  fibroblasts	  formed	  tight,	  spherical,	  and	  nutrient-­‐limited	  spheroids.	  	  Beyond	  the	  applications	  we	  describe	  here,	  we	  expect	  the	  hanging	  drop	  spheroid	  plate	  and	  complementary	  TRIM	  plate	  to	  facilitate	  analyses	  of	  spheroids	  across	  the	  spectrum	  of	  throughput,	  particularly	  for	  bulk	  collection	  of	  spheroids	  and	  high-­‐content	  imaging.	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3.2 Introduction	  Many	  cell	  culture	  applications	  are	  moving	  towards	  more	  physiological	  three	  dimensional	  model	  systems	  to	  bridge	  the	  gap	  between	  non-­‐physiological	  two-­‐dimensional	  platforms	  and	  in	  vivo	  conditions.	  	  Mass	  transport	  of	  drugs,	  nutrients,	  and	  metabolites	  in	  these	  systems	  is	  more	  representative	  of	  profiles	  of	  parameters	  such	  as	  hypoxia	  and	  metabolism.	  	  Despite	  these	  advantages,	  previous	  technologies	  for	  spheroid	  cultures	  were	  not	  used	  extensively	  due	  to	  lack	  of	  throughput	  (e.g.	  microfluidics),	  limited	  spheroid	  uniformity	  (e.g.	  rotating	  flasks),	  and	  cumbersome	  non-­‐standardized	  handling	  and	  analysis.	  	  Challenges	  to	  standardization,	  implementation,	  and	  analysis	  of	  three-­‐dimensional	  tissue	  cultures,	  have	  limited	  widespread	  adoption	  (1).	  	  Comparison	  and	  standardization	  of	  spheroid	  formation	  systems	  is	  also	  necessary	  to	  reconcile	  observed	  differences	  in	  gene	  expression	  and	  respiratory	  status	  for	  spheroids	  formed	  in	  hanging	  as	  compared	  to	  microfluidic	  systems	  (2).	  To	  address	  many	  of	  these	  issues,	  we	  developed	  a	  384	  hanging	  drop	  plate	  for	  high	  throughput	  formation	  and	  analysis	  of	  individual	  and	  uniform	  spheroids	  (3,	  4).	  	  Our	  hanging	  drop	  system	  consists	  of	  384	  through-­‐holes	  to	  facilitate	  formation	  of	  uniform	  spheroids	  and	  ready	  access	  to	  the	  medium	  via	  the	  through-­‐hole	  to	  exchange	  media,	  add	  treatments,	  or	  add	  cells	  at	  a	  defined	  time	  points.	  	  Other	  groups	  have	  developed	  systems	  for	  hanging	  drop	  formation	  that	  rely	  on	  gravity-­‐enforced	  cell	  assembly	  (5).	  	  The	  simplest	  but	  least	  stable	  strategy	  for	  hanging	  drop	  formation	  is	  to	  plate	  droplets	  on	  the	  underside	  of	  non-­‐adherent	  culture	  dishes	  (6).	  	  The	  company,	  InSphero	  also	  developed	  a	  96	  well	  gravity-­‐driven	  hanging	  drop	  system	  that	  uses	  a	  similar	  through-­‐hole	  strategy	  as	  our	  384	  well	  plate	  (7,	  8).	  	  Many	  imaging-­‐based	  analyses,	  however,	  require	  a	  spheroid	  to	  be	  transferred	  to	  a	  secondary	  dish	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for	  stable	  focusing.	  High	  fidelity	  transfer	  of	  hanging	  drop	  spheroids	  to	  a	  fixed	  substrate	  for	  downstream	  analysis	  requires	  highly	  parallel	  and	  consistent	  pipetting,	  which	  is	  inefficient	  and	  time	  consuming	  by	  hand	  and	  costly	  to	  automate.	  	  While	  the	  InSphero	  GravityTrap	  system	  enables	  transfer	  of	  96-­‐well	  array	  format	  hanging	  drop	  spheroids	  to	  a	  secondary	  96	  well	  plate	  substrate,	  it	  disallows	  immersion-­‐based	  imaging	  and	  facile	  bulk	  collection.	  	  	  Here	  we	  report	  the	  development	  of	  a	  transfer	  and	  imaging	  (TRIM)	  plate	  to	  expand	  the	  usefulness	  of	  the	  384	  hanging	  drop	  system	  and	  facilitate	  these	  previously	  difficult	  downstream	  analyses.	  	  We	  differentiate	  our	  system	  from	  the	  InSphero	  system	  based	  on	  increased	  throughput	  (384-­‐well	  array	  format	  vs	  96)	  and	  low	  aspect	  transfer	  wells	  that	  facilitate	  high-­‐fidelity	  spheroid	  capture,	  immersion-­‐based	  imaging,	  bulk	  spheroid	  collection,	  and	  timely	  enzyme-­‐substrate	  kinetic	  studies.	  	  
3.3 Materials	  and	  Methods	  
3.3.1 Plate	  design	  We	  used	  SolidWorks	  to	  conceptualize	  the	  TRIM	  plate	  in	  three	  dimensions.	  	  We	  fabricated	  the	  TRIM	  plate	  in	  the	  material	  Accura	  ®	  60	  (3DSystems)	  using	  the	  SLA	  Viper	  si2	  dual	  resolution	  SLA	  system,	  which	  is	  conducted	  by	  the	  University	  of	  Michigan	  Medical	  Innovation	  Center.	  	  The	  dimensions	  of	  the	  384	  wells	  are	  a	  total	  depth	  of	  1.25	  mm,	  which	  serves	  as	  the	  optical	  working	  distance,	  and	  a	  total	  well	  diameter	  of	  4	  mm.	  	  The	  wells	  are	  formatted	  as	  a	  standard	  384	  well	  plate	  to	  match	  the	  384	  hanging	  drop	  plate	  with	  a	  16	  by	  24	  array	  spaced	  every	  4.5	  mm.	  The	  inner-­‐wall	  dimensions	  of	  the	  original	  384	  hanging	  drop	  plate	  match	  the	  outer-­‐wall	  of	  the	  TRIM	  plate	  and	  serve	  as	  physical	  guides	  for	  high	  fidelity	  matching	  between	  droplets	  and	  wells.	  	  We	  developed	  a	  multi-­‐radial	  well	  contour	  to	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facilitate	  settling	  of	  the	  spheroid	  in	  the	  center	  of	  the	  well	  while	  limiting	  spheroids	  sticking	  in	  corners	  due	  to	  surface	  tension	  (Fig.	  B.2).	  	  Around	  the	  periphery	  of	  the	  plate	  there	  is	  a	  2	  mm	  ridge	  that	  guides	  medium	  overflow	  during	  bulk	  spheroid	  collection.	  
3.3.2 Cells	  and	  spheroid	  cultures	  We	  cultured	  all	  cells	  in	  DMEM	  supplemented	  with	  10%	  fetal	  bovine	  serum	  and	  1%	  antibiotic.	  	  We	  used	  several	  cell	  types	  to	  form	  spheroids,	  including	  MDA-­‐MB-­‐231	  breast	  cancer	  cells	  (ATCC),	  HeyA8	  ovarian	  cancer	  cells	  (gift	  of	  Gordon	  Mills,	  MD	  Anderson	  Cancer	  Center),	  and	  a	  human	  mammary	  fibroblast	  cell	  line	  expressing	  green	  fluorescent	  protein	  (GFP)	  (9).	  	  We	  transduced	  HeyA8	  ovarian	  cancer	  cells	  with	  a	  lentiviral	  vector	  for	  GFP	  and	  sorted	  for	  a	  population	  of	  stably	  transduced	  cells	  by	  flow	  cytometry	  (10).	  	  We	  previously	  have	  described	  MDA-­‐MB-­‐231	  cells	  stably	  expressing	  eqFP650,	  GFP,	  or	  firefly	  luciferase	  (11).	  	  We	  formed	  and	  maintained	  spheroids	  in	  25	  μl	  of	  culture	  medium	  as	  we	  described	  previously	  using	  the	  384	  hanging	  drop	  plate	  (3,	  4).	  	  
3.3.3 Contact	  based	  spheroid	  transfer	  and	  collection	  To	  transfer	  hanging	  drop	  spheroids	  we	  aligned	  the	  TRIM	  plate	  based	  on	  designed	  plate	  guides	  and	  lowered	  the	  hanging	  drop	  plate	  to	  contact	  the	  TRIM	  plate	  (Fig.	  3.1A-­‐D).	  	  We	  allowed	  spheroids	  to	  settle	  into	  the	  transfer	  wells	  for	  1-­‐2	  minutes	  to	  improve	  transfer	  efficiency.	  	  We	  evenly	  lifted	  and	  separated	  the	  hanging	  drop	  plate	  from	  the	  recipient	  TRIM	  plate	  for	  spheroid	  transfer.	  
3.3.4 Spheroid	  analysis	  and	  imaging	  For	  two-­‐photon	  imaging	  of	  spheroids,	  we	  used	  a	  25X	  objective	  (XLPLN,	  NA:	  1.05)	  and	  upright	  confocal	  and	  two-­‐photon	  microscope	  (Olympus	  MPE	  Twin)	  as	  we	  have	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described	  before	  (12).	  	  We	  imaged	  individual	  HeyA8	  spheroids	  and	  HMF	  spheroids	  both	  containing	  15,000	  cells	  per	  droplet.	  	  We	  very	  gently	  immersed	  the	  TRIM	  plate	  in	  growth	  medium	  after	  spheroid	  transfer	  for	  upright	  immersion	  microscopy.	  	  For	  imaging	  we	  maintained	  resolution	  and	  z-­‐step	  increment	  but	  varied	  the	  laser	  intensity	  between	  HMF	  and	  HeyA8	  spheroids	  due	  to	  differences	  in	  their	  overall	  fluorescent	  intensity.	  We	  collected	  100	  spheroids	  containing	  10,000	  cells	  total	  with	  different	  ratios	  (1:1	  and	  1:9)	  of	  231	  cells	  expressing	  either	  nuclear-­‐GFP	  or	  FP650	  for	  flow	  cytometry	  analysis	  (Fig.	  3.2).	  To	  collect	  spheroids	  we	  transferred	  them	  to	  the	  TRIM	  plate	  and	  used	  ~50	  ml	  of	  DMEM	  culture	  medium	  to	  wash	  spheroids	  from	  the	  TRIM	  plate	  into	  a	  50	  ml	  conical	  tube.	  	  We	  centrifuged	  the	  spheroids	  and	  resuspended	  the	  pellet	  in	  0.25%	  trypsin	  with	  EDTA.	  	  Once	  spheroids	  were	  dissociated,	  we	  neutralized	  trypsin	  with	  full	  DMEM	  medium,	  centrifuged	  the	  sample,	  and	  resuspended	  the	  cells	  in	  phosphate	  buffered	  saline	  for	  flow	  cytometry	  analysis.	  	  Flow	  cytometry	  was	  done	  using	  a	  Becton	  Dickinson	  FACS	  DiVa	  Flow	  Cytometer.	  	  We	  set	  the	  sort	  quadrants	  with	  excitation	  at	  488	  and	  633	  nm	  based	  on	  fluorescence	  negative	  MDA-­‐MB-­‐231	  cells	  (Fig.	  3.2B	  -­‐	  Negative	  Control).	  	  The	  quadrant	  statistics	  were	  determined	  with	  the	  Becton	  Dickinson	  software.	  	  	  For	  bioluminescence	  imaging	  we	  seeded	  154	  spheroids	  (every	  other	  well	  in	  384	  wells)	  containing	  10,000	  cells	  per	  drop	  total	  at	  a	  ratio	  of	  9:1	  HMF	  cells	  and	  MDA-­‐MB-­‐231	  cells	  expressing	  firefly	  luciferase.	  	  We	  plated	  water	  in	  the	  outer	  wells	  to	  minimize	  evaporation.	  	  Prior	  to	  transfer	  of	  spheroids	  to	  the	  TRIM	  plate,	  we	  added	  3	  μl	  of	  15	  mg/ml	  luciferin	  diluted	  4X	  in	  phosphate	  buffered	  saline	  to	  each	  corresponding	  well	  on	  the	  TRIM	  plate.	  	  Contact	  between	  the	  spheroid	  droplet	  and	  the	  pre-­‐plated	  luciferin	  caused	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simultaneous	  mixing	  of	  all	  transferred	  droplets.	  	  We	  quantified	  the	  number	  of	  wells	  with	  detectable	  bioluminescence	  of	  firefly	  luciferase	  as	  we	  have	  described	  before	  (Fig.	  B.1)	  (13).	  	  	  We	  stained	  HMF	  spheroids	  with	  trypan	  blue	  after	  3-­‐4	  days	  of	  culture	  to	  increase	  contrast	  by	  staining	  for	  dead	  cells.	  	  To	  stain	  the	  cells	  we	  added	  2	  μl	  of	  4X	  dilution	  of	  trypan	  blue	  in	  PBS	  to	  each	  droplet	  for	  4	  hours	  prior	  to	  transfer.	  	  We	  exchanged	  10	  μl	  of	  media	  twice	  to	  remove	  the	  residual	  trypan	  blue	  in	  each	  droplet.	  	  After	  transfer	  we	  imaged	  the	  TRIM	  plate	  with	  a	  white	  light	  back	  light	  using	  a	  5MP	  camera	  (Fig.	  3.1F).	  	  
3.4 Results	  and	  Discussion	  
3.4.1 Spheroid	  transfer	  and	  imaging	  The	  TRIM	  plate	  structure	  is	  complementary	  to	  the	  384	  hanging	  drop	  plate	  designed	  by	  our	  group	  with	  designs	  to	  enable:	  1)	  gentle,	  high-­‐fidelity	  contact-­‐based	  drop	  and	  spheroid	  transfer,	  2)	  bulk	  spheroid	  collection,	  and	  3)	  high-­‐resolution	  imaging	  with	  short	  optical	  working	  distance	  objectives	  (Fig.	  3.1,	  3.2,	  and	  3.3,	  respectively).	  	  The	  low	  aspect	  ratio	  of	  our	  plate	  is	  markedly	  different	  from	  the	  InSphero	  GravityTrap	  system,	  which	  disallows	  immersion	  imaging	  and	  bulk	  collection	  (7).	  	  We	  designed	  low	  aspect	  ratio	  wells	  less	  than	  2	  mm	  in	  depth,	  which	  is	  less	  than	  the	  height	  of	  the	  hanging	  25	  μl	  droplets	  for	  contact-­‐based	  drop	  transfer	  and	  low	  working	  distance	  immersion	  imaging	  	  (Fig.	  3.1D).	  	  A	  visual	  demonstration	  with	  dyed	  droplets	  illustrates	  the	  simple	  high-­‐fidelity	  transfer	  process	  using	  384	  droplets	  (Fig.	  3.1E-­‐F).	  	  The	  residual	  volume	  of	  liquid	  (~5μl)	  remains	  in	  the	  384	  hanging	  drop	  plate	  (Fig.	  3.1E	  top),	  but	  spheroids	  localize	  to	  the	  bottom	  of	  the	  droplet	  by	  gravity	  and	  transfer	  robustly	  (Fig.	  3.1F).	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We	  demonstrate	  100%	  spheroid	  capture	  efficiency	  (154/154)	  based	  on	  the	  number	  of	  bioluminescent	  spheroids	  that	  transferred	  to	  TRIM	  plate	  wells	  containing	  pre-­‐plated	  enzymatic	  substrate,	  luciferin	  (Fig.	  B.1).	  	  The	  benefit	  of	  measuring	  bioluminescence	  in	  spheroids	  was	  two-­‐fold.	  	  First	  we	  provided	  a	  quantitative	  demonstration	  of	  robust	  spheroid	  transfer,	  where	  only	  existing	  spheroids	  expressing	  firefly	  luciferase	  that	  transferred	  to	  wells	  with	  pre-­‐plated	  luciferin	  emitted	  a	  signal.	  	  Second,	  we	  highlighted	  the	  simultaneous	  initiation	  of	  bioluminescence	  kinetics	  for	  all	  spheroids	  via	  addition	  of	  enzymatic	  substrate	  to	  the	  spheroids	  at	  a	  discrete	  time.	  	  The	  timing	  and	  kinetics	  of	  enzyme-­‐substrate	  interactions	  are	  critical	  to	  many	  assays.	  	  Also,	  the	  magnitude	  and	  trajectory	  of	  the	  signal	  from	  an	  enzymatic	  assay	  in	  spheroids	  may	  be	  limited	  by	  enzyme	  concentration,	  substrate	  or	  ligand	  concentration,	  diffusion	  into	  the	  cell,	  or	  diffusion	  into	  the	  spheroid.	  	  For	  researchers	  performing	  time-­‐sensitive	  kinetics	  assays	  without	  access	  to	  an	  automated	  liquid	  handler,	  simultaneous	  administration	  of	  reagents	  is	  a	  distinct	  advantage.	  	  Rather	  than	  pipetting	  substrate	  or	  ligand	  into	  individual	  hanging	  drop	  wells	  in	  a	  time-­‐dependent	  manner,	  the	  TRIM	  plate	  enables	  facile	  and	  simultaneous	  administration	  of	  luciferin	  substrate	  to	  initiate	  measurements	  for	  kinetic	  assays.	  	  We	  envision	  using	  this	  strategy	  for	  administration	  of	  ligand	  and	  or	  luciferase	  substrate	  for	  more	  advanced	  bioluminescence	  applications,	  such	  as	  quantifying	  ligand-­‐receptor	  interactions	  or	  intracellular	  signaling	  in	  spheroids	  (14).	  	  In	  this	  situation	  we	  could	  use	  a	  multi-­‐channel	  or	  single	  pipette	  to	  dispense	  the	  ligand	  into	  the	  receiving	  plate,	  followed	  by	  initiation	  of	  signaling	  at	  the	  time	  of	  spheroid	  transfer.	  One	  challenge	  with	  analysis	  of	  adherence-­‐independent	  cultures	  like	  spheroids	  is	  to	  physically	  but	  reversibly	  immobilize	  the	  sample	  to	  minimize	  movement	  and	  facilitate	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organized	  downstream	  analysis.	  	  We	  highlight	  these	  challenges	  particularly	  for	  immersion	  imaging,	  where	  sample	  stability	  is	  at	  a	  premium	  and	  imaging	  in	  the	  hanging	  drop	  plate	  is	  impossible.	  	  Transfer	  of	  spheroids	  to	  a	  rigid	  substrate	  enhanced	  stability	  and	  allowed	  for	  immersion	  imaging.	  	  Although	  transfer	  to	  standard	  culture	  dishes	  is	  possible,	  movement	  due	  to	  flow	  in	  standard	  culture	  formats	  disrupts	  imaging.	  	  To	  improve	  this	  we	  implemented	  a	  multi-­‐curvature	  well	  contour	  (Fig.	  B.2)	  to	  facilitate	  settling	  of	  the	  spheroid	  to	  the	  direct	  center	  of	  each	  well	  (Fig.	  3.1F),	  rather	  than	  to	  the	  peripheral	  edges	  of	  standard	  flat	  bottom	  dishes.	  	  We	  found	  our	  well	  depth	  was	  optimal	  for	  low	  working	  distance	  objectives,	  but	  provided	  adequate	  resistance	  to	  spheroid	  movement	  by	  fluid	  flow.	  	  Organized	  transfer	  maintains	  the	  experimental	  setup	  of	  multiple	  conditions	  and	  enables	  imaging	  of	  spheroid	  conditions	  sequentially	  without	  losing	  track	  of	  particular	  conditions	  and	  the	  experiment	  organization.	  	  
3.4.2 Spheroid	  collection	  and	  analysis	  Standard	  two-­‐dimensional	  cell	  culture	  platforms	  are	  amenable	  to	  subcellular,	  single	  cell,	  and	  population	  analysis.	  	  While	  three-­‐dimensional	  and	  high-­‐resolution	  imaging	  applications	  discussed	  above	  address	  the	  two	  former	  analysis	  scales,	  population	  analysis	  for	  population-­‐,	  DNA-­‐,	  RNA-­‐,	  protein-­‐,	  and	  metabolite-­‐level	  assays	  requires	  high	  efficiency	  recovery	  of	  many	  cells,	  which	  is	  difficult	  in	  most	  three-­‐dimensional	  culture	  formats.	  	  We	  used	  the	  TRIM	  plate	  to	  collect	  bulk	  spheroids	  simultaneously	  for	  dissociation	  and	  analysis	  using	  flow	  cytometry.	  	  After	  transfer	  of	  spheroids,	  we	  released	  them	  by	  tilting	  the	  TRIM	  plate,	  directing	  flow	  from	  a	  pipette	  down	  into	  the	  wells,	  and	  collecting	  the	  overflow	  in	  a	  50	  ml	  conical	  tube	  (Fig.	  3.2A).	  	  Following	  enzymatic	  dissociation	  of	  the	  spheroids	  with	  trypsin,	  we	  analyzed	  spheroids	  containing	  1:9	  and	  1:1	  ratios	  of	  231	  cells	  expressing	  either	  GFP	  or	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FP650	  (Fig.	  3.2C-­‐D).	  	  We	  note	  that	  the	  FP650	  cells	  were	  not	  homogeneously	  expressing,	  causing	  them	  to	  show	  up	  in	  both	  bottom	  quadrants	  of	  the	  flow	  cytometry	  plot.	  	  However,	  these	  are	  still	  intensity	  shifted	  for	  FP650	  relative	  to	  the	  negative	  control	  (Fig.	  3.2C-­‐E).	  	  Our	  flow	  cytometry	  analysis	  closely	  matched	  the	  proportion	  of	  1:1	  and	  1:9	  for	  GFP	  to	  FP650	  by	  summing	  the	  bottom	  quadrants	  for	  the	  FP650	  cells	  and	  top	  quadrants	  for	  the	  GFP	  cells	  (Fig.	  3.2E-­‐F).	  	  	  
3.4.3 High	  resolution	  three	  dimensional	  imaging	  Since	  the	  spheroid	  settles	  to	  the	  lower	  curvature	  and	  is	  relatively	  fixed,	  we	  demonstrate	  imaging	  of	  the	  three-­‐dimensional	  volume	  of	  large	  spheroids	  using	  two	  photon	  microscopy	  (Fig.	  3.3A-­‐D)	  for	  HeyA8	  ovarian	  cancer	  (Fig.	  3.3A-­‐B)	  and	  HMF	  spheroids,	  both	  expressing	  GFP.	  	  We	  note	  the	  hemispherical	  disc	  shape	  of	  the	  ovarian	  cancer	  “spheroid”	  to	  be	  striking	  (Fig.	  3.3B),	  as	  the	  perception	  of	  a	  spheroid	  is	  understandably	  spherical.	  	  The	  HMF	  cells	  formed	  a	  smaller,	  tight	  structure	  with	  largely	  spherical	  morphology.	  	  The	  density	  of	  the	  HMF	  spheroid	  also	  led	  to	  metabolic	  limitations	  in	  the	  center	  of	  the	  spheroid,	  which	  we	  speculate	  decreased	  protein	  synthesis	  and	  resulted	  in	  lower	  GFP	  intensity.	  	  Based	  on	  the	  morphology	  of	  the	  spheroids,	  the	  shape	  of	  the	  HeyA8	  spheroid	  seems	  to	  be	  physically	  dictated	  by	  the	  droplet	  radius	  (Fig.	  3.3E,G).	  	  Others	  have	  observed	  disc-­‐like	  ovarian	  cancer	  spheroids	  that	  were	  formed	  in	  hanging	  droplets	  and	  cite	  the	  importance	  of	  defining	  the	  geometric	  spheroid	  morphology	  (15).	  	  The	  strong	  intracellular	  forces	  between	  the	  HMF	  cells,	  on	  the	  other	  hand,	  lead	  to	  a	  tight	  spherical	  shape	  (Fig.	  3.3F,H).	  	  Others	  have	  defined	  nutrient	  transfer	  limitations	  and	  hypoxia	  in	  three	  dimensional	  cell	  spheroids	  for	  structures	  above	  ~100-­‐200	  μm	  in	  diameter	  (16).	  	  However,	  nutrient	  limitations	  are	  very	  much	  cell-­‐type	  and	  spheroid-­‐shape	  dependent	  and	  must	  be	  characterized	  for	  new	  cells	  at	  the	  onset	  of	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a	  project.	  	  For	  defining	  nutrient	  limitations	  and	  hypoxia	  the	  complementary	  hanging	  drop	  and	  TRIM	  plates	  enable	  three-­‐dimensional	  multi-­‐photon	  image-­‐based	  screening	  of	  many	  combinations	  of	  cell	  types	  and	  conditions	  in	  parallel.	  	  
3.5 Future	  directions	  and	  opportunities	  Widespread	  adoption	  of	  three-­‐dimensional	  tissue	  culture	  is	  dependent	  on	  three	  aspects:	  ease-­‐of-­‐use,	  standardization,	  and	  scale.	  	  We	  previously	  developed	  a	  384	  well	  hanging	  drop	  plate	  to	  improve	  standardization	  of	  spheroid	  culture	  and	  spheroid	  uniformity.	  	  However,	  it	  is	  biased	  towards	  facilitating	  high-­‐throughput	  analyses,	  such	  as	  robotic	  automation	  and	  standard	  plate	  reader	  assays.	  	  Efficient	  tools	  for	  recovery	  of	  spheroids	  will	  broaden	  applicability	  of	  hanging	  drop	  spheroids	  and	  encompass	  the	  full	  spectrum	  of	  throughput,	  from	  high-­‐throughput	  analysis	  to	  low-­‐	  and	  moderate-­‐throughput	  analyses,	  such	  as	  high-­‐resolution	  imaging	  and	  flow	  cytometry.	  	  We	  used	  the	  TRIM	  plate	  to	  demonstrate	  facile	  handling	  for	  high	  resolution	  imaging	  of	  individual	  spheroids	  and	  flow	  cytometric	  analysis	  of	  bulk-­‐collected	  spheroids.	  	  The	  TRIM	  plate	  improves	  compatibility	  of	  hanging	  drop	  spheroids	  with	  low	  and	  moderate	  throughput	  analyses	  that	  are	  bioassay	  staples.	  	  We	  believe	  these	  systems	  substantially	  improve	  the	  utility	  of	  spheroid	  cultures	  for	  biomedical	  research,	  bridging	  the	  gap	  between	  low-­‐throughput	  in	  vivo	  models	  and	  standard	  two	  dimensional	  tissue	  culture	  systems.	  	  
3.6 Figures	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Figure	  3.1.	  	  Transfer	  and	  imaging	  of	  384	  hanging	  drop	  spheroids.	  (A)	  	  Schematic	  representation	  of	  the	  hanging	  drop	  plate	  and	  complementary	  TRIM	  plate.	  	  The	  circle	  in	  (A)	  defines	  the	  region	  detailed	  in	  panel	  (B).	  	  (C)	  Schematic	  depiction	  of	  hanging	  drop	  plate	  transfer	  with	  user-­‐independent	  alignment	  guides.	  	  The	  circle	  in	  (C)	  defines	  the	  region	  detailed	  in	  panel	  (D),	  showing	  contact	  dependent	  drop	  transfer.	  (E)	  Example	  images	  of	  the	  residual	  dye	  in	  the	  hanging	  drop	  plate	  (top)	  after	  transfer	  to	  the	  TRIM	  plate	  (bottom).	  	  The	  inset	  shows	  the	  bottom	  view	  of	  the	  hanging	  droplets	  prior	  to	  transfer.	  (F)	  Example	  image	  of	  500	  μm	  spheroids	  transferred	  from	  the	  hanging	  drop	  plate	  to	  the	  TRIM	  plate.	  	  Spheroids	  were	  stained	  with	  trypan	  blue	  for	  4	  hours	  prior	  to	  transfer	  to	  improve	  image	  contrast.	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Figure	  3.2.	  	  Spheroid	  collection	  for	  analysis	  by	  flow	  cytometry.	  (A)	  We	  co-­‐seeded	  spheroids	  with	  MDA-­‐MB-­‐231	  cells	  at	  ratios	  of	  9:1	  and	  1:1	  of	  cells	  expressing	  FP650	  or	  GFP,	  respectively.	  Schematic	  of	  spheroid	  collection	  by	  directing	  pipette	  flow	  into	  each	  well	  and	  collecting	  the	  overflow.	  	  After	  collection,	  centrifugation,	  and	  spheroid	  dissociation,	  we	  performed	  flow	  cytometry.	  	  (B-­‐F)	  Flow	  cytometry	  scatter	  plots	  show	  MDA-­‐MB-­‐231	  cells	  with	  no	  fluorescent	  protein	  (B),	  FP650	  only	  (C),	  GFP	  only	  (D),	  and	  9:1	  (E)	  and	  1:1	  (F)	  ratios	  of	  FP650	  and	  GFP	  cells,	  respectively.	  	  Note	  that	  we	  compare	  the	  top	  two	  quartiles	  to	  the	  bottom	  quartiles	  to	  estimate	  the	  relative	  seeding	  of	  FP650	  and	  GFP	  cells	  in	  order	  to	  capture	  the	  heterogeneity	  of	  the	  FP650	  cells.	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Figure	  3.3.	  Three	  dimensional	  imaging	  with	  the	  TRIM	  plate.	  	  (A)	  Example	  two-­‐photon	  z-­‐stack	  image	  of	  a	  large	  spheroid	  of	  HeyA8	  ovarian	  cancer	  cells	  expressing	  GFP	  and	  (B)	  the	  corresponding	  cross	  section	  with	  the	  location	  denoted	  by	  the	  dotted	  line	  in	  (A).	  	  (C)	  Example	  two-­‐photon	  z-­‐stack	  image	  of	  a	  large	  spheroid	  of	  HMF	  expressing	  GFP	  spheroid	  and	  (D)	  the	  corresponding	  cross	  section	  with	  the	  location	  denoted	  by	  the	  dotted	  line	  in	  (A).	  	  Arrows	  (B	  and	  D)	  denote	  the	  upward	  direction	  towards	  the	  objective.	  	  Unlike	  the	  ovarian	  cancer	  spheroid,	  the	  HMF	  spheroid	  is	  dense	  and	  nutrient	  limited	  resulting	  in	  lower	  internal	  fluorescence	  intensity	  denoted	  by	  *	  (D,H).	  	  Schematics	  of	  the	  spheroid	  morphology	  show	  HeyA8	  spheroids	  to	  curve	  with	  the	  droplet	  radius	  (E)	  and	  the	  HMF	  spheroid	  to	  be	  spherical	  (F).	  	  Loose	  interactions	  between	  HeyA8	  cells	  are	  permissive	  to	  nutrient	  transport	  within	  the	  spheroid	  (G),	  but	  tight	  intracellular	  forces	  limit	  transport	  into	  the	  spheroid	  (H).	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4 Chapter Four: Bone Marrow Co-Culture Model to Selectively Eliminate 
Quiescent Cancer Cells 
4.1 Summary	  Patients	  with	  many	  types	  of	  malignancy	  commonly	  harbor	  quiescent	  cancer	  cells	  in	  bone	  marrow.	  These	  cells	  ultimately	  may	  resume	  proliferation,	  causing	  late	  onset	  recurrences.	  Quiescent	  cells	  in	  bone	  marrow	  frequently	  resist	  current	  treatments	  because	  anticancer	  drugs	  typically	  are	  screened	  against	  dividing	  cancer	  cells.	  To	  meet	  the	  challenge	  of	  eliminating	  quiescent	  cancer	  cells	  from	  bone	  marrow	  while	  minimizing	  toxicity	  to	  stromal	  cells,	  we	  developed	  a	  384-­‐well	  3D	  spheroid	  model	  with	  few	  breast	  cancer	  cells	  co-­‐cultured	  with	  bone	  marrow	  stromal	  cells.	  Fluorescence	  and	  bioluminescence	  imaging	  revealed	  that	  cancer	  cells	  became	  reversibly	  arrested	  in	  G1	  phase	  of	  the	  cell	  cycle	  when	  co-­‐cultured	  with	  HS5	  bone	  marrow	  stromal	  cells,	  but	  proliferated	  rapidly	  with	  HS27A	  stromal	  cells.	  We	  identified	  individual	  and	  combinations	  of	  compounds	  that	  preferentially	  eliminated	  quiescent	  cancer	  cells	  but	  not	  stromal	  cells,	  establishing	  a	  new	  platform	  for	  analyzing	  and	  targeting	  quiescent	  cancer	  cells.	  We	  found	  that	  within	  quiescent	  co-­‐cultures	  and	  under	  cytotoxic	  stress,	  MDA-­‐MB-­‐231	  breast	  cancer	  cells	  become	  more	  sensitive	  to	  MEK	  inhibition.	  Extending	  this	  finding	  to	  a	  mouse	  model,	  we	  more	  effectively	  diminished	  bone	  marrow	  metastases	  using	  a	  combination	  of	  doxorubicin	  and	  MEK	  inhibition.	  This	  bone	  marrow	  co-­‐culture	  model	  provides	  a	  new	  platform	  to	  identify	  compounds	  that	  selectively	  target	  quiescent	  cancer	  cells.	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4.2 Introduction	  Current	  anticancer	  drugs	  typically	  target	  proliferating	  cells	  but	  have	  lower	  efficacy	  against	  quiescent	  cancer	  cells,	  leaving	  residual	  cancer	  cells	  that	  ultimately	  may	  cause	  recurrent	  disease	  even	  decades	  later.	  A	  major	  challenge	  in	  cancer	  therapy	  is	  eliminating	  quiescent	  cancer	  cells	  while	  limiting	  toxicities	  to	  normal	  tissues.	  To	  identify	  drugs	  and	  drug	  combinations	  that	  eradicate	  residual	  quiescent	  cancer	  cells,	  there	  is	  an	  unmet	  need	  for	  platforms	  that	  reproduce	  reversible	  cancer	  cell	  quiescence;	  allow	  simultaneous	  monitoring	  of	  cancer	  and	  stromal	  cells;	  and	  enable	  testing	  in	  formats	  amenable	  to	  high	  throughput	  testing.	  We	  meet	  these	  needs	  with	  a	  novel	  combination	  of	  multi-­‐modal	  imaging,	  a	  multi-­‐well	  format,	  and	  a	  3D	  spheroid	  co-­‐culture	  model	  that	  replicates	  quiescence	  of	  cancer	  cells.	  	  We	  focus	  on	  quiescent	  cancer	  cells	  in	  bone	  marrow,	  a	  major	  reservoir	  for	  single	  or	  microscopic	  foci	  of	  malignant	  cells	  in	  patients.	  Bone	  marrow	  biopsies	  show	  that	  as	  many	  as	  60%	  of	  patients	  with	  malignancies	  including	  breast,	  prostate,	  pancreas,	  non-­‐small	  cell	  lung,	  and	  melanoma	  have	  detectable	  cancer	  cells	  even	  in	  the	  absence	  of	  overt	  metastases	  (1,	  2).	  Interactions	  between	  cancer	  and	  bone	  marrow	  stromal	  cells	  critically	  regulate	  quiescence	  of	  malignant	  cells,	  potentially	  allowing	  malignant	  cells	  to	  remain	  viable	  for	  decades	  (3).	  Quiescent	  cancer	  cells	  ultimately	  may	  resume	  proliferation,	  contributing	  to	  established	  correlations	  of	  cancer	  cells	  in	  bone	  marrow	  with	  higher	  risk	  of	  disease	  recurrence	  and	  mortality	  (4,	  5).	  	  In	  addition	  to	  inducing	  quiescence	  of	  cancer	  cells,	  bone	  marrow	  is	  a	  key	  determinant	  of	  efficacy	  and	  side	  effects	  of	  chemotherapy.	  Bone	  marrow	  stromal	  cells	  confer	  drug	  resistance	  to	  malignant	  cells	  (6-­‐8),	  allowing	  cancer	  cells	  to	  survive	  standard	  chemotherapy.	  Ten	  to	  15%	  of	  patients	  with	  breast	  cancer	  have	  detectable	  malignant	  cells	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in	  bone	  marrow	  after	  adjuvant	  therapy,	  and	  these	  patients	  have	  a	  greater	  than	  three-­‐fold	  higher	  risk	  of	  disease	  recurrence	  (9).	  Conversely,	  damage	  to	  cells	  and	  the	  environment	  of	  bone	  marrow	  commonly	  complicates	  cancer	  chemotherapy,	  limiting	  dosing	  of	  many	  drugs	  and	  the	  ability	  to	  cure	  patients.	  Therefore,	  a	  drug-­‐testing	  platform	  to	  target	  cancer	  cells	  in	  bone	  marrow	  must	  model	  cancer-­‐stromal	  interactions	  and	  account	  for	  viability	  of	  malignant	  and	  stromal	  cell	  populations	  during	  treatment.	  	  The	  many	  cellular	  components	  of	  the	  bone	  marrow	  make	  modeling	  its	  physiology	  very	  difficult.	  Similar	  to	  the	  dichotomous	  maintenance	  or	  expansion	  of	  the	  hematopoietic	  stem	  cell	  (HSC)	  population,	  cancer	  cells’	  quiescence	  or	  growth	  takes	  place	  in	  different	  marrow	  niches,	  including	  the	  endosteal	  niche	  and/or	  the	  perivascular	  sinusoid.	  These	  marrow	  niches	  contain	  mesenchymal	  stroma,	  vascular,	  and	  immune	  cells,	  to	  name	  a	  few	  (10).	  We	  began	  with	  a	  simpler	  model	  by	  creating	  3D	  stromal	  spheroids	  of	  bone	  marrow	  derived	  mesenchymal	  stromal	  cell	  lines.	  The	  human	  stromal	  cell	  lines	  that	  we	  use	  (HS-­‐5,	  and	  HS-­‐27A)	  have	  divergent	  properties	  in	  their	  gene	  expression	  (11),	  secreted	  cytokines,	  extracellular	  matrix	  production,	  and	  morphology	  (12).	  These	  differences	  determine	  maintenance,	  growth,	  differentiation	  (12),	  apoptosis	  (13),	  engraftment	  (14),	  and	  drug	  sensitivity	  (15)	  of	  HSCs	  and/or	  cancer	  cells	  in	  vitro	  and	  in	  vivo.	  	  Existing	  in	  vitro	  models	  capture	  some	  aspects	  of	  the	  bone	  marrow	  environment	  but	  lack	  features	  needed	  for	  drug	  targeting	  of	  quiescent	  cancer	  cells.	  Two	  recent	  studies	  used	  a	  2D	  bone	  marrow	  co-­‐culture	  system	  or	  stromal	  conditioned	  media	  to	  identify	  compounds	  that	  overcome	  stromal-­‐mediated	  drug	  resistance.	  However,	  these	  studies	  did	  not	  consider	  cancer	  quiescence	  or	  toxicity	  to	  stromal	  cells	  (15,	  16).	  Studies	  in	  2D	  models	  also	  minimize	  or	  eliminate	  key	  aspects	  of	  bone	  marrow,	  including	  intercellular	  contacts,	  hypoxia	  and	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mass	  transport	  limitations	  of	  drugs	  (17-­‐19).	  Marlow	  et	  al	  used	  GelfoamTM	  3D	  biomatrix	  co-­‐cultures	  with	  different	  stromal	  cells	  to	  support	  growth	  or	  quiescence	  of	  cancer	  cells	  (20).	  While	  useful	  for	  mechanistic	  studies,	  the	  assay	  format	  precludes	  large-­‐scale	  screening	  of	  compounds	  to	  selectively	  eliminate	  cancer	  but	  not	  stromal	  cells.	  Our	  group	  and	  others	  also	  have	  shown	  cancer	  cell	  growth	  is	  diminished	  in	  3D	  co-­‐cultures,	  which	  also	  may	  also	  contribute	  to	  quiescent	  phenotypes	  (21).	  Therefore,	  both	  stromal	  co-­‐culture	  and	  the	  dimensionality	  of	  the	  assay	  control	  the	  growth	  of	  cancer	  cells.	  We	  developed	  a	  new	  3D	  spheroid	  co-­‐culture	  spheroid	  model	  of	  breast	  cancer	  cells	  and	  bone	  marrow	  stromal	  cells,	  using	  a	  combination	  of	  fluorescence	  and	  bioluminescence	  imaging	  to	  verify	  that	  cancer	  cells	  were	  in	  a	  quiescent	  or	  growing	  state.	  To	  quantify	  viability	  of	  both	  cancer	  and	  stromal	  cells	  in	  the	  same	  spheroid,	  we	  implemented	  a	  dual-­‐color	  click	  beetle	  luciferase	  assay	  in	  which	  cancer	  and	  stromal	  cells	  express	  green	  and	  red	  spectral	  variants,	  respectively.	  We	  demonstrated	  use	  of	  this	  dual-­‐color	  luciferase	  method	  to	  identify	  combinations	  of	  compounds	  that	  preferentially	  eliminate	  breast	  cancer	  cells	  from	  spheroids	  while	  minimizing	  toxicity	  to	  stromal	  cells.	  Importantly,	  a	  combination	  therapy	  identified	  in	  our	  spheroid	  model	  effectively	  eliminated	  quiescent	  breast	  cancer	  cells	  from	  bone	  marrow	  in	  a	  mouse	  tumor	  model,	  establishing	  that	  our	  spheroid	  assay	  models	  treatment	  efficacy	  in	  vivo.	  
4.3 Materials	  and	  Methods	  
4.3.1 Reagents	  We	  purchased	  all	  cell	  culture	  reagents	  from	  Life	  Technologies	  (Carlsbad,	  CA,	  USA)	  unless	  otherwise	  stated.	  We	  obtained	  drugs,	  compounds,	  and	  hormone	  supplements	  from	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the	  following	  sources:	  AG-­‐490,	  PD0325901,	  CP724714,	  MK-­‐2206	  2HCl,	  MK-­‐8669,	  GDC-­‐0941,	  Bazedoxifene	  HCl,	  Trametinib	  (GSK112021),	  and	  Fulvestrant	  from	  SelleckChem	  (Houston,	  TX,	  USA);	  AMD3100	  from	  Tocris	  Bioscience	  (Bristol,	  UK);	  SB-­‐431542	  from	  Caymen	  Chemical	  (MI,	  USA),	  4-­‐hydroxytamoxifen	  and	  β-­‐estradiol	  from	  Sigma	  Aldrich	  (St.	  Louis,	  MO,	  USA);	  and	  Cisplatin	  (NDC-­‐0703-­‐5748-­‐11),	  Paclitaxel	  (NDC-­‐55390-­‐304-­‐50),	  and	  Doxorubicin	  (NDC-­‐0069-­‐3030-­‐20),	  from	  the	  University	  of	  Michigan	  Hospital	  Pharmacy	  as	  clinical	  formulations.	  We	  prepared	  10	  mM	  stocks	  of	  estrogen	  in	  ethanol,	  while	  we	  used	  other	  drugs	  in	  formulations	  supplied	  or	  specified	  by	  manufacturers.	  Accumax	  was	  purchased	  from	  Innovative	  Cell	  Technologies	  (San	  Diego,	  CA,	  USA).	  
4.3.2 Cell	  lines	  and	  reporters	  All	  cells	  were	  maintained	  in	  10%	  FBS	  (HyClone,	  ThermoScientific,	  Waltham,	  MA,	  USA)	  DMEM	  (#11995,	  Life	  Technologies)	  supplemented	  with	  penicillin,	  streptomycin,	  and	  glutamine	  (Life	  Technologies).	  We	  passaged	  cells	  every	  two	  to	  four	  days	  by	  trypsinizing	  and	  resuspending.	  We	  received	  immortalized	  human	  mammary	  fibroblasts	  (HMF)	  as	  a	  gift	  from	  R.	  Weinberg	  (22).	  We	  obtained	  immortalized	  human	  bone	  marrow	  stromal	  cell	  lines	  HS-­‐5	  and	  HS27A,	  and	  breast	  cancer	  cell	  lines	  MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐468,	  SKBR3	  and	  T47D	  from	  the	  American	  Type	  Culture	  Collection.	  Plasmid	  contructs:	  CBRed	  was	  amplified	  from	  plasmid	  pCBR-­‐Basic	  (Promega,	  WI,	  USA)	  with	  PCR	  primers	  XbaI	  CBR	  forward	  5’-­‐ATTATCTAGAACCGCCATGGTAAAGCGTGAGAAAAATGTC-­‐3’	  and	  XbaI	  CBR	  reverse	  5’-­‐	  ATTATCTAGATTACTAACCGCCGGCCTTCACCAAC-­‐3’	  and	  CBG99	  was	  amplified	  from	  plasmid	  pCBG99-­‐Basic	  (Promega,	  WI,	  USA)	  with	  primers	  XbaI	  CBG99	  forward	  5’-­‐	  ATTATCTAGAACCGCCATGGTGAAGCGTGAGAAAAATGTC-­‐3’	  and	  XbaI	  CBG99	  reverse	  5’-­‐	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ATTATCTAGACTAACCGCCGGCCTTCTCCAACAATTG-­‐3’.	  These	  products	  were	  digested	  with	  XbaI	  and	  cloned	  into	  the	  XbaI	  site	  of	  FUW	  (gift	  of	  D.	  Baltimore).	  Clones	  were	  screened	  for	  forward	  orientation	  of	  the	  cDNA.	  Luc2	  was	  PCR	  amplified	  from	  the	  pGL4.10	  vector	  (Promega,	  WI,	  USA)	  with	  EcoRI	  and	  BamHI	  compatible	  ends	  and	  the	  resulting	  PCR	  product	  was	  digested	  and	  ligated	  into	  the	  EcoRI	  and	  BamHI	  multiple	  cloning	  site	  of	  pLVX-­‐EF1a-­‐IRES-­‐mCherry	  (Clontech,	  CA,	  USA).	  Plasmids	  Fucci	  C	  mKO2-­‐hCdt1(30/120)/pCSII-­‐EF-­‐MCS	  and	  Fucci	  D	  mAcGFP-­‐hGeminin(1/110)/pCSII-­‐EF-­‐MCS	  were	  a	  gift	  of	  A.	  Miyawaki	  (23).	  
4.3.3 Spheroid	  co-­‐culture	  model	  We	  formed	  spheroids	  in	  384-­‐well	  low	  volume,	  non-­‐adhesive,	  round	  bottom	  plates	  (Corning	  Incorporated	  #3676,	  Corning,	  NY,	  USA),	  which	  we	  sterilized	  with	  UV	  radiation.	  To	  form	  spheroids,	  we	  collected	  cells	  via	  trypsinization,	  neutralized	  trypsin	  with	  serum-­‐containing	  growth	  medium,	  centrifuged	  cells	  and	  aspirated	  medium	  to	  remove	  trypsin	  and	  serum,	  and	  re-­‐suspended	  cells	  in	  low	  serum	  phenol	  red	  free	  spheroid	  medium.	  Spheroid	  medium	  contains	  phenol	  red	  free	  DMEM	  (#31053,	  Life	  Technologies)	  supplemented	  with	  1%	  FBS	  (HyClone),	  0.1nM	  estrogen,	  penicillin/streptomycin/glutamine	  (Life	  Technologies),	  and	  pyruvate	  to	  match	  all	  but	  the	  serum	  content	  and	  phenol	  in	  standard	  growth	  medium.	  We	  seeded	  each	  well	  with	  1%	  MDA-­‐MB-­‐231	  or	  5%	  T47D	  cells	  expressing	  CBGreen	  FUCCI	  cells	  and	  the	  balance	  HS5s	  or	  HMFs	  expressing	  CBRed	  totaling	  3,000	  cells	  (200-­‐300μm	  diameter	  spheroids).	  The	  difference	  in	  percentage	  of	  cancer	  cells	  is	  based	  on	  initial	  viability	  of	  cells	  after	  seeding	  spheroids	  and	  brightness	  of	  CBGreen	  expression	  to	  optimize	  dual-­‐color	  measurements.	  For	  both	  spheroid	  maintenance	  and	  drug	  treatments,	  we	  replaced	  spheroid	  media	  in	  each	  plate	  every	  other	  day	  for	  the	  duration	  of	  an	  experiment	  by	  removing	  up	  to	  20µl	  from	  each	  well	  and	  replacing	  it	  with	  20µl	  fresh	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spheroid	  medium.	  For	  long-­‐term	  culture,	  we	  filled	  the	  outside	  wells	  around	  the	  periphery	  of	  the	  plate	  with	  medium	  only	  to	  minimize	  evaporation	  within	  experimental	  wells.	  We	  replicated	  each	  experimental	  condition	  in	  4-­‐7	  wells	  and	  performed	  experiments	  at	  least	  twice.	  We	  distributed	  controls	  both	  on	  the	  interior	  and	  exterior	  of	  each	  plate.	  	  We	  highlight	  the	  simplicity	  and	  flexibility	  of	  using	  existing,	  relatively	  low-­‐cost,	  low-­‐binding	  384	  round	  bottom	  plates	  to	  form	  co-­‐culture	  spheroids	  and	  induce	  cancer	  cell	  quiescence.	  Facile,	  long-­‐term	  culture	  is	  necessary	  for	  following	  quiescent	  cells,	  as	  changes	  in	  growth	  or	  death	  are	  prolonged.	  While	  the	  plates	  we	  selected	  were	  developed	  for	  chemical	  assays,	  the	  low-­‐binding	  surface	  and	  optimal	  geometry	  facilitate	  singular	  uniform	  spheroid	  formation.	  Spheroids	  in	  this	  format	  form	  rapidly	  (<24	  hours);	  are	  stable	  at	  least	  16	  days;	  and	  are	  amenable	  to	  high	  throughput	  robotic	  manipulation	  and/or	  analyses	  (bioluminescence,	  fluorescence,	  colorimetric,	  etc).	  Historically,	  multiple	  spheroids	  have	  been	  formed	  in	  lower-­‐throughput,	  non-­‐adherent	  96	  well	  plates.	  However,	  the	  larger	  volumes	  of	  these	  wells	  and	  movement	  of	  spheroids	  within	  a	  well	  limited	  the	  ease	  of	  exchanging	  medium,	  spheroid	  collection,	  and	  imaging.	  With	  our	  system,	  spheroids	  are	  geometrically	  restricted	  to	  the	  bottom	  and	  center	  of	  the	  small	  wells,	  facilitating	  rapid,	  albeit	  incomplete	  media	  exchange.	  We	  have	  adapted	  this	  spheroid	  culture	  to	  multiple	  cell	  types,	  including	  multiple	  cell-­‐type	  co-­‐cultures	  as	  we	  have	  described	  here.	  The	  flexibility	  of	  this	  system	  can	  be	  applied	  to	  many	  cell	  types,	  including,	  but	  not	  limited	  to,	  HS5	  and	  HMF	  stromal	  cells,	  as	  we	  show	  here.	  We	  highlight	  the	  ability	  to	  control	  growth	  kinetics	  of	  cancer	  cells	  depending	  on	  the	  stromal	  cell	  type.	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4.3.4 In	  vitro	  drug	  treatments	  	   We	  formed	  spheroids	  for	  two	  days	  in	  spheroid	  medium	  before	  beginning	  treatments	  with	  compounds	  at	  indicated	  concentrations.	  To	  establish	  baseline	  bioluminescence	  before	  treatment,	  we	  quantified	  bioluminescence	  in	  2-­‐4	  columns	  of	  each	  plate	  before	  adding	  compounds	  to	  remaining	  wells.	  We	  exchanged	  medium	  with	  fresh	  compounds	  diluted	  in	  spheroid	  medium	  every	  other	  day.	  For	  the	  treatment	  and	  recovery	  experiments,	  we	  imaged	  bioluminescence	  after	  8	  days	  of	  treatment	  and	  then	  exchanged	  20	  μl	  of	  media	  three	  times,	  which	  removes	  >99%	  of	  luciferin	  and	  drugs	  from	  each	  well.	  For	  recovery	  we	  continued	  exchange	  with	  fresh	  medium	  every	  other	  day.	  
4.3.5 Quiescence,	  dissociation,	  and	  colony	  outgrowth	  To	  test	  reversibility	  of	  cancer	  cell	  quiescence,	  we	  formed	  spheroids	  of	  MDA-­‐MB-­‐231	  or	  T47D	  cells	  as	  described	  above.	  After	  2	  and	  10	  days	  in	  spheroid	  culture,	  we	  performed	  two-­‐photon	  fluorescence	  microscopy	  of	  spheroids	  cell	  cycle	  status	  based	  on	  FUCCI	  reporters	  (orange,	  G1;	  green,	  S/G2/M).	  On	  the	  same	  days,	  we	  dissociated	  parallel	  spheroids	  for	  colony	  outgrowth	  in	  optimal	  2D	  growth	  conditions	  with	  full	  serum	  medium.	  To	  dissociate	  spheroids,	  we	  collected	  spheroids	  from	  a	  384	  well	  plate,	  washed	  in	  excess	  PBS,	  aspirated	  PBS,	  trypsinized	  briefly,	  and	  plated	  dissociated	  cells	  in	  6	  well	  plates	  containing	  full	  growth	  medium.	  After	  allowing	  1,	  4,	  and	  8	  days	  in	  adherent	  culture	  we	  imaged	  FUCCI	  status	  of	  colonies	  using	  epifluorescence	  and	  subsequent	  bioluminescence.	  For	  bioluminescence	  in	  2D	  cultures,	  we	  used	  1:100	  final	  dilution	  of	  150	  µg/ml	  luciferin.	  We	  note	  that	  faster	  outgrowth	  of	  cancer	  cells	  in	  2D	  cultures	  required	  discounting	  the	  CBRed	  image	  due	  to	  substantial	  CBGreen	  signal.	  After	  bioluminescence	  imaging,	  we	  replaced	  medium	  to	  remove	  luciferin.	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4.3.6 Animal	  models	  of	  bone	  metastasis	  and	  drug	  treatment	  All	  animal	  procedures	  were	  approved	  by	  the	  University	  of	  Michigan	  Committee	  for	  the	  Use	  and	  Care	  of	  Animals.	  To	  model	  bone	  metastases	  in	  mice,	  we	  delivered	  1	  x	  105	  MDA-­‐MB-­‐231	  cells	  expressing	  CBRed	  and	  FUCCI	  in	  100	  µl	  0.9%	  NaCl	  solution	  via	  intracardiac	  injection	  into	  the	  left	  ventricle	  of	  5-­‐9	  week	  old	  female	  NSG	  mice.	  We	  quantified	  bone	  metastases	  by	  bioluminescence	  imaging	  (24).	  We	  followed	  three	  separate	  protocols	  for	  dosing	  and	  observing	  mice.	  For	  monitoring	  the	  effect	  of	  trametinib	  on	  cell	  cycle	  status	  of	  MDA-­‐MB-­‐231	  cells	  in	  bone	  marrow,	  we	  allowed	  metastases	  to	  establish	  for	  16	  days.	  Thereafter,	  we	  treated	  daily	  with	  trametinib	  (1	  mg/kg	  by	  oral	  gavage)	  or	  vehicle	  control	  for	  11	  days	  at	  which	  time	  we	  recovered	  tissues	  for	  flow	  cytometry	  and/or	  ex	  vivo	  microscopy.	  For	  treatment	  with	  trametinib	  and/or	  doxorubicin,	  we	  began	  dosing	  either	  3	  or	  7	  days	  after	  intracardiac	  injection	  of	  cancer	  cells	  in	  experiments	  with	  few	  cancer	  cells	  or	  larger	  metastases,	  respectively.	  We	  administered	  a	  single	  dose	  of	  doxorubicin	  (5	  mg/kg	  i.p.)	  or	  vehicle	  control.	  We	  used	  only	  a	  single	  dose	  of	  doxorubicin	  because	  multiple	  doses	  of	  this	  drug	  are	  toxic	  to	  NSG	  mice.	  We	  treated	  mice	  with	  1	  mg/kg	  trametinib	  by	  oral	  gavage	  daily	  for	  5	  days	  beginning	  at	  the	  same	  time	  as	  dosing	  with	  doxorubicin.	  For	  all	  experiments,	  we	  formulated	  trametinib	  for	  gavage	  as	  described	  (25,	  26).	  Control	  mice	  received	  vehicle	  for	  both	  doxorubicin	  and	  trametinib	  in	  combination	  treatment	  studies.	  	  
4.3.7 Flow	  cytometery	  for	  FUCCI	  analysis	  To	  analyze	  the	  cell	  cycle	  status	  of	  cancer	  cells	  expressing	  the	  FUCCI	  reporter	  using	  flow	  cytometry,	  we	  collected	  spheroids	  from	  384	  wells	  of	  each	  stromal	  culture	  condition	  (HS5	  and	  HS27A).	  We	  allowed	  spheroids	  to	  settle,	  aspirated	  excess	  media,	  washed	  with	  an	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excess	  of	  PBS,	  allowed	  the	  cells	  to	  settle	  again,	  aspirated,	  and	  gently	  dissociated	  spheroids	  in	  Accumax	  per	  the	  manufacturer’s	  protocol.	  As	  a	  benchmark	  for	  FACS	  gating,	  MDA-­‐MB-­‐231	  cells	  that	  were	  plated	  24	  hours	  prior	  were	  collected	  at	  ~80%	  confluence.	  Gating	  was	  set	  such	  that	  ~50%	  of	  the	  single	  positive	  cells	  (mKO	  only	  or	  AcGFP	  only)	  from	  2D	  mono-­‐culture	  were	  in	  S/G2/M.	  This	  gating	  matches	  our	  microscopy-­‐based	  measure	  of	  cell	  cycle	  distributions.	  For	  flow	  cytometry	  analysis	  of	  bone	  marrow,	  we	  used	  PBS	  to	  flush	  bone	  marrow	  from	  the	  femur	  and	  tibia	  as	  described	  (27).	  We	  analyzed	  1x104	  events	  for	  spheroids	  and	  5	  x	  105	  events	  for	  bone	  marrow	  samples.	  Flow	  cytometry	  was	  performed	  on	  a	  BD	  FACS	  Aria	  II	  (Becton	  Dickenson,	  Franklin	  Lakes,	  NJ).	  	  
4.3.8 Click	  Beetle	  Red	  and	  Green	  Bioluminescence	  Imaging	  We	  captured	  all	  bioluminescence	  images	  with	  an	  IVIS	  Lumina	  Series	  III	  (Perkin	  Elmer,	  Waltham,	  MA,	  USA)	  and	  analyzed	  data	  with	  Living	  Image	  4.3.1.	  We	  separated	  signals	  from	  click	  beetle	  red	  and	  green	  luciferase	  as	  discussed	  previously	  (28).	  Briefly,	  we	  replaced	  5	  μl	  of	  each	  384	  well	  with	  a	  1:4	  dilution	  of	  150	  µg/ml	  luciferin,	  resulting	  in	  1:20	  final	  dilution	  of	  luciferin.	  After	  incubating	  at	  37°C	  for	  5	  minutes,	  we	  captured	  a	  3-­‐5	  minute	  exposure	  with	  medium	  binning	  and	  either	  520nm	  or	  680nm	  band	  pass	  filters.	  For	  imaging	  in	  2D	  standard	  culture	  conditions	  we	  used	  1:100	  final	  dilution	  of	  luciferin.	  	   	  
4.3.9 Fluorescence	  Microscopy	  We	  captured	  all	  microscopic	  images	  of	  spheroids	  with	  an	  upright	  Olympus	  MPE	  using	  a	  25X	  NIR	  corrected	  objective	  (XLPLN25XWMP,	  NA=1.05,	  Olympus,	  Tokyo,	  Japan).	  To	  facilitate	  semi-­‐high-­‐throughput	  upright	  immersion	  microscopy,	  we	  transferred	  spheroids	  from	  384	  well	  plates	  to	  low	  aspect	  ratio	  wells	  as	  we	  described	  previously	  (29).	  For	  images	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of	  hCDT-­‐mKO	  and	  hGeminin-­‐AcGFP	  (FUCCI)	  cells,	  we	  used	  920nm	  excitation	  and	  collected	  emitted	  light	  in	  green	  (495-­‐540nm)	  and	  red	  (575-­‐630nm)	  channels.	  For	  imaging	  cells	  expressing	  mCherry,	  we	  used	  740	  nm	  excitation.	  To	  limit	  signal	  attenuation	  throughout	  150	  μm	  stacks	  (5μm	  step	  size),	  we	  used	  the	  Olympus	  Bright-­‐Z	  function	  to	  adjust	  laser	  transmission	  to	  the	  sample	  and	  detector	  gain	  to	  maximize	  signal	  per	  slice	  as	  we	  have	  demonstrated	  previously	  (29).	  We	  used	  the	  same	  acquisition	  parameters	  for	  all	  spheroids	  compared	  within	  a	  single	  experiment.	  For	  epifluorescence	  images,	  we	  used	  an	  Olympus	  IX70	  microscope	  with	  a	  10X	  objective,	  imaging	  red	  and	  green	  channels	  as	  we	  have	  described	  previously	  (30).	  For	  imaging	  of	  mouse	  bone	  metastases,	  we	  removed	  femurs	  and	  rapidly	  cleaned	  the	  bone	  of	  adherent	  soft	  tissues.	  Using	  a	  Dremel	  Stylus	  and	  a	  small	  rounded	  tip,	  we	  gently	  removed	  cortical	  bone	  overlying	  sites	  of	  breast	  cancer	  cells	  identified	  by	  bioluminescence	  imaging.	  We	  imaged	  breast	  cancer	  cells	  by	  two	  photon	  microscopy	  as	  described	  for	  spheroids.	  	  
4.3.10 Data	  processing,	  plotting,	  and	  statistics	  We	  used	  Microsoft	  Excel	  (Seattle,	  WA,	  USA)	  to	  process	  bioluminescence	  photon	  flux	  data	  before	  plotting	  data	  using	  GraphPad	  Prism	  (San	  Diego,	  CA,	  USA).	  GraphPad	  Prism	  was	  also	  used	  for	  calculating	  statistics.	  Using	  GraphPad	  Prism,	  we	  also	  estimated	  IC50’s	  using	  four-­‐parameter	  non-­‐linear	  regression	  without	  weighting	  on	  log-­‐transformed	  concentration	  data.	  We	  generated	  surface	  plots	  with	  the	  surf	  function	  in	  MATLAB.	  All	  graphs	  display	  mean	  values	  ±	  standard	  error	  of	  the	  mean	  (S.E.M.)	  unless	  stated	  otherwise.	  We	  normalized	  curves	  to	  photon	  flux	  measurements	  obtained	  2	  and	  10	  days	  post	  seeding	  for	  growth	  and	  cytotoxicity	  assays,	  respectively.	  	  We	  propagated	  errors	  along	  each	  point	  for	  normalization.	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We	  calculated	  well-­‐by-­‐well	  selectivity	  of	  compounds	  by	  taking	  the	  log2	  transform	  of	  CBRed	  flux	  (R)	  divided	  by	  CBGreen	  flux	  (G).	  The	  log2	  transformation	  normalizes	  the	  distribution	  and	  facilitates	  visualization	  of	  results.	  We	  then	  subtract	  the	  log2	  ratio	  of	  the	  untreated	  control,	  which	  adjusts	  for	  differences	  in	  baseline	  CBRed	  and	  CBGreen	  brightness.	  Negative	  selectivity	  corresponds	  to	  either	  preferential	  growth	  of	  the	  CBGreen	  cancer	  cells	  or	  death	  of	  the	  CBRed	  HS5s.	  	  To	  quantify	  the	  fraction	  of	  cells	  in	  S/G2/M	  cells	  using	  the	  FUCCI	  reporter,	  a	  person	  blinded	  to	  experimental	  conditions	  manually	  counted	  the	  number	  of	  red	  or	  green	  cells	  using	  images	  with	  pseudo-­‐colored	  overlay.	  For	  2D	  cultures,	  we	  quantified	  a	  single	  slice	  for	  multiple	  view	  fields.	  For	  spheroids,	  we	  quantified	  a	  slice	  every	  15	  μm	  through	  a	  150	  μm	  volume.	  We	  calculated	  the	  ratio	  of	  cells	  in	  G1/0	  by	  dividing	  the	  number	  of	  green	  (G)	  cells	  divided	  by	  total	  orange	  and	  green	  (R+G)	  for	  each	  image.	  We	  noted	  very	  few	  cells	  with	  both	  green	  and	  orange,	  and	  we	  discounted	  these	  cells	  from	  calculations.	  For	  statistical	  comparisons	  of	  2D	  monoculture	  and	  3D	  co-­‐culture	  FUCCI	  ratios	  we	  applied	  the	  t-­‐test	  in	  GraphPad	  Prism.	  




4.4.1 Co-­‐culture	  spheroids	  induce	  growth	  of	  cancer	  cells	  or	  reversible	  quiescence	  	  We	  combined	  breast	  cancer	  cells	  (1-­‐5%	  of	  total	  cells)	  with	  human	  bone	  marrow	  stromal	  cells	  (HS5,	  HS27A),	  or	  human	  mammary	  fibroblasts	  (HMF)	  in	  non-­‐adherent	  384	  well	  plates.	  This	  low	  percentage	  of	  breast	  cancer	  cells	  in	  spheroids	  models	  the	  small	  numbers	  of	  cancer	  cells	  typically	  found	  in	  bone	  marrow	  while	  still	  giving	  sufficient	  signal	  for	  imaging.	  All	  stromal	  types	  formed	  uniform,	  compact	  spheroids	  by	  24	  (Supplemental	  Fig.	  C.1)	  hours	  and	  remained	  stable	  for	  at	  least	  16	  days.	  MDA-­‐MB-­‐231	  cells,	  a	  triple-­‐negative	  cell	  line,	  grew	  differently	  in	  HS5,	  HS27A,	  or	  HMF	  spheroids	  as	  quantified	  by	  green	  click	  beetle	  luciferase	  (Fig.	  4.1A,	  p	  <	  0.0001).	  Long	  doubling	  times	  for	  MDA-­‐MB-­‐231	  cells	  in	  spheroids	  (9.1,	  2.4,	  and	  3.3	  days,	  corresponding	  to	  1.8,	  10.3,	  and	  5.4-­‐fold	  change	  over	  8	  days)	  contrast	  starkly	  with	  24	  hour	  doubling	  in	  2D	  mono-­‐culture	  as	  we	  (Fig.	  4.1D)	  and	  others	  report	  (31).	  Doubling	  times	  for	  cell	  lines	  representing	  three	  other	  breast	  cancer	  subtypes	  (MDA-­‐MB-­‐468,	  triple-­‐negative;	  SKBR3,	  Her2	  amplified;	  and	  T47D,	  ER+/PR+)	  also	  were	  prolonged	  in	  spheroids,	  ranging	  from	  5.4-­‐10.2	  days	  (corresponding	  to	  2.8-­‐1.7	  fold	  change,	  respectively,	  over	  8	  days),	  regardless	  of	  stromal	  cell	  type	  (Fig.	  4.1A).	  Additionally,	  growth	  is	  increased	  for	  MDA-­‐MB-­‐231	  cells	  with	  all	  stromal	  cell	  types	  by	  increasing	  the	  percentage	  of	  fetal	  bovine	  serum	  in	  the	  cultures	  from	  1	  to	  10%	  (p	  <0.0001;	  Supplemental	  Fig.	  C.5A-­‐B).	  However,	  with	  increased	  fetal	  bovine	  serum	  the	  trends	  in	  cancer	  cell	  growth	  between	  stromal	  cell	  types	  remain	  with	  increasing	  growth	  in	  the	  order	  of	  HS5	  <	  HS27A	  (p	  <	  0.0001).	  To	  test	  whether	  the	  HS5	  cells	  were	  essential	  for	  viability	  of	  MDA-­‐MB-­‐231	  cells,	  we	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measured	  growth	  of	  the	  same	  number	  of	  cancer	  cells	  alone	  in	  non-­‐adherent	  suspension	  culture	  (Supplemental	  Fig.	  C.1B).	  Without	  stromal	  support	  the	  MDA-­‐MB-­‐231	  cells	  quickly	  die,	  suggesting	  that	  HS5	  cells	  limit	  growth	  of	  breast	  cancer	  cells	  while	  maintaining	  viability.	  This	  is	  in	  contrast	  to	  previous	  reports	  showing	  HS5	  and	  HS27A	  conditioned	  medium	  initiates	  apoptosis	  of	  cancer	  cells	  (13).	  In	  our	  system	  the	  stromal	  cells	  were	  necessary	  to	  maintain	  the	  cancer	  population.	  	  To	  further	  validate	  quiescence	  of	  cancer	  cells,	  we	  used	  an	  established	  fluorescent	  cell	  cycle	  indicator	  (FUCCI)	  to	  show	  that	  MDA-­‐MB-­‐231	  and	  T47D	  cells	  arrested	  in	  G1	  by	  day	  2	  in	  HS5	  spheroids	  relative	  to	  2D	  culture	  (Fig.	  4.1B-­‐C,	  Supplemental	  Fig.	  C.2)	  (23).	  Despite	  quiescence	  of	  breast	  cancer	  cells	  after	  2	  or	  10	  days	  in	  HS5	  spheroids,	  both	  MDA-­‐MB-­‐231	  and	  T47D	  cells	  remained	  viable,	  as	  evidenced	  by	  doubling	  times	  of	  ~0.9	  and	  1.5-­‐2	  days,	  respectively,	  after	  dissociating	  spheroids	  and	  returning	  cells	  to	  2D	  culture	  (Fig.	  4.1D-­‐E).	  Limited	  3D	  growth	  and	  substantial	  2D	  growth	  of	  T47D	  cells	  suggests	  these	  cells	  are	  more	  quiescent	  in	  spheroid	  cultures	  and	  may	  better	  reflect	  the	  likelihood	  of	  ER+	  cells	  to	  contribute	  to	  relapse.	  After	  dissociating	  co-­‐culture	  spheroids,	  cancer	  cells	  resume	  growth	  despite	  the	  presence	  of	  HS5	  cells	  in	  2D	  culture,	  suggesting	  quiescence	  is	  induced	  by	  3D	  interactions	  between	  cancer	  and	  stromal	  cells.	  	  
4.4.2 Dual-­‐color	  click	  beetle	  luciferase	  imaging	  of	  two	  cell	  populations	  To	  quantify	  effects	  of	  compounds	  on	  cancer	  versus	  stromal	  cells	  in	  intact	  spheroids,	  we	  implemented	  dual-­‐color	  bioluminescence	  imaging	  with	  click	  beetle	  green	  (CBGreen)	  and	  red	  (CBRed)	  luciferases	  (32)	  (Fig.	  4.2).	  Similar	  to	  firefly	  luciferase,	  click	  beetle	  green	  and	  red	  luciferases	  are	  ATP-­‐dependent	  enzymes	  that	  sensitively	  quantify	  relative	  numbers	  of	  viable	  cells.	  To	  characterize	  our	  ability	  to	  measure	  dual-­‐color	  luciferase	  activity	  without	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spectral	  deconvolution,	  we	  generated	  spheroids	  with	  increasing	  percentages	  of	  MDA-­‐MB-­‐231	  or	  HS5	  cells	  expressing	  CBGreen	  or	  CBRed,	  respectively.	  Based	  on	  the	  spectral	  overlap	  of	  CBGreen	  and	  CBRed	  (Fig.	  4.2A),	  we	  acquired	  images	  with	  filters	  centered	  at	  520	  and	  680	  nm.	  An	  increasing	  fraction	  of	  CBGreen	  cells	  produces	  linearly	  increasing	  signal	  measured	  in	  the	  520	  (green)	  and	  680	  nm	  (red)	  channels	  (Fig.	  4.2B,	  Supplemental	  Fig.	  C.3	  A-­‐E).	  The	  CBGreen	  signal	  is	  an	  order	  of	  magnitude	  less	  than	  CBRed	  when	  cancer	  cells	  are	  seeded	  at	  1-­‐10%	  of	  total	  cells	  in	  a	  spheroid	  (Fig.	  3.2B,	  Supplemental	  Fig.	  C.3A).	  Conversely,	  increasing	  the	  fraction	  of	  CBRed	  HS5	  cells	  in	  spheroids	  of	  unmarked	  HS5	  cells	  produced	  negligible	  overlap	  in	  the	  520	  nm	  channel	  with	  linearly	  increasing	  detection	  in	  the	  680	  nm	  channel	  (Fig.	  4.2B,	  Supplemental	  Fig.	  C.3B).	  These	  results	  established	  that	  CBRed	  does	  not	  leak	  into	  our	  CBGreen	  channel.	  Only	  when	  more	  than	  10%	  cancer	  cells	  are	  present	  in	  a	  spheroid	  does	  signal	  from	  CBGreen	  luciferase	  contribute	  substantially	  to	  signal	  from	  CBRed	  luciferase	  in	  the	  680	  nm	  channel.	  To	  avoid	  this	  problem,	  we	  maintained	  low	  levels	  (1-­‐5%)	  of	  cancer	  cells	  with	  CBGreen	  luciferase	  in	  all	  spheroid	  experiments.	  	  
4.4.3 Selective	  elimination	  of	  proliferating	  and	  quiescent	  cancer	  cells	  with	  cytotoxic	  and	  
targeted	  therapies	  We	  initially	  tested	  standard	  chemotherapy	  drugs	  against	  quiescent	  and	  proliferating	  breast	  cancer	  cells	  in	  bone	  marrow	  spheroids,	  using	  CBGreen	  and	  CBRed	  to	  quantify	  relative	  cytotoxicity	  to	  each	  population.	  To	  visualize	  the	  effects	  of	  drugs,	  we	  plotted	  the	  untreated-­‐	  and	  background-­‐normalized	  dose-­‐response	  curves	  for	  both	  cancer	  CBGreen	  and	  the	  stromal	  CBRed	  components,	  for	  both	  HS-­‐5	  and	  HS-­‐27	  co-­‐cultures	  (Fig.	  4.2C-­‐D).	  To	  quantify	  selectivity	  of	  a	  drug	  for	  cancer	  cells	  at	  defined	  concentrations,	  we	  calculated	  the	  log-­‐2-­‐scale	  ratio	  of	  CBRed	  (stromal)	  to	  CBGreen	  (cancer)	  bioluminescence.	  Log-­‐2	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normalization	  is	  typical	  for	  bioinformatics	  measures	  that	  compare	  to	  internal	  references	  (33)	  and	  for	  biological	  samples	  where	  doubling	  is	  physiological.	  Selectivity	  is	  always	  zero	  for	  untreated	  spheroids	  as	  both	  dose-­‐response	  curves	  start	  at	  one.	  Bioluminescence	  <	  1%	  of	  starting	  values	  produces	  high	  variability	  as	  the	  signal	  is	  close	  to	  background	  of	  the	  imaging	  system,	  so	  we	  removed	  these	  selectivity	  points	  from	  graphs.	  	  	  To	  compare	  effects	  of	  a	  compound	  to	  selectively	  eliminate	  MDA-­‐MB-­‐231	  cells	  in	  co-­‐cultures	  with	  HS5	  or	  HS27A	  cells,	  we	  plotted	  the	  CBGreen	  (cancer)	  dose-­‐response	  and	  corresponding	  selectivity	  from	  both	  stromal	  cell	  types	  on	  the	  same	  plot	  (Fig.	  4.3;	  green	  and	  black	  curves	  from	  Fig.	  4.2C-­‐D	  combined	  into	  Fig.	  4.3C).	  Treatment	  with	  cisplatin,	  paclitaxel,	  and	  doxorubicin	  produced	  typical	  sigmoidal	  cytotoxicity	  curves	  for	  MDA-­‐MB-­‐231	  cells	  within	  HS5	  and	  HS27A	  spheroids	  (Fig.	  4.3A-­‐C).	  Cisplatin	  produced	  markedly	  higher	  IC50	  values	  for	  quiescent	  MDA-­‐MB-­‐231	  cells	  than	  their	  counterpart	  HS5	  cells,	  reflecting	  negative	  selectivity	  and	  greater	  toxicity	  of	  this	  drug	  to	  HS5s	  (Fig.	  4.3A,C;	  IC50’s	  summarized	  in	  Supplemental	  Fig.	  C.10).	  By	  comparison,	  these	  drugs	  had	  lower	  IC50	  values	  and	  positive	  selectivity	  for	  MDA-­‐MB-­‐231	  cells	  relative	  to	  HS27A	  cells,	  likely	  due	  to	  greater	  proliferation	  of	  the	  cancer	  cells	  in	  this	  environment.	  Doxorubicin	  was	  the	  only	  cytotoxic	  therapy	  to	  have	  highly	  positive	  selectivity	  against	  MDA-­‐MB-­‐231	  cells	  in	  HS27A	  spheroids	  and	  non-­‐negative	  selectivity	  when	  cultured	  with	  HS5	  cells.	  Unlike	  the	  mainly	  cell	  cycle-­‐based	  mechanism	  for	  cytotoxicity	  of	  cisplatin	  and	  paclitaxel,	  doxorubicin	  has	  multiple	  mechanisms	  including	  both	  cell	  cycle-­‐based	  (intercalating	  DNA)	  and	  mitochondrial-­‐based	  effects	  (34).	  We	  also	  measured	  a	  similar	  IC50	  shift	  for	  MDA-­‐MB-­‐231	  cells	  proliferating	  in	  HMF	  spheroids	  as	  compared	  with	  quiescent	  of	  cancer	  cells	  in	  HS5	  spheroids	  (Supplemental	  Fig.	  C.1D).	  Quiescent	  T47D	  cells	  responded	  similarly	  to	  MDA-­‐MB-­‐231	  cells	  cultured	  in	  HS5	  spheroids	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(Supplemental	  Fig.	  C.4A-­‐C).	  Overall,	  only	  doxorubicin	  showed	  modest	  selectivity	  in	  eliminating	  proliferating	  and	  quiescent	  MDA-­‐MB-­‐231	  cells	  and	  quiescent	  T47Ds.	  These	  data	  show	  that	  looking	  at	  IC50	  shifts	  along	  with	  selective	  elimination	  of	  cancer	  cells	  is	  more	  informative	  than	  IC50	  shift	  only.	  	   We	  also	  targeted	  constitutively	  active	  KRas	  in	  MDA-­‐MB-­‐231	  cells	  with	  PD0325901,	  an	  inhibitor	  of	  the	  downstream	  mitogen	  activated	  protein	  kinase,	  MEK	  (35).	  While	  PD0325901	  selectively	  eliminated	  MDA-­‐MB-­‐231	  cells	  in	  both	  quiescent	  and	  proliferative	  settings,	  selectivity	  increased	  and	  the	  IC50	  value	  decreased	  for	  eliminating	  quiescent	  MDA-­‐MB-­‐231	  cells	  in	  HS5	  spheroids	  as	  compared	  with	  proliferating	  cancer	  cells	  in	  HS27A	  spheroids	  (Fig.	  4.3D).	  This	  result	  is	  opposite	  to	  effects	  of	  doxorubicin	  in	  these	  two	  different	  bone	  marrow	  environments.	  The	  trends	  in	  efficacy	  and	  selectivity	  between	  doxorubicin	  and	  PD0325901	  become	  more	  pronounced	  when	  proliferation	  is	  stimulated	  by	  adding	  10%	  serum	  to	  spheroid	  cultures	  (Supplemental	  Fig.	  C.5).	  The	  IC50	  and	  selectivity	  of	  PD0325901	  for	  MDA-­‐MB-­‐231	  cells	  decreased	  with	  additional	  serum	  stimulating	  growth,	  suggesting	  reduced	  dependence	  on	  MEK	  signaling.	  The	  opposite	  was	  true	  for	  doxorubicin,	  again	  supporting	  that	  the	  drug	  preferentially	  affects	  dividing	  cells,	  but	  maintains	  activity	  against	  quiescent	  cells.	  
4.4.4 Limited	  or	  non-­‐selective	  effect	  for	  many	  cancer	  compounds	  A	  provocative	  result	  revealed	  by	  our	  dual-­‐color	  spheroid	  system	  was	  that	  many	  compounds	  and	  drugs	  developed	  to	  eliminate	  proliferating	  cancer	  cells	  were	  ineffective	  against	  quiescent	  cancer	  cells	  in	  spheroids.	  These	  compounds	  include	  inhibitors	  of	  PI3-­‐kinase,	  mTOR,	  TGF-­‐β,	  Her2,	  and	  CXCR4	  (Tables	  C.1-­‐4).	  Notably,	  estrogen	  receptor	  (ER)	  inhibitors	  did	  not	  affect	  quiescent	  ER+	  T47D	  cells	  in	  bone	  marrow	  spheroids,	  which	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parallels	  persistence	  of	  breast	  cancer	  cells	  in	  patients	  treated	  with	  these	  drugs.	  Additionally,	  we	  found	  several	  compounds	  with	  non-­‐selective	  toxicity	  to	  both	  cancer	  cells	  and	  stromal	  cells	  (Supplemental	  Fig.	  C.7-­‐8)	  or	  preferential	  elimination	  of	  stromal	  cells	  (PI3-­‐kinase	  inhibitor	  GDC-­‐0491)	  (Supplemental	  Fig.	  C.7B,	  C.8B).	  These	  results	  highlight	  the	  utility	  of	  our	  dual	  color	  imaging	  strategy	  to	  differentially	  measure	  effects	  of	  various	  targeted	  compounds	  on	  quiescent	  cancer	  versus	  stromal	  cells.	  	  
4.4.5 Drug	  combinations	  increase	  selectivity	  in	  vitro	  We	  tested	  combination	  treatments	  to	  expand	  the	  therapeutic	  window	  for	  doxorubicin	  against	  quiescent	  MDA-­‐MB-­‐231	  cells.	  We	  incubated	  cells	  with	  increasing	  concentrations	  of	  PD0325901	  and	  doxorubicin	  alone	  or	  in	  combination	  for	  8	  days	  and	  quantified	  selectivity.	  After	  removing	  drugs,	  we	  also	  cultured	  spheroids	  for	  an	  additional	  6	  days	  to	  identify	  delayed	  effects	  on	  cell	  viability,	  similar	  to	  patients	  treated	  with	  intermittent	  cycles	  of	  chemotherapy.	  3D	  surface	  plots	  showed	  that	  treatment	  with	  PD0325901	  alone	  produced	  a	  maximum	  selectivity	  of	  ~4.0	  at	  100nM	  after	  8	  days	  (Fig.	  4.4A).	  Interestingly,	  selectivity	  for	  doxorubicin	  against	  cancer	  cells	  increased	  after	  6	  days	  of	  recovery	  (Fig.	  4.4B).	  Conversely,	  selectivity	  for	  intermediate	  concentrations	  of	  PD0325901	  decreased	  after	  recovery,	  perhaps	  due	  to	  cytostatic	  rather	  than	  cytotoxic	  effects	  at	  sub-­‐lethal	  concentrations	  of	  this	  compound.	  Treatment	  with	  100nM	  PD0325901	  and	  1μM	  doxorubicin	  produced	  additive	  effects	  with	  peak	  selectivity	  of	  6.6	  after	  recovery.	  MEK	  activation	  has	  been	  shown	  to	  be	  a	  compensatory	  response	  to	  doxorubicin	  treatment	  in	  multiple	  types	  of	  cancer,	  so	  combination	  treatment	  with	  PD0325901	  can	  block	  this	  potential	  mechanism	  of	  drug	  resistance	  (36-­‐38).	  These	  results	  also	  show	  cancer	  burden	  is	  reflected	  accurately	  by	  imaging	  after	  8	  days	  of	  treatment.	  Post	  treatment	  rebound	  is	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minimized	  due	  to	  more	  effective	  elimination	  of	  cancer	  cells	  with	  the	  combination	  of	  doxorubicin	  and	  PD0325901.	  	  We	  also	  targeted	  Jak2	  signaling	  in	  MDA-­‐MB-­‐231	  cells	  since	  HS5	  cells	  constitutively	  secrete	  IL6,	  a	  known	  activator	  of	  Jak2-­‐Stat3	  signaling	  in	  breast	  cancer	  progression	  (Supplemental	  Fig.	  C.6A-­‐C)	  (39,	  40).	  While	  treatment	  with	  the	  Jak2	  inhibitor	  AG490	  produced	  minimal	  selectivity	  for	  cancer	  cells,	  we	  observed	  highest	  post-­‐recovery	  selectivity	  for	  AG490	  combined	  with	  doxorubicin	  (Supplemental	  Fig.	  C.6B-­‐C).	  These	  results	  highlight	  how	  our	  system	  can	  identify	  combinations	  of	  compounds	  with	  greater	  toxicity	  to	  quiescent	  cancer	  versus	  stromal	  cells.	  	  
4.4.6 Modeling	  and	  imaging	  bone	  marrow	  metastasis	  	  To	  model	  formation	  of	  metastases	  and	  drug	  response	  in	  mice,	  we	  delivered	  MDA-­‐MB-­‐231	  cells	  carrying	  both	  FUCCI	  and	  CBGreen	  via	  intracardiac	  injection.	  By	  one	  week	  ~80%	  of	  mice	  carried	  bone	  marrow	  metastases	  detectable	  by	  bioluminescence.	  We	  observed	  quiescent	  cells	  in	  metastases	  in	  bone	  marrow	  based	  on	  ex	  vivo	  two	  photon	  imaging	  of	  cell	  cycle	  status	  (Fig.	  4.5A-­‐C).	  Most	  metastases	  were	  located	  near	  metaphases	  of	  bone,	  but	  the	  size,	  cell	  density,	  microenvironment,	  and	  cell	  cycle	  status	  of	  separate	  lesions	  varied	  greatly.	  As	  representative	  examples,	  we	  found	  small	  metastases	  comprised	  predominantly	  of	  cells	  in	  G1/G0	  near	  the	  endosteum	  of	  bone	  (Fig.	  4.5A).	  Large,	  cell-­‐dense,	  established	  metastases	  showed	  a	  proliferative	  exterior	  and	  cell	  cycle	  arrested	  interior,	  similar	  to	  the	  stratifications	  in	  a	  primary	  tumor	  (Fig.	  4.5B).	  We	  also	  observed	  proliferating	  breast	  cancer	  cells	  near	  blood	  vessels	  and	  bone	  marrow	  stroma	  (Fig	  4.5C).	  These	  images	  demonstrate	  the	  presence	  of	  quiescent	  and	  proliferating	  environments	  in	  bone	  marrow,	  comparable	  to	  our	  spheroid	  models	  and	  prior	  studies	  on	  hematopoietic	  stem	  cells	  (41,	  42).	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To	  verify	  these	  imaging	  findings,	  we	  recovered	  bone	  marrow	  from	  tumor-­‐bearing	  mice	  and	  analyzed	  cell	  cycle	  status	  by	  flow	  cytometry	  (Fig.	  4.5D-­‐E;	  Supplemental	  Fig.	  C.9).	  Approximately	  10%	  of	  MDA-­‐MB-­‐231	  cells	  from	  bone	  marrow	  were	  in	  S/G2/M	  (Fig.	  4.5D),	  comparable	  to	  the	  percentage	  measured	  by	  two	  photon	  microscopy	  and	  flow	  cytometry	  in	  MDA-­‐MB-­‐231	  cells	  co-­‐cultured	  with	  HS5	  cells	  in	  spheroids	  (Fig.	  4.1B,	  Supplemental	  Fig.	  C.2).	  Daily	  treatment	  with	  trametinib,	  a	  clinically	  approved	  MEK	  inhibitor	  that	  closely	  replicates	  kinetics	  and	  functions	  of	  PD0325901,	  shifted	  essentially	  all	  breast	  cancer	  cells	  to	  G1/G0	  phase	  of	  the	  cell	  cycle	  and	  decreased	  the	  total	  amount	  of	  cancer	  cells	  in	  bone	  marrow	  (Fig	  4.5D-­‐G).	  These	  data	  indicate	  that	  trametinib	  diminishes	  cancer	  burden	  in	  both	  quiescent	  and	  proliferative	  bone	  marrow	  environments,	  paralleling	  results	  in	  spheroids.	   	  
4.4.7 Bone	  marrow	  spheroid	  model	  predicts	  combination	  therapy	  effective	  against	  bone	  
marrow	  metastases.	  	  We	  tested	  combination	  therapy	  with	  MEK	  inhibition	  and	  doxorubicin	  on	  experimental	  bone	  metastases	  with	  MDA-­‐MB-­‐231	  cells.	  To	  replicate	  limited	  numbers	  of	  cancer	  cells	  in	  bone	  marrow,	  we	  began	  treatment	  three	  days	  after	  intracardiac	  injection	  of	  cancer	  cells.	  We	  treated	  mice	  with	  either	  a	  single	  dose	  of	  doxorubicin,	  four	  doses	  of	  trametinib,	  both	  drugs,	  or	  vehicle	  only.	  We	  used	  bioluminescence	  to	  quantify	  bone	  metastases	  and	  regrowth.	  After	  treatment	  of	  mice	  (8	  days	  post-­‐intracadiac	  injection)	  and	  an	  additional	  week	  of	  no	  treatment,	  we	  recovered	  and	  dissociated	  bone	  marrow	  from	  lower	  extremities	  and	  allowed	  outgrowth	  of	  cancer	  cells	  in	  standard	  2D	  cell	  culture.	  Combination	  treatment	  with	  doxorubicin	  and	  trametinib	  completely	  eliminated	  outgrowth	  of	  MDA-­‐MB-­‐231	  cells	  in	  vitro	  with	  0/8	  legs	  measuring	  positive	  for	  cancer	  cells	  (Fig.	  4.6D-­‐E).	  Doxorubicin	  and	  trametinib	  individually	  reduced	  the	  numbers	  of	  mice	  with	  viable	  cancer	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cells	  in	  lower	  extremity	  bone	  marrow	  to	  3/8	  and	  5/11,	  respectively,	  as	  compared	  to	  7/10	  for	  the	  vehicle	  (Fig.	  4.6A-­‐C,E).	  For	  bone	  marrow	  plates,	  trametinib,	  doxorubicin,	  and	  their	  combination	  significantly	  decreased	  growth	  of	  bioluminescent	  cancer	  cells	  in	  vitro	  by	  86%,	  99%,	  and	  100%	  as	  compared	  to	  vehicle	  (p	  <	  0.05).	  	  In	  a	  separate	  experiment,	  we	  tested	  these	  same	  drug	  treatments	  in	  mice	  with	  larger	  metastases	  established	  7	  days	  after	  intracardiac	  injection.	  While	  single	  agent	  therapy	  showed	  a	  trend	  toward	  reduced	  tumor	  burden	  in	  bone,	  only	  combined	  treatment	  with	  trametinib	  and	  doxorubicin	  statistically	  lowered	  growth	  compared	  with	  vehicle	  control	  (Fig.	  C.11C;	  p	  <	  0.01).	  Combination	  therapy	  was	  most	  effective	  in	  a	  subset	  of	  metastases,	  as	  highlighted	  by	  responsive	  lesions	  below	  the	  dotted	  line	  in	  Figure	  C.11C,	  which	  correspond	  to	  the	  top	  pair	  of	  bioluminescence	  images	  in	  Figure	  C.11B.	  The	  partial	  response	  may	  be	  due	  to	  heterogeneity	  of	  microenvironments	  in	  bone	  marrow	  (see	  Fig	  4.5A-­‐C).	  Variations	  in	  response	  also	  may	  reflect	  that	  large	  and/or	  growing	  metastases	  dominate	  the	  bioluminescent	  signal.	  	  
4.5 Discussion	  Eliminating	  quiescent	  cancer	  cells	  is	  a	  major	  challenge	  to	  successfully	  and	  completely	  eradicate	  cancer	  from	  patients	  for	  at	  least	  three	  reasons.	  Firstly,	  drugs	  are	  typically	  designed	  to	  target	  functions	  of	  rapidly	  dividing	  cells	  (e.g.	  mitosis,	  DNA	  replication/repair,	  growth	  signals)	  but	  not	  quiescent	  cancer	  cells.	  Secondly,	  malignant	  cells	  are	  housed	  in	  protective	  microenvironments	  (e.g.	  bone	  marrow),	  which	  may	  contribute	  to	  quiescence	  or	  other	  resistance	  phenotypes.	  Thirdly,	  dosing	  is	  often	  attenuated	  or	  terminated	  due	  to	  toxicity	  to	  other	  tissues,	  such	  as	  the	  hematopoietic	  system.	  Therefore,	  experimental	  models	  are	  needed	  to	  identify	  and	  test	  therapies	  to	  eliminate	  quiescent	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cancer	  cells	  while	  sparing	  stromal	  cells	  within	  a	  representative	  microenvironment.	  Our	  bone	  marrow	  model	  addresses	  these	  shortcomings	  for	  drug	  screening	  by	  providing	  a	  facile	  approach	  to	  test	  compounds	  selectively	  targeting	  quiescent	  or	  dividing	  cancer	  cells	  but	  not	  the	  surrounding	  bone	  stromal	  cells.	  The	  novelty	  of	  our	  system	  is	  three-­‐fold:	  1)	  we	  establish	  a	  simple	  but	  flexible	  model	  of	  cancer	  cell	  quiescence	  in	  a	  3D	  environment;	  2)	  we	  use	  multiple	  modes	  of	  imaging	  to	  monitor	  cell	  cycle	  status	  and	  viability	  of	  both	  cancer	  and	  stromal	  cells;	  and	  3)	  we	  investigate	  single	  and	  combinatorial	  treatments	  to	  identify	  compounds	  that	  selectively	  eliminate	  quiescent	  cancer	  cells.	  Data	  from	  our	  animal	  model	  indicate	  the	  spheroid	  system	  can	  identify	  treatments	  effective	  against	  cancer	  cells	  in	  actual	  bone	  marrow	  environments.	  	  As	  compared	  with	  other	  existing	  co-­‐culture	  systems,	  our	  3D	  bone	  marrow	  spheroid	  model	  is	  simple,	  reproducible	  and	  amenable	  to	  high	  throughput	  applications.	  Several	  systems	  exist	  on	  a	  continuum	  of	  complexity	  for	  recreating	  the	  microenvironment	  of	  the	  bone	  marrow	  environment.	  These	  assays	  include	  standard	  2D	  assays	  (16),	  3D	  spheroids,	  and	  more	  complicated	  GelfoamTM	  3D	  biomatrix-­‐based	  assays	  (20).	  Co-­‐culture	  2D	  assays	  are	  less	  than	  physiological	  in	  terms	  of	  cell-­‐cell	  interactions,	  substrate	  stiffness,	  induction	  of	  quiescence,	  and	  replication	  of	  a	  3D	  environment	  in	  vivo.	  Here	  we	  confirm	  and	  build	  upon	  our	  previous	  results	  that	  cancer	  cells	  grow	  more	  slowly	  in	  3D	  co-­‐cultures	  as	  compared	  to	  2D	  (21).	  3D	  spheroids	  better	  reproduce	  parameters	  including	  hypoxia,	  cell-­‐cell	  contacts,	  stiffness,	  and	  concentration	  of	  secreted	  factors,	  which	  may	  contribute	  to	  differences	  in	  growth	  based	  on	  dimensionality.	  However,	  optimizing	  spheroid	  uniformity,	  ease	  of	  use,	  and	  throughput	  has	  been	  an	  area	  of	  substantial	  work	  in	  the	  past	  several	  decades.	  We	  have	  developed	  several	  systems	  for	  establishing	  defined,	  uniform,	  and	  stable	  spheroids	  in	  both	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microfluidic	  channels	  (21)	  and	  a	  high	  throughput	  384	  hanging	  drop	  plate	  (43,	  44).	  These	  systems	  have	  challenges	  of	  throughput	  and	  stability,	  respectively.	  Other	  methods	  for	  spheroid	  assays	  also	  are	  limited	  by	  ease	  of	  use	  and	  throughput,	  including	  rotary	  flasks,	  non-­‐adherent	  dishes,	  or	  other	  more	  advanced	  surface	  or	  device	  configurations	  (17,	  18).	  We	  describe	  additional	  practical	  considerations	  and	  advantages	  of	  our	  system	  in	  the	  Methods.	  We	  leveraged	  our	  spheroid	  system	  and	  fluorescence	  and	  bioluminescence	  imaging	  modalities	  to	  monitor	  cancer	  cell	  quiescence	  and	  viability	  of	  both	  cancer	  and	  stromal	  cells.	  Firstly,	  we	  used	  two-­‐photon	  imaging	  of	  spheroids	  to	  monitor	  cell	  cycle	  arrest	  of	  cancer	  cells	  with	  an	  established	  fluorescent	  ubiquitin-­‐based	  cell	  cycle	  indicator	  (FUCCI)	  (23).	  Using	  this	  strategy	  we	  confirmed	  that	  cancer	  cells	  reversibly	  arrested	  in	  G0/1	  in	  spheroids	  with	  HS5	  bone	  stromal	  cells.	  Secondly,	  we	  optimized	  dual-­‐color	  click	  beetle	  luciferase	  imaging	  to	  measure	  two	  cell	  populations	  without	  spectral	  deconvolution.	  The	  high	  sensitivity	  of	  bioluminescence	  imaging	  allowed	  us	  to	  readily	  measure	  very	  low	  numbers	  of	  cancer	  cells	  (30-­‐150	  cells	  per	  spheroid,	  or	  1-­‐5%	  of	  total	  cells).	  By	  forming	  spheroids	  with	  few	  cancer	  cells,	  we	  not	  only	  modeled	  rare	  numbers	  of	  quiescent	  cancer	  cells	  in	  bone	  marrow	  but	  also	  cleanly	  separated	  click	  beetle	  green	  and	  red	  bioluminescence	  from	  cancer	  and	  stromal	  cells,	  respectively.	  	  Although	  few	  tested	  compounds	  effectively	  or	  selectively	  eliminated	  cancer	  cells,	  we	  found	  combinations	  of	  therapies	  that	  improved	  elimination	  of	  MDA-­‐MB-­‐231	  cells	  after	  sequential	  dosing	  and	  recovery	  for	  six	  and	  eight	  days,	  respectively.	  By	  measuring	  selectivity	  of	  responses,	  we	  also	  found	  that	  an	  inhibitor	  of	  Jak2-­‐Stat3	  only	  selectively	  eliminated	  cancer	  cells	  in	  combination	  with	  doxorubicin.	  The	  MEK	  inhibitor	  PD0325901	  produced	  strongly	  selective	  reduction	  of	  MDA-­‐MB-­‐231	  burden,	  particularly	  in	  combination	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with	  doxorubicin.	  Multiple	  reports	  show	  compensatory	  MEK-­‐dependent	  response	  upon	  challenge	  with	  doxorubicin	  (36-­‐38).	  Combination	  of	  sub-­‐maximal	  doses	  of	  both	  doxorubicin	  and	  PD0325901	  may	  limit	  toxicities	  and	  improve	  elimination	  of	  cancer	  cells	  from	  bone	  marrow.	  	  Several	  lines	  of	  evidence	  support	  that	  MDA-­‐MB-­‐231	  cells	  become	  additionally	  dependent	  on	  MEK	  signaling	  both	  while	  quiescent	  in	  HS5	  co-­‐cultures	  and	  stressed	  via	  doxorubicin.	  Firstly,	  efficacy	  of	  PD0325901	  is	  diminished	  in	  growth	  supportive	  environments	  with	  increased	  serum	  and	  HS27A	  co-­‐culture.	  Secondly,	  selective	  elimination	  of	  cancer	  cells	  persisted	  after	  six	  days	  of	  compound-­‐free	  recovery	  only	  when	  PD0325901	  was	  combined	  with	  doxorubicin.	  These	  data	  suggest	  that	  challenge	  with	  doxorubicin	  or	  quiescence	  culture	  conditions	  suppress	  growth	  and	  make	  cancer	  cells	  more	  susceptible	  to	  MEK	  inhibition.	  We	  highlight	  three	  aspects	  of	  our	  bone	  marrow	  model	  system	  as	  it	  relates	  to	  replicating	  bone	  marrow	  metastases.	  Firstly,	  our	  in	  vitro	  models	  of	  cancer	  growth	  and	  quiescence	  begin	  to	  capture	  the	  heterogeneity	  of	  bone	  marrow	  microenvironments	  and	  their	  resulting	  phenotypes.	  Screening	  for	  drugs	  that	  selectively	  eliminate	  cancer	  cells	  in	  multiple	  stromal	  support	  conditions	  will	  better	  predict	  successful	  treatment	  of	  bulk,	  growing	  disease,	  and	  quiescent	  cells	  that	  contribute	  to	  late	  relapse.	  Secondly,	  our	  in	  vitro	  spheroid	  model	  with	  HS5	  cells	  showed	  ≈	  90%	  of	  MDA-­‐MB-­‐231	  cells	  in	  G1/G0,	  comparable	  to	  that	  quantified	  for	  cancer	  cells	  recovered	  from	  mouse	  bone	  marrow.	  Finally,	  the	  combination	  treatment	  with	  a	  MEK	  inhibitor	  and	  doxorubicin	  effectively	  eliminated	  breast	  cancer	  cells	  in	  bone	  marrow	  as	  predicted	  by	  our	  in	  vitro	  model.	  Our	  in	  vitro	  model	  predicted	  in	  vivo	  decrease	  of	  tumor	  cell	  burden	  upon	  single	  agent	  treatment	  with	  trametinib	  or	  doxorubicin.	  More	  provocatively,	  our	  in	  vitro	  model	  predicted	  substantial	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outgrowth	  of	  cancer	  cells	  post-­‐treatment	  for	  single	  agent	  therapy	  but	  near	  total	  elimination	  with	  dual	  therapy.	  Together	  these	  data	  suggest	  that	  our	  in	  vitro	  system	  begins	  to	  capture	  the	  quiescent	  phenotype	  and	  heterogeneity	  of	  responses	  in	  the	  bone	  marrow.	  Results	  from	  our	  model	  system	  highlight	  the	  value	  of	  combined	  fluorescence	  and	  bioluminescence	  imaging	  to	  reveal	  effects	  of	  treatment.	  Bioluminescence	  imaging	  provides	  a	  real	  time	  measure	  of	  relative	  cancer	  burden	  in	  spheroids	  and	  mice.	  Additionally,	  we	  use	  bioluminescence	  to	  locate	  in	  vivo	  metastases	  for	  fluorescence	  imaging	  of	  cell	  cycle	  status	  within	  different	  bone	  marrow	  locations.	  	  Pairing	  bioluminescence-­‐based	  in	  vivo	  location	  and	  burden	  with	  fluorescence-­‐based	  analyses	  of	  cell-­‐level	  status	  provides	  a	  detailed	  view	  of	  treatment	  efficacy.	  This	  optical	  imaging	  strategy	  is	  amenable	  to	  many	  other	  bioluminescent	  and	  fluorescent	  reporters,	  such	  as	  tracking	  receptor-­‐ligand	  binding	  via	  bioluminescence	  (45)	  and/or	  apoptosis	  via	  fluorescence	  (46).	  We	  expect	  further	  testing	  with	  this	  spheroid	  model	  and	  multi-­‐modal	  imaging	  will	  reveal	  additional	  compounds	  and/or	  combinations	  to	  effectively	  eliminate	  quiescent	  cancer	  cells	  while	  sparing	  stromal	  cells.	  	   Our	  high	  throughput,	  simple,	  long-­‐term,	  3D	  model	  of	  cancer	  cell	  quiescence	  is	  a	  significant	  advance	  over	  previous	  2D	  systems	  and	  existing,	  more	  complex	  3D	  models.	  The	  system	  facilitates	  maintenance	  of	  384	  well	  format	  cultures	  for	  at	  least	  16	  days,	  which	  enables	  extended	  dosing	  and	  recovery	  to	  identify	  optimal	  drugs	  and	  drug	  combinations	  effective	  against	  quiescent	  cells.	  These	  3D	  culture	  and	  imaging	  strategies	  are	  amenable	  to	  high	  throughput	  screening	  and	  many	  other	  co-­‐culture	  models.	  The	  system	  also	  could	  be	  modified	  to	  include	  cells	  expressing	  reporters	  of	  cellular	  and	  molecular	  events	  other	  than	  cell	  cycle	  status,	  thereby	  allowing	  real	  time	  imaging	  of	  drug	  targeting.	  Since	  many	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Figure	  4.1.	  Long	  term	  spheroid	  culture	  with	  different	  stroma	  results	  in	  growth	  or	  reversible	  
quiescence	  of	  cancer	  cells.	  (A)	  Stromal	  cells	  from	  human	  bone	  marrow	  (HS5,	  HS27A)	  and	  mammary	  tissue	  (HMF)	  support	  different	  levels	  of	  growth	  and/or	  quiescence	  as	  measured	  by	  bioluminescence	  fold	  change	  for	  four	  breast	  cancer	  cell	  lines	  (MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐468,	  SKBR3,	  and	  T47D).	  Inset	  text	  lists	  the	  main	  variable	  effects	  (stroma,	  cancer,	  or	  their	  interactions)	  from	  2-­‐way	  ANOVA	  results	  and	  bars	  demarcate	  the	  post	  




Figure	  4.2.	  Validation	  of	  dual-­‐color	  luciferase	  for	  monitoring	  selective	  response	  of	  cancer	  cells	  in	  bone	  
marrow	  co-­‐culture	  spheroids.	  (A)	  Representative	  bioluminescence	  spectra	  of	  MDA-­‐MB-­‐231	  or	  HS5	  cells	  expressing	  click	  beetle	  red	  or	  green	  luciferases,	  respectively.	  The	  spectra	  are	  normalized	  to	  their	  maxima	  for	  viewing	  purposes.	  Each	  data	  point	  represents	  mean	  ±	  SEM	  (n	  =	  4	  per	  point).	  (B)	  Representative	  log-­‐scale	  pseudo-­‐color	  images	  of	  520nm	  and	  680nm	  band	  pass	  filters	  for	  conditions	  of	  only	  CBGreen	  cells,	  only	  CBRed	  cells,	  or	  a	  mixture	  of	  the	  two.	  For	  the	  CBGreen	  only	  and	  mixture,	  the	  CBGreen	  cells	  are	  10%	  of	  the	  total.	  See	  Figure	  S3	  for	  more	  detailed	  characterization.	  (C-­‐D)	  Graphs	  depict	  dose-­‐response	  cytotoxicity	  of	  MDA-­‐MB-­‐231	  cells	  (CBGreen,	  green	  curves)	  and	  their	  counterpart	  (C)	  HS5	  and	  (D)	  HS27A	  cells	  (CBRed,	  red	  curves)	  after	  8	  days	  of	  treatment.	  After	  background	  subtraction,	  we	  normalized	  photon	  flux	  values	  for	  both	  CBGreen	  and	  CBRed	  luciferases	  in	  cancer	  and	  stromal	  cells,	  respectively,	  to	  their	  respective	  untreated	  controls.	  We	  calculated	  selective	  toxicity	  for	  cancer	  cells	  based	  on	  the	  log-­‐2-­‐scale	  ratio	  of	  CBRed	  to	  CBGreen	  signal	  adjusted	  to	  center	  around	  the	  untreated	  control	  (black	  curve).	  Positive	  values	  for	  selectivity	  (black	  curve)	  that	  lie	  above	  the	  horizontal	  dotted	  line	  denote	  selective	  loss	  of	  bioluminescence	  from	  cancer	  cells.	  As	  CBRed	  and	  CBGreen	  dose-­‐response	  curves	  both	  decrease	  below	  1%	  of	  untreated	  (fall	  below	  the	  horizontal	  line),	  we	  omit	  selectivity	  points	  because	  measurements	  are	  dominated	  by	  noise	  of	  the	  instrument.	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Figure	  4.3.	  Treatment	  responses	  of	  cancer	  and	  stromal	  cells	  in	  spheroids.	  To	  directly	  demonstrate	  selective	  elimination	  of	  cancer	  cells	  in	  HS5	  and	  HS27A	  co-­‐cultures,	  we	  plotted	  the	  CBGreen	  dose-­‐response	  and	  selectivity	  curves	  from	  HS5	  and	  HS27A	  co-­‐cultures	  (green	  and	  black	  curves	  from	  Fig.	  2C-­‐D)	  together	  on	  the	  same	  plot	  (C).	  (A-­‐D)	  Graphs	  show	  dose-­‐response	  cytoxicity	  for	  cisplatin	  (A),	  doxorubicin	  (B),	  paclitaxel	  (C),	  and	  PD0325901	  (D)	  against	  MDA-­‐MB-­‐231	  cells	  after	  8	  days	  of	  treatment	  in	  HS5	  and	  HS27A	  spheroids	  (solid	  and	  dotted	  curves,	  respectively).	  Note	  that	  negative	  selectivity	  indicates	  that	  the	  counterpart	  CBRed	  stromal	  dose-­‐response	  would	  be	  left-­‐shifted	  relative	  to	  the	  depicted	  CBGreen	  curve.	  We	  present	  dose-­‐response	  and	  selectivity	  curves	  as	  mean	  values	  ±	  SEM	  (n	  =	  7	  spheroids	  per	  condition).	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Figure	  4.4.	  Dual-­‐color	  click	  beetle	  bioluminescence	  reveals	  selectivity	  of	  combinatorial	  treatments	  on	  
cancer	  versus	  stromal	  cells	  in	  bone	  marrow	  spheroids.	  Combinations	  produce	  enhanced	  selectivity	  after	  dose	  (A)	  and	  recovery	  (B).	  Surface	  plots	  show	  cancer	  cell	  bioluminescence	  (CBGreen)	  normalized	  to	  control	  after	  8	  days	  of	  treatment	  (A)	  and	  again	  after	  6	  days	  of	  recovery	  without	  compounds	  (B)	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  PD0325901	  and	  doxorubicin.	  The	  dotted	  purple	  and	  red	  lines	  represent	  the	  doxorubicin	  only	  and	  PD0325901	  only	  curves,	  respectively.	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Figure	  4.5.	  Heterogeneity	  of	  bone	  marrow	  microenvironment	  leads	  to	  different	  MDA-­‐MB-­‐231	  cell	  
cycle	  status	  and	  responsiveness	  to	  MEK	  inhibition.	  (A-­‐C)	  Established	  bone	  metastases	  reveal	  heterogeneity	  of	  location	  and	  cell	  cycle	  status.	  Two	  photon	  microscopy	  showed	  (A)	  a	  quiescent	  bone	  lesion	  adjacent	  to	  bone;	  (B)	  	  large	  metastasis	  with	  growth	  arrested	  core	  (white	  *)	  and	  a	  cycling	  periphery	  (white	  arrow);	  and	  (C)	  diffusely	  populated,	  cycling	  cells	  adjacent	  to	  autofluorescent	  bone	  marrow	  stroma	  (white	  *)	  and	  a	  blood	  vessel	  (white	  arrow).	  Blue	  signal	  originates	  from	  collagen	  in	  the	  structural	  bone.	  (D,	  E)	  Daily	  dosing	  with	  trametinib	  decreased	  the	  (D)	  G/(G+R)	  fraction	  of	  cycling	  cells	  (C)	  and	  total	  burden	  of	  cancer	  cells	  in	  bone	  marrow	  as	  measured	  by	  flow	  cytometry.	  Example	  flow	  cytometry	  scatter	  plots	  and	  gating	  are	  found	  in	  Supplemental	  Fig.	  C.9.	  The	  horizontal	  dotted	  line	  in	  D	  depicts	  less	  than	  10%	  cycling	  cells	  in	  S/G2/M.	  Presented	  data	  are	  mean	  +	  SEM	  for	  N	  =	  8	  and	  4	  for	  vehicle	  and	  trametinib,	  respectively.	  (F,	  G)	  Microscopy	  of	  femur	  bone	  marrow	  depicts	  cell	  cycle	  arrest	  of	  cancer	  cells	  in	  G1/G0	  after	  trametinib	  treatment	  (F)	  as	  compared	  to	  vehicle	  (G).	  Scale	  bar	  denotes	  100	  µm	  (A,	  B)	  and	  	  150	  µm	  (F,	  G).	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Figure	  4.6.	  Bioluminescence	  reveals	  elimination	  of	  bone	  metastases	  with	  combination	  treatment	  with	  
doxorubicin	  and	  trametinib.	  (A-­‐D)	  Example	  pseudo-­‐colored	  bioluminescence	  images	  dissociated	  bone	  marrow	  in	  60	  mm	  dishes	  after	  7	  days	  of	  culture	  for	  animals	  treated	  with	  vehicle	  (A),	  doxorubicin	  (B),	  trametinib	  (C),	  and	  dual	  doxorubicin	  and	  trametinib	  (D).	  Scale	  bar	  depicts	  2	  mm	  and	  color	  scale	  denotes	  photon	  flux	  values.	  (E)	  Flux	  measurements	  of	  outgrowth	  plates	  after	  single	  agent	  and	  combination	  treatments.	  The	  fraction	  below	  each	  dataset	  represents	  the	  fraction	  of	  lower	  extremities	  from	  which	  we	  detected	  cancer	  cells	  above	  background	  (dotted	  line	  at	  105).	  The	  statistical	  demarcation	  shows	  difference	  between	  vehicle	  and	  all	  other	  samples,	  using	  multiple	  t-­‐tests	  (*	  p<0.05)	  for	  the	  number	  of	  extremities	  listed	  in	  the	  denominator	  of	  the	  fractions.	  Other	  comparisons	  showed	  no	  statistical	  difference.	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5 Chapter Five: Sensitivity of Quiescent Cancer Cells to Metabolic 
Perturbations in Bone Marrow Spheroids 
5.1 Summary	  Metastatic	  cancer	  cells	  harbored	  in	  the	  bone	  marrow	  are	  often	  quiescent,	  and	  as	  a	  result,	  resistant	  to	  standard	  cytotoxic	  therapies	  and	  capable	  of	  regrowth	  even	  decades	  after	  initial	  disease.	  	  The	  bone	  marrow	  regulates	  quiescence	  of	  cancer	  and	  stem	  cells	  in	  part	  via	  the	  metabolic	  microenvironment	  created	  by	  the	  surrounding	  stromal	  cells.	  	  Development	  of	  strategies	  to	  target	  cancer	  cells	  in	  this	  microenvironment	  has	  been	  hindered	  by	  the	  lack	  of	  experimental	  models	  that	  robustly	  recreate	  bone	  marrow	  interactions	  that	  induce	  quiescence.	  	  Here	  we	  further	  develop	  a	  3D	  bone	  marrow	  spheroid	  model	  of	  cancer	  quiescence	  in	  order	  to	  analyze	  the	  resulting	  metabolic	  microenvironment,	  its	  impact	  on	  cancer	  viability,	  and	  their	  sensitivity	  to	  therapies.	  	  Using	  optical	  metabolic	  imaging,	  metabolic	  flux	  analysis,	  molecular	  perturbations	  of	  metabolism,	  and	  dual-­‐colored	  bioluminescence	  of	  cancer	  and	  stromal	  cell	  viability,	  we	  assessed	  role	  of	  metabolic	  microenvironments	  in	  cancer	  quiescence.	  	  Using	  this	  model,	  we	  found	  the	  bone	  marrow	  stromal	  cell	  line	  HS-­‐5,	  to	  be	  basally	  glycolytic,	  have	  minimal	  metabolic	  responsiveness,	  and	  minimally	  protect	  the	  quiescent	  cells	  from	  metabolic	  perturbations.	  	  Conversely,	  we	  found	  the	  HS-­‐27A	  stromal	  cell	  line	  to	  be	  metabolically	  responsive	  in	  spheroids,	  to	  harbor	  both	  oxidative	  and	  glycolytic	  niches	  of	  cancer	  cells,	  and	  to	  robustly	  protect	  multiple	  breast	  cancer	  subtypes	  from	  metabolic	  perturbations.	  	  	  This	  combined	  approach	  of	  spheroid	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culture,	  optical	  metabolic	  imaging,	  and	  bioluminescence	  screen	  provides	  a	  platform	  for	  identifying	  strategies	  to	  robustly	  and	  selectively	  eliminate	  quiescent	  cancer	  cells	  in	  the	  bone	  marrow.	  
5.2 Introduction	  Quiescent	  cancer	  cells	  are	  relatively	  insensitive	  to	  cytotoxic	  therapies	  and	  may	  contribute	  to	  late	  relapse	  even	  decades	  after	  initial	  diagnosis	  of	  disease	  (1-­‐3).	  	  Disseminated	  cancer	  cells	  reside	  in	  microenvironments	  that	  support	  cancer	  cell	  quiescence	  and	  confer	  resistance	  to	  chemotherapy,	  allowing	  these	  cells	  to	  persist	  in	  a	  viable	  state	  after	  adjuvant	  treatment	  (4,	  5).	  	  In	  particular,	  bone	  marrow	  is	  regarded	  as	  a	  major	  site	  of	  quiescent	  cancer	  cells.	  Bone	  marrow	  is	  thought	  to	  maintain	  cellular	  quiescence	  of	  cancer	  cells	  in	  a	  similar	  fashion	  as	  hematopoietic	  stem	  cells,	  using	  metabolism,	  cell	  contacts,	  and	  secreted	  factors	  to	  control	  distribution	  (endosteal	  versus	  vascular	  niches)	  and	  proliferation	  of	  these	  cells	  (6-­‐9).	  	  One	  strategy	  towards	  eliminating	  quiescent	  cancer	  cells	  is	  to	  selectively	  target	  unique	  metabolic	  demands	  of	  these	  cells,	  which	  is	  a	  hallmark	  feature	  of	  cancer	  that	  may	  be	  exacerbated	  by	  hypoxia	  in	  bone	  marrow	  niches	  (10).	  	  Understanding	  differences	  in	  metabolism	  between	  disseminated	  cancer	  cells	  and	  stroma	  cells	  in	  bone	  marrow	  and	  developing	  therapies	  selectively	  targeting	  cancer	  metabolism	  offer	  the	  potential	  to	  eliminate	  quiescent	  cancer	  cells	  and	  prevent	  late	  replaces	  of	  disease.	  	  Growing	  cancer	  cells	  often	  have	  modified	  energetic	  profiles	  as	  compared	  to	  normal	  cells	  (10-­‐13),	  yet	  relatively	  little	  is	  known	  about	  metabolism	  of	  quiescent	  cancer	  cells	  in	  bone	  marrow.	  	  Cancer	  cells,	  hematopoietic	  stem	  cells,	  and	  other	  mesenchymal	  stem	  cells	  have	  commonalities	  and	  differences	  in	  energetic	  and	  biosynthetic	  demands	  during	  growth,	  quiescence,	  and	  in	  response	  to	  hypoxia	  that	  may	  inform	  potential	  therapies	  (14).	  	  Similar	  to	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hematopoietic	  stem	  cells	  in	  hypoxic	  bone	  marrow,	  cancer	  cells	  become	  increasingly	  dependent	  on	  glycolysis	  via	  activation	  of	  HIFα,	  which	  inhibits	  glucose-­‐derived	  pyruvate	  from	  entering	  mitochondria	  (12).	  Mesenchymal	  stem	  cells	  exhibit	  metabolic	  flexibility	  between	  oxidative	  versus	  glycolytic	  states;	  differentiate	  towards	  chondrogenic	  not	  osteogenic	  lineages	  under	  hypoxia;	  and	  are	  locked	  in	  glycolytic	  or	  oxidative	  metabolisms	  upon	  differentiation	  into	  chondrogenic	  or	  osteogenic/adipogenic	  lineages,	  respectively	  (15-­‐18).	  	  Within	  the	  hypoxic	  bone	  marrow	  environment,	  hematopoietic	  stem	  cells,	  cancer	  cells,	  and	  mesenchymal	  stromal	  cells	  produce	  higher	  levels	  of	  molecules	  that	  scavenge	  reactive	  oxygen	  species;	  increase	  pentose	  phosphate	  pathway	  metabolism;	  and	  replace	  mitochondrial	  flux	  with	  reductive	  glutamine	  pathways	  (4,	  14,	  17,	  19).	  Despite	  commonalities	  in	  hypoxia-­‐responsiveness	  among	  resident	  bone	  marrow	  cells,	  hypoxia	  induces	  cell-­‐type	  specific	  differences	  that	  may	  be	  leveraged	  to	  selectively	  eliminate	  cancer	  cells.	  	  For	  example,	  hematopoietic	  stem	  cells	  decrease	  mitochondrial	  mass	  under	  hypoxia,	  decreasing	  production	  of	  reactive	  oxygen	  species	  (20,	  21).	  	  Conversely,	  hypoxic	  cancer	  cells	  enlarge	  their	  mitochondria,	  inhibiting	  apoptosis	  with	  a	  concomitant	  elevation	  in	  reactive	  oxygen	  species	  (22).	  	  In	  response	  to	  reactive	  oxygen	  species,	  cancer	  cells	  may	  regain	  proliferative	  capacity	  and/or	  acquire	  additional	  mutagenic	  stress,	  but	  hematopoietic	  stem	  cells	  terminally	  differentiate	  and/or	  undergo	  apoptosis	  (21,	  23).	  Leveraging	  fine	  balances	  between	  responsiveness	  to	  reactive	  oxygen	  species,	  energetic	  demands,	  and	  biosynthetic	  needs	  may	  reveal	  ways	  to	  selectively	  eliminate	  quiescent	  cancer	  cells	  in	  heterogeneous	  bone	  marrow	  microenvironments	  (24).	  Recent	  studies	  show	  heterogeneous	  metabolic	  microenvironments	  in	  bone	  marrow,	  which	  may	  differently	  regulate	  cancer	  cell	  quiescence.	  For	  example,	  high	  metabolic	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demands	  of	  bone	  marrow	  create	  intravascular	  hypoxia	  with	  additional	  oxygen	  depletion	  proceeding	  away	  from	  the	  vascular	  compartment	  towards	  endosteal	  niches	  (10).	  Sharply	  graded	  hypoxic	  microenvironments	  lead	  to	  different	  locations,	  levels	  of	  differentiation,	  and	  abundance	  of	  hematopoietic,	  mesenchymal,	  immune,	  vascular,	  and	  cancer	  cells	  (25-­‐27).	  	  Although	  the	  metabolic	  status	  in	  vivo	  is	  the	  summation	  of	  all	  of	  these	  interacting	  components,	  as	  a	  model	  system	  we	  begin	  by	  considering	  the	  metabolically	  diverse	  status	  of	  mesenchymal	  stem	  cell	  lineages,	  particularly	  the	  mesenchymal	  stem	  cell	  derived	  cell	  lines,	  HS-­‐5	  and	  HS-­‐27A.	  	  HS-­‐5	  and	  HS-­‐27A	  cells	  support	  either	  expansion	  or	  maintenance	  of	  hematopoietic	  stem	  cells,	  respectively	  (28).	  	  Multiple	  studies	  of	  these	  cells	  describe	  	  dichotomous	  regulation	  of	  gene	  expression,	  secretion	  of	  growth	  factors,	  matrix	  deposition,	  and	  support	  of	  bone	  marrow	  transplant	  efficiency	  among	  other	  effects	  on	  cancer	  and	  hematopoietic	  stem	  cells	  (28-­‐32).	  	  Additionally,	  one	  recent	  gene	  expression	  study	  revealed	  that	  unlike	  HS-­‐5	  cells,	  HS-­‐27A	  cells	  are	  more	  pluripotent	  and	  express	  markers	  of	  the	  hematopoietic	  niche	  (33,	  34).	  These	  results	  suggest	  HS27A	  cells	  also	  have	  greater	  metabolic	  flexibility	  between	  glycolytic	  and	  oxidative	  metabolic	  states	  (15).	  	  	  How	  the	  metabolic	  microenvironment	  supported	  by	  these	  stromal	  cells	  and	  their	  metabolic	  coupling	  with	  cancer	  cells	  supports	  cancer	  growth	  or	  quiescence	  is	  largely	  unknown.	  While	  prior	  studies	  have	  emphasized	  interconnected	  signaling	  networks	  in	  tumor	  environments	  (35,	  36),	  recent	  research	  reveals	  that	  metabolic	  links	  among	  malignant	  and	  stromal	  cells	  control	  growth,	  quiescence,	  and	  drug	  sensitivity	  of	  cancer	  cells	  (37,	  38).	  	  Malignant	  cells	  promote	  metabolic	  reprogramming	  of	  stromal	  cells	  to	  supply	  metabolites,	  such	  as	  lactate	  and	  glutamine,	  necessary	  to	  fuel	  growth	  of	  neighboring	  epithelial	  cancer	  cells	  (39,	  40).	  	  Cancer	  and	  stromal	  cells	  may	  exhibit	  different	  responses	  to	  molecules	  such	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as	  glutamine,	  suggesting	  the	  potential	  to	  uncouple	  tumor-­‐stromal	  metabolism	  without	  toxicity	  to	  normal	  cells.	  To	  capitalize	  on	  cancer	  metabolism	  as	  a	  target	  to	  eliminate	  disseminated	  tumor	  cells	  from	  bone	  marrow,	  there	  is	  an	  unmet	  need	  for	  cell-­‐based	  assays	  that	  reproduce	  intracellular	  interactions	  in	  vivo	  while	  enabling	  facile	  analyses	  of	  metabolic	  states	  and	  drug	  efficacy.	  	  Here	  we	  investigate	  how	  the	  metabolic	  status	  of	  3D	  cancer-­‐stromal	  spheroids	  determines	  growth	  and	  drug	  sensitivity	  of	  multiple	  breast	  cancer	  cell	  lines.	  	  We	  use	  optical	  imaging	  of	  endogenous	  NADH	  as	  a	  label-­‐free	  method	  for	  determining	  metabolic	  gradients	  within	  3D	  culture	  environments.	  	  We	  also	  use	  extracellular	  flux	  measurements,	  molecular	  inhibition	  of	  metabolic	  pathways,	  and	  bioluminescence-­‐based	  quantification	  of	  viability	  of	  cancer	  and	  stromal	  cells	  to	  assess	  the	  collective	  metabolic	  environment	  of	  our	  model	  system.	  We	  found	  that	  metabolic	  differences	  in	  bone	  marrow	  stromal	  cells	  differently	  support	  quiescence	  of	  multiple	  cancer	  cells,	  interdependence	  on	  glucose	  and	  glutamine,	  and	  sensitivity	  to	  molecular	  inhibition	  of	  metabolic	  pathways.	  	  Specifically	  we	  found	  HS-­‐5	  stromal	  cells	  to	  be	  glycolytic,	  induce	  quiescence	  of	  multiple	  breast	  cancer	  subtypes	  (including	  aggressive,	  triple	  negative	  MDA-­‐MB-­‐231	  cells),	  and	  provide	  limited	  support	  to	  cancer	  cells	  upon	  metabolic	  perturbations.	  	  We	  also	  found	  HS-­‐27A	  stromal	  cells	  to	  be	  more	  metabolically	  flexible,	  supporting	  cancer	  cell	  resistance	  to	  nutrient	  withdrawal.	  	  Together	  these	  data	  can	  be	  used	  to	  screen	  for	  therapies	  that	  target	  the	  metabolic	  phenotypes	  of	  quiescent	  cancer	  cells	  in	  bone	  marrow	  and	  eliminate	  their	  contribution	  to	  late	  relapse.	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5.3 Material	  and	  Methods	  
5.3.1 Reagents	  	  Unless	  otherwise	  stated	  we	  purchased	  all	  cell	  culture	  reagents	  from	  Life	  Technologies	  (Carlsbad,	  CA,	  USA).	  	  We	  obtained	  drugs	  and	  compounds	  from	  the	  following	  sources:	  PD0325901	  from	  SelleckChem	  (Houston,	  TX,	  USA);	  D-­‐glucose,	  2-­‐deoxy-­‐D-­‐glucose,	  rotenone,	  and	  sodium	  dichloroacetate	  from	  Sigma	  Aldrich	  (St.	  Louis,	  MO,	  USA);	  and	  oligomycin	  from	  Seahorse	  Biosciences	  (Massachusetts,	  USA).	  	  We	  prepared	  a	  rotenone	  stock	  at	  10	  mM	  in	  ethanol.	  	  We	  prepared	  all	  other	  compounds	  in	  formulations	  supplied	  or	  specified	  by	  manufacturers.	  	  
5.3.2 Cell	  culture	  and	  spheroid	  assays	  We	  grew	  HS-­‐5,	  HS-­‐27A,	  MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐468,	  and	  T47D	  cells	  as	  we	  described	  previously	  (41).	  	  Briefly,	  we	  maintained	  all	  cells	  in	  10%	  FBS	  (HyClone,	  ThermoScientific,	  Waltham,	  MA,	  USA)	  DMEM	  (#11995,	  Life	  Technologies)	  supplemented	  with	  penicillin,	  streptomycin,	  and	  glutamine	  (Life	  Technologies).	  	  Cells	  were	  maintained	  at	  subconfluence	  and	  passaged	  every	  2	  to	  4	  days.	  	  Stromal	  and	  cancer	  cells	  express	  Click	  Beetle	  Red	  and	  Green,	  respectively.	  	  Cancer	  cells	  also	  expressed	  fluorescent	  ubiquitin-­‐based	  cell	  cycle	  indicator	  (42).	  	  	  We	  detailed	  our	  spheroid	  assays	  previously	  (41).	  	  Briefly,	  3x103	  cells	  were	  distributed	  as	  a	  suspension	  in	  25	  μl	  per	  well	  to	  black	  384	  shallow,	  round	  bottom	  well	  plates	  (Corning	  Incorporated	  #3676,	  Corning,	  NY,	  USA).	  	  For	  cancer	  cell	  growth	  and	  dose-­‐response	  assays	  we	  composed	  the	  spheroids	  of	  1%	  MDA-­‐MB-­‐231	  with	  the	  balance	  of	  stromal	  cells.	  	  For	  experiments	  looking	  at	  the	  distribution	  of	  cancer	  cells	  throughout	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spheroids	  we	  seeded	  3.3x103	  total	  cells	  with	  the	  additional	  10%	  MDA-­‐MB-­‐231	  cells.	  	  For	  optical	  metabolic	  imaging	  in	  different	  sized	  spheroids	  we	  seeded	  300,	  1000,	  and	  3000	  mesenchymal	  stem	  cells.	  	  For	  comparison	  of	  metabolic	  gradients	  in	  different	  stromal	  cell	  types	  we	  seeded	  spheroids	  with	  3x103	  HS-­‐5,	  HS-­‐27A,	  and	  MSCs.	  	  For	  optical	  metabolic	  imaging	  in	  2D,	  we	  seeded	  106	  HS-­‐5,	  HS-­‐27A,	  or	  primary	  mesenchymal	  stem	  cells	  in	  a	  35	  mm	  dishes	  in	  spheroid	  media,	  but	  containing	  10%	  FBS.	  	  Once	  cells	  were	  firmly	  adhered	  we	  replaced	  medium	  with	  that	  used	  for	  spheroids.	  	  The	  culture	  conditions	  of	  all	  spheroids	  were	  consistent	  unless	  otherwise	  stated.	  	  We	  seeded	  and	  maintained	  all	  spheroids	  in	  phenol	  red	  free	  DMEM	  (#31053,	  Life	  Technologies),	  supplemented	  with	  1%	  FBS	  (HyClone,	  ThermoScientific,	  Waltham,	  MA,	  USA),	  penicillin/streptomycin/glutamine	  (Life	  Technologies),	  and	  pyruvate	  (Life	  Technologies).	  For	  experiments	  modulating	  the	  glucose	  and	  glutamine	  levels,	  the	  base	  medium	  was	  replaced	  with	  glucose-­‐	  and	  glutamine-­‐free	  DMEM,	  supplemented	  with	  glutamine-­‐free	  penicillin/streptomycin	  (Life	  Technologies),	  and	  pyruvate.	  	  We	  then	  supplemented	  D-­‐glucose	  (Sigma	  Aldrich,	  St.	  Louis,	  MO,	  USA)	  and	  glutamine	  (Life	  Technologies)	  at	  listed	  concentrations.	  	  We	  exchanged	  about	  80%	  of	  the	  volume	  of	  media	  every	  second	  day	  for	  the	  entirety	  of	  each	  assay.	  The	  timing	  of	  each	  assay	  was	  consistent	  unless	  otherwise	  stated.	  	  For	  growth	  assays,	  we	  measured	  bioluminescence	  flux	  at	  two	  and	  ten	  days,	  change	  media	  with	  fresh	  spheroid	  media	  every	  two	  days.	  	  For	  dose-­‐response	  curves,	  after	  cells	  spheroids	  formed	  for	  two	  days,	  we	  initialized	  treatment	  by	  exchanging	  media	  on	  the	  second	  day	  and	  every	  two	  thereafter	  for	  a	  total	  assay	  time	  of	  ten	  days.	  	  For	  optical	  metabolic	  imaging	  in	  2D	  and	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spheroids	  and	  for	  microscopy	  of	  cancer	  cell	  distribution,	  we	  imaged	  spheroids	  24	  hours	  after	  seeding.	  	  
5.3.3 Bioluminescence	  imaging	  We	  previously	  described	  Click	  Beetle	  Green	  and	  Red	  imaging	  in	  detail	  (41).	  
5.3.4 Microscopy	  For	  microscopy	  of	  2D	  and	  3D	  cultures	  we	  used	  an	  Olympus	  MPE	  using	  a	  25X	  NIR	  corrected	  objective	  (XLPLN25XWMP,	  NA=1.05,	  Olympus,	  Tokyo,	  Japan).	  	  We	  facilitated	  stable	  imaging	  of	  spheroids	  by	  transferring	  spheroids	  to	  a	  custom	  spheroid	  imaging	  plate	  that	  we	  described	  previously	  (43).	  	  To	  image	  the	  fluorescence	  ubiquitin-­‐based	  cell	  cycle	  indicator,	  we	  excited	  both	  AcGFP	  and	  mKO	  fluorophores	  with	  920nm	  excitation	  and	  collected	  green	  (495-­‐540nm)	  and	  red	  (575-­‐630nm)	  channels	  with	  their	  respective	  band-­‐pass	  filters.	  	  	  
5.3.5 Intensity-­‐based	  metabolic	  imaging	  For	  intensity-­‐based	  optical	  metabolic	  imaging	  we	  used	  two	  paired	  excitation	  and	  emission	  wavelengths	  for	  NADH	  and	  FAD	  imaging	  similar	  to	  previous	  descriptions	  (44).	  	  For	  NADH	  intensities,	  we	  excited	  with	  740	  nm	  and	  collected	  light	  with	  a	  band-­‐pass	  filter	  (420-­‐460nm).	  	  For	  FAD	  intensities,	  we	  excited	  with	  890	  nm	  and	  collected	  light	  with	  a	  band-­‐pass	  filter	  (495-­‐540nm).	  	  We	  maintained	  constant	  imaging	  parameters	  within	  each	  experimental	  run,	  including	  laser	  power,	  detector	  voltage,	  and	  offset.	  	  To	  quantify	  image	  intensities	  and	  ratios,	  we	  exported	  pixel-­‐by-­‐pixel	  intensities	  from	  Fluoview	  (Olympus,	  Tokyo,	  Japan)	  into	  Microsoft	  Excel	  (Seattle,	  WA,	  USA),	  where	  we	  removed	  below	  background	  pixels	  (determined	  from	  cell-­‐free	  regions)	  and	  performed	  additional	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calculations.	  	  We	  also	  used	  Excel	  to	  determine	  frequency	  distributions	  and	  NADH	  to	  FAD	  ratios.	  
5.3.6 Frequency	  domain	  fluorescence	  imaging	  and	  data	  analysis	  For	  lifetime-­‐based	  measure	  of	  metabolic	  status,	  we	  used	  the	  ISS	  FastFLIM	  system,	  containing	  a	  Spartan	  6	  processor,	  and	  coupled	  with	  our	  Olympus	  MPE	  microscope.	  	  We	  calibrated	  the	  FLIM	  system	  to	  a	  fluorescein	  dye	  slide,	  using	  open	  filters	  and	  740	  nm	  excitation	  and	  an	  expected	  single	  component	  lifetime	  of	  about	  4.1	  ns.	  	  Using	  an	  excitation	  of	  740	  nm	  with	  mode-­‐locked	  80MHz	  Ti:Sapphire	  laser	  system	  (Spectra-­‐Physics	  Mai	  Tai)	  and	  a	  690	  dichroic	  to	  block	  internal	  reflectance	  from	  the	  IR	  laser,	  we	  collected	  NADH	  emission	  using	  a	  X	  dichroic	  and	  Y	  band-­‐pass	  filters.	  We	  also	  measured	  FAD	  lifetime	  simultaneously	  using	  the	  long-­‐pass	  dichroic	  cut	  and	  Y	  nm	  band-­‐pass	  filter.	  	  The	  caveat	  with	  the	  FAD	  measurement	  with	  740nm	  excitation	  is	  that	  there	  is	  a	  small	  spectral	  overlap	  with	  NADH	  (45).	  	  Using	  excitation	  of	  890	  eliminates	  NADH	  excitation	  but	  would	  require	  recalibration	  of	  the	  FLIM	  system	  with	  each	  laser	  wavelength	  change.	  We	  used	  a	  256x256	  view	  field	  and	  100μs	  dwell	  time	  for	  all	  frequency-­‐domain	  images.	  	  We	  captured	  between	  15	  and	  25	  frames	  and	  adjusted	  laser	  intensity	  in	  order	  to	  maximize	  pixels	  above	  our	  count	  threshold.	  	  To	  image	  size-­‐based	  gradients	  in	  spheroids,	  we	  used	  smaller	  view	  fields	  for	  smaller	  spheroids	  in	  order	  to	  maximize	  the	  view	  area	  occupied	  by	  the	  spheroid.	  	  	  To	  analyze	  the	  lifetime	  data,	  we	  exported	  the	  phase	  lifetime	  and	  counts	  from	  the	  VistaVision	  software	  into	  Excel.	  	  In	  Excel	  we	  removed	  lifetime	  and	  count	  values	  that	  fell	  outside	  0.5-­‐5	  ns	  for	  phase	  lifetime	  and	  below	  5	  for	  counts.	  	  We	  then	  applied	  a	  count-­‐weighted	  average	  for	  imaging	  segments	  as	  described	  in	  Figure	  S3.	  	  For	  images	  of	  stromal	  cells	  cultured	  in	  2D,	  we	  used	  the	  count-­‐weighted	  average	  for	  the	  entire	  frame.	  	  For	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spheroids,	  we	  used	  radial	  cuts	  in	  four	  directions	  for	  each	  spheroid	  consisting	  of	  1x50	  pixel	  vectors	  that	  progressed	  from	  exterior	  to	  interior	  of	  each	  spheroid.	  	  Aligning	  the	  spheroid	  edge	  for	  each	  of	  four	  radial	  cross-­‐sections	  for	  four	  spheroids	  from	  two	  independent	  setups,	  we	  used	  average	  the	  lifetime	  across	  the	  radius	  profile.	  
5.3.7 Glucose	  measurements	  To	  measure	  bulk	  glucose	  from	  cell	  culture	  supernatants	  we	  used	  commercial	  blood	  glucose	  meter	  Accu-­‐chek	  Aviva	  Plus	  (Roche	  Diagnostics).	  	  Samples	  were	  diluted	  50%	  in	  PBS	  containing	  20	  wt%	  Probumin	  (EMD	  Millipore,	  Billerica,	  MA,	  USA)	  in	  order	  to	  bypass	  blood	  quality	  errors.	  	  All	  values	  were	  benchmarked	  against	  high	  glucose	  measurements	  in	  spheroid	  culture	  medium	  (25mM,	  450	  mg/dl).	  	  We	  measured	  supernatants	  pooled	  from	  4	  spheroid	  wells,	  from	  20	  separate	  spheroids,	  totaling	  N	  =	  5	  measurements	  for	  each	  stromal	  combination.	  	  	  
5.3.8 Extracellular	  Flux	  Assays	  We	  performed	  extracellular	  flux	  assays	  using	  a	  Seahorse	  Bioscience	  (Massachusetts,	  USA)	  XFe96	  Extracellular	  Flux	  Analyzer.	  	  We	  performed	  the	  XF	  Glycolysis	  Stress	  test	  per	  manufacturer	  specifications.	  	  We	  seeded	  cells	  overnight	  at	  a	  density	  of	  15x103	  cells	  per	  well.	  	  Injections	  were	  performed	  sequentially	  with	  25mM	  D-­‐glucose,	  1μM	  oligomycin,	  and	  100	  mM	  2-­‐deoxy-­‐D-­‐glucose.	  For	  pretreatment	  with	  PD0325901,	  we	  treated	  cells	  with	  10	  nM	  overnight	  and	  during	  the	  1-­‐hour	  incubation	  in	  unbuffered	  assay	  medium.	  	  Data	  are	  plotted	  for	  average	  of	  N	  =	  6	  wells	  over	  three	  measurement	  cycles.	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5.3.9 Statistical	  analysis	  and	  plotting	  We	  processed	  bioluminescence	  and	  optical	  metabolic	  data	  in	  Microsoft	  Excel	  (Seattle,	  WA,	  USA)	  before	  plotting	  data	  using	  GraphPad	  Prism	  (San	  Diego,	  CA,	  USA).	  	  All	  graphs	  display	  mean	  values	  ±	  standard	  error	  of	  the	  mean	  (S.E.M.)	  unless	  stated	  otherwise.	  	  We	  propagated	  error	  for	  all	  data	  normalized	  to	  experimental	  measurements.	  We	  described	  our	  strategy	  for	  measuring	  selective	  elimination	  of	  cancer	  cells	  but	  not	  stromal	  cells	  using	  dual-­‐colored	  Click	  Beetle	  luciferase	  previously	  (41).	  	  For	  growth	  curves	  we	  divided	  average	  bioluminescence	  flux	  for	  red	  and	  green	  signals	  at	  day	  10	  by	  their	  corresponding	  value	  at	  day	  2.	  	  For	  dose-­‐response	  curves,	  we	  divide	  background	  subtracted	  flux	  values	  by	  their	  corresponding	  untreated	  condition	  for	  both	  green	  and	  red	  signals.	  	  To	  visualize	  the	  selectivity	  of	  cancer	  cell	  elimination,	  we	  plotted	  the	  log-­‐2	  ratio	  of	  the	  red	  signal	  divided	  by	  the	  red	  signal	  and	  subtract	  the	  value	  of	  the	  untreated	  control.	  	  Selectivity	  for	  the	  untreated	  control	  is	  zero	  and	  positive	  selectivity	  corresponds	  to	  relatively	  lower	  cancer	  (green)	  as	  compared	  to	  stromal	  (red)	  signals.	  	  	  
5.4 Results	  
5.4.1 Bone	  marrow	  stromal	  spheroids	  support	  growth	  or	  quiescence	  of	  breast	  cancer	  cells	  We	  used	  long-­‐term	  co-­‐cultures	  of	  bone	  marrow	  stromal	  cell	  lines	  (HS-­‐5	  and	  HS-­‐27A)	  to	  recreate	  metastatic	  growth	  or	  quiescence	  in	  bone	  marrow	  (41).	  To	  investigate	  relative	  effects	  of	  HS5	  and	  HS27A	  stromal	  cells	  on	  quiescence	  or	  growth	  of	  triple	  negative	  (ER-­‐/PR-­‐/Her2-­‐)	  MDA-­‐MB-­‐231	  cells,	  we	  varied	  the	  composition	  of	  the	  stromal	  environment	  and	  independently	  monitored	  growth	  of	  cancer	  and	  stromal	  cells	  with	  stably	  expressed	  Click	  Beetle	  Green	  and	  Red	  luciferases,	  respectively.	  Increasing	  the	  fraction	  of	  HS27A	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compared	  to	  HS5	  cells	  while	  maintaining	  total	  cell	  number,	  we	  determined	  that	  relatively	  few	  HS5	  cells	  (EC50	  ~27%)	  diminished	  growth	  of	  MDA-­‐MB-­‐231	  cells	  (Fig.	  5.1A).	  	  HS-­‐27A	  cells	  supported	  rapid	  growth	  of	  cancer	  cells	  as	  compared	  with	  the	  quiescence-­‐supporting	  HS-­‐5	  cells,	  similar	  to	  our	  previous	  report	  (41).	  MDA-­‐MB-­‐231	  co-­‐cultures	  with	  untransformed	  primary	  human	  mesenchymal	  stem	  cells	  (MSC)	  grew	  rapidly	  as	  compared	  to	  HS-­‐5	  cells,	  which	  suggests	  HS-­‐27A	  cells	  represent	  the	  subtype	  of	  mesenchymal	  stromal	  cells	  that	  typically	  is	  enriched	  through	  in	  vitro	  isolation	  (data	  not	  shown).	  	  	  	  	  Despite	  quiescence	  of	  cancer	  and	  stromal	  cells	  in	  the	  HS-­‐5	  spheroid	  environment,	  we	  observed	  substantial	  acidification	  of	  their	  supernatant	  as	  compared	  to	  HS-­‐27A	  cells	  based	  on	  phenol	  red	  in	  culture	  medium.	  To	  measure	  whether	  lactate-­‐based	  acidification	  corresponded	  to	  decreased	  glucose	  levels	  in	  HS-­‐5	  spheroids,	  we	  measured	  glucose	  levels	  in	  medium	  after	  2	  days	  of	  culture.	  	  Corresponding	  with	  the	  decreased	  pH	  in	  the	  HS-­‐5	  cultures,	  these	  cells	  reduced	  glucose	  in	  the	  bulk	  media	  by	  ~20%	  relative	  to	  ~10%	  for	  HS-­‐27A	  (Fig.	  5.1B).	  	  Although	  this	  is	  a	  relatively	  small	  decrement	  considering	  the	  typical	  non-­‐physiologically	  high	  glucose	  culture	  medium	  (25mM)	  as	  compared	  to	  in	  vivo	  (5mM),	  we	  expect	  that	  local,	  cell-­‐scale	  depletion	  of	  glucose	  for	  cancer	  cells	  within	  HS-­‐5	  spheroids	  may	  surpass	  20%	  depletion.	  	  To	  confirm	  differences	  between	  glucose	  consumption	  between	  these	  cell	  types,	  we	  used	  the	  Seahorse	  extracellular	  flux	  analyzer	  (XFe96)	  to	  compare	  levels	  of	  oxygen	  consumption	  and	  extracellular	  acidification.	  	  Under	  conditions	  of	  glutamine	  only,	  or	  sequential	  glucose	  and	  oligomycin	  (inhibition	  of	  oxidative	  metabolism)	  injections,	  we	  found	  HS5	  cells	  to	  have	  both	  higher	  oxygen	  consumption	  and	  lactate	  production	  (Fig.	  5.1B,	  i	  to	  ii	  glucose	  injection,	  ii	  to	  iii	  oligomycin	  injection).	  	  HS5	  and	  HS27A	  cells	  were	  both	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relatively	  unaffected	  by	  inhibition	  of	  oxidative	  metabolism	  by	  oligomycin,	  as	  shown	  by	  the	  relatively	  small	  shift	  between	  Fig.	  1Bii-­‐iii.	  	  On	  a	  per	  cell	  basis	  these	  results	  suggest	  that	  glucose	  consumption	  is	  different	  between	  stromal	  cells	  and	  between	  2D	  and	  3D	  cultures.	  	  To	  test	  this,	  we	  estimated	  the	  glucose	  consumption	  from	  two	  different	  analysis	  modalities,	  both	  Seahorse	  extracellular	  flux	  analyzer	  and	  direct	  glucose	  measurements.	  	  From	  Seahorse	  data	  (Fig.	  5.1Bii),	  assuming	  that	  two	  lactate	  protons	  are	  derived	  from	  a	  single	  glucose	  molecule	  (an	  imperfect	  but	  reasonable	  estimate),	  we	  calculated	  glucose	  consumption	  rates	  of	  about	  3.1	  and	  2.5	  fmol/minute/cell	  for	  HS-­‐5	  and	  HS-­‐27A	  in	  2D	  culture,	  respectively,	  after	  normalizing	  to	  15x103	  cells	  per	  well.	  	  Assuming	  constant	  per	  cell	  glucose	  consumption,	  the	  glucose	  consumption	  rates	  are	  14.5	  and	  7.2	  fmol/minute/cell	  for	  HS-­‐5	  and	  HS-­‐27A	  in	  3D	  spheroids,	  respectively,	  after	  normalizing	  to	  3x103	  cells	  per	  spheroid.	  	  These	  estimates	  suggest	  that	  on	  a	  per	  cell	  basis,	  cells	  are	  more	  glycolytic	  in	  3D	  cultures,	  which	  is	  consistent	  with	  other	  reports	  comparing	  2D	  and	  3D	  cultures	  (46).	  
5.4.2 Optical	  metabolic	  imaging	  to	  study	  metabolic	  microenvironment	  	  To	  confirm	  the	  glucose	  consumption	  of	  the	  bone	  marrow	  stromal	  cells,	  we	  used	  optical	  metabolic	  imaging	  to	  capture	  intensities	  and	  redox	  ratio	  of	  endogenous	  NADH	  and	  FAD.	  	  There	  was	  a	  rank-­‐order	  increase	  in	  NADH	  intensities	  (MSC	  <	  HS-­‐27A	  <	  HS-­‐5)	  and	  reverse-­‐order	  increase	  in	  FAD,	  intensities	  (Fig.	  5.1C-­‐D).	  	  Likewise,	  the	  background	  adjusted	  pixel-­‐by-­‐pixel	  ratio	  of	  NADH	  to	  FAD	  showed	  a	  similar	  rank-­‐order	  increase	  in	  redox	  ratio	  for	  MSC,	  HS-­‐27A,	  and	  HS-­‐5	  cells	  grown	  in	  2D	  (Fig.	  5.2E).	  	  Based	  on	  a	  previous	  report	  linking	  redox	  ratio	  to	  glycolytic	  index	  (glucose	  consumption	  per	  lactate	  production),	  these	  data	  suggest	  that	  HS5	  are	  more	  glycolytic	  than	  HS27A	  cells	  and	  MSCs	  (44).	  	  Despite	  improved	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optics	  of	  two-­‐photon	  microscopy,	  intensity-­‐based	  measures	  of	  fluorescence	  are	  complicated	  at	  depth	  within	  3D	  tissues	  because	  of	  preferential	  absoption	  of	  blue	  (NADH)	  versus	  green	  (FAD)	  light.	  	  Therefore,	  we	  also	  used	  frequency	  domain	  fluorescence	  lifetime	  imaging	  to	  measure	  changes	  in	  free	  and	  bound	  NADH	  for	  theses	  stromal	  cell	  types	  (Fig.	  5.2F).	  	  Increased	  glycolysis	  has	  been	  associated	  with	  increased	  fraction	  of	  free,	  protein	  unbound	  NADH	  and	  corresponds	  to	  a	  decreased	  fluorescence	  lifetime	  (44,	  47).	  	  The	  phase	  lifetime	  differences	  of	  NADH	  did	  not	  follow	  the	  same	  intensity-­‐based	  order	  for	  HS5,	  HS27A,	  and	  MSCs.	  	  Instead,	  MSCs	  presented	  the	  lowest	  NADH	  phase	  lifetime,	  followed	  by	  HS5	  and	  HS27A.	  	  	   To	  assess	  the	  impact	  of	  stromal	  cell	  type	  on	  the	  metabolic	  microenvironment	  of	  3D	  spheroids,	  we	  measured	  the	  intensity-­‐independent	  lifetime	  profile	  of	  NADH	  across	  the	  diameter	  of	  different	  cell	  type	  and	  size	  spheroids.	  Two	  factors	  determine	  the	  metabolic	  status	  of	  these	  spheroids:	  the	  exterior	  NADH	  lifetime	  and	  the	  slope	  of	  the	  NADH	  lifetime	  over	  the	  first	  60	  μm	  of	  the	  spheroid.	  	  The	  former	  reflects	  the	  non-­‐nutrient	  limited	  condition	  and	  the	  latter	  measures	  the	  responsiveness	  of	  stromal	  cell	  types	  to	  radial	  nutrient	  density	  and	  distance	  to	  the	  center	  of	  the	  spheroid.	  	  To	  measure	  radial	  lifetime	  profiles,	  we	  used	  four	  radial	  sections	  of	  multiple	  spheroids	  and	  a	  count-­‐weighted	  average	  of	  above-­‐threshold	  pixels	  to	  calculate	  average	  lifetime	  for	  radial	  positions	  (Supplemental	  Fig.	  D.1).	  As	  proof	  of	  concept	  for	  this	  approach,	  we	  show	  the	  size	  of	  MSC	  spheroids	  dictated	  the	  slope	  of	  the	  NADH	  lifetime	  gradient	  but	  not	  the	  exterior	  starting	  value	  (Fig.	  5.2).	  	  Small	  spheroids	  showed	  limited	  slope	  of	  change	  in	  NADH	  lifetime	  from	  exterior	  to	  interior,	  and	  we	  observed	  a	  rank-­‐order	  increase	  in	  slope	  with	  increasing	  size	  of	  spheroid	  (Fig.	  5.2B-­‐C).	  	  Lifetime	  did	  not	  change	  through	  depth	  of	  small	  non-­‐nutrient	  limited	  spheroids	  
	  117	  
(Supplemental	  Fig.	  D.2).	  	  Previous	  reports	  describe	  hypoxia	  and/or	  anoxia	  at	  around	  100	  μm	  from	  blood	  vessels	  in	  vivo	  rat	  mesentery	  (48),	  100-­‐150	  μm	  in	  tumor	  sections	  (49),	  and	  beyond	  several	  cell-­‐diameters	  in	  silico	  bone	  marrow	  models	  (50).	  	  Although	  it	  is	  difficult	  to	  decouple	  oxygen	  and	  other	  metabolic	  gradients	  from	  NADH	  lifetime	  profiles,	  our	  data	  suggest	  sensing	  of	  metabolic	  changes	  at	  distances	  smaller	  than	  described	  for	  hypoxia.	  	   Comparing	  among	  large	  spheroids	  of	  different	  stromal	  cell	  types,	  we	  found	  the	  non-­‐nutrient	  limited	  exterior	  condition	  reflects	  the	  NADH	  phase	  lifetimes	  measured	  in	  2D	  cultures,	  with	  MSCs	  having	  the	  lowest	  exterior	  lifetime,	  followed	  by	  HS-­‐5,	  and	  HS-­‐27A	  cells	  (Fig.	  5.3A-­‐B).	  	  This	  result	  suggests	  that	  the	  exterior	  of	  these	  spheroids	  have	  similar	  metabolic	  status	  as	  2D	  cultures	  with	  no	  metabolic	  limitations.	  	  HS-­‐5	  spheroids	  produced	  the	  lowest	  slope	  of	  NADH	  lifetime	  at	  0.00283	  ns/μm	  (95%	  CI:	  0.0025-­‐0.0032),	  followed	  by	  MSC	  at	  0.0039	  ns/μm	  (95%	  CI:	  0.0034-­‐0.0044),	  and	  HS-­‐27A	  at	  0.0041	  ns/μm	  (95%	  CI:	  0.0038-­‐0.0046).	  	  High	  slopes	  reflect	  flexibility	  between	  oxidative	  and	  glycolytic	  metabolism.These	  data	  reflect	  that	  HS-­‐5	  spheroids	  are	  the	  least	  responsive	  to	  radial	  nutrient	  gradients,	  followed	  by	  MSCs	  and	  HS-­‐27A	  	  cells	  both	  having	  similar	  high	  levels	  of	  responsiveness.	  	  	  To	  establish	  how	  MDA-­‐MB-­‐231	  cells	  distribute	  in	  spheroids	  with	  different	  metabolic	  profiles,	  we	  imaged	  locations	  of	  these	  breast	  cancer	  cells	  24	  hours	  after	  forming	  spheroids.	  	  MDA-­‐MB-­‐231	  cells	  distributed	  solely	  on	  the	  exterior	  of	  the	  more	  glycolytic,	  less	  metabolically	  responsive	  HS-­‐5	  spheroids.	  By	  comparison,	  we	  identified	  MDA-­‐MB-­‐231	  cells	  both	  in	  the	  interior	  and	  exterior	  of	  spheroids	  with	  the	  more	  metabolically	  responsive	  HS-­‐27A	  cells	  (Fig.	  5.3C-­‐D).	  	  Since	  spheroids	  are	  seeded	  with	  a	  homogenous	  mix	  of	  stromal	  and	  cancer	  cells,	  the	  interior-­‐exterior	  distribution	  must	  be	  an	  active	  migratory	  process	  by	  the	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cancer	  and/or	  stromal	  cells.	  	  These	  localization	  differences	  persist	  at	  longer	  time	  points.	  Over	  time	  the	  exterior	  cancer	  cells	  in	  HS-­‐27A	  spheroids	  grow	  substantially,	  whereas	  the	  interior	  MDA-­‐MB-­‐231	  cells	  do	  not	  (Fig.	  5.3C-­‐D).	  	  	  
5.4.3 Metabolic	  balance	  between	  glycolysis	  and	  glutaminolysis	  for	  cancer-­‐stromal	  co-­‐culture	  Increased	  glycolysis	  by	  HS-­‐5	  depletes	  bulk	  glucose	  levels	  by	  about	  20%,	  which	  we	  expect	  limits	  the	  local	  concentration	  available	  to	  the	  cancer	  cells.	  	  With	  depleted	  glucose,	  we	  expect	  cancer	  cells	  to	  be	  increasingly	  dependent	  on	  other	  sources	  of	  carbon,	  i.e.	  lactate,	  glutamine,	  amino	  acids,	  or	  fatty	  acids.	  Here	  we	  tested	  the	  interdependence	  of	  three	  breast	  cancer	  subtypes	  (MDA-­‐MB-­‐231,	  MDA-­‐MD-­‐468,	  and	  T47D)	  on	  combinations	  of	  glucose	  and	  glutamine	  when	  cultured	  with	  more	  metabolically	  responsive	  HS-­‐27A	  or	  unresponsive	  HS-­‐5	  stromal	  cells	  (Fig.	  5.4).	  	  After	  2	  days	  formation	  in	  full	  spheroid	  media	  and	  8	  days	  of	  culture	  in	  various	  glucose	  and	  glutamine	  concentrations,	  we	  plotted	  the	  fold	  change	  for	  cancer	  cell	  bioluminescence	  as	  compared	  to	  the	  high	  glucose	  and	  high	  glutamine	  condition,	  color-­‐coded	  for	  the	  log-­‐2	  based	  ratio	  of	  cancer	  to	  stromal	  signals	  (Fig.	  5.4).	  	  Corresponding	  surface	  plots	  for	  stromal	  components	  with	  the	  same	  color-­‐coding	  are	  found	  in	  the	  Supplemental	  Information	  (Fig.	  D.3).	  Comparing	  between	  breast	  cancer	  subtypes	  and	  their	  culture	  in	  the	  two	  stromal	  environments,	  each	  had	  a	  unique	  response	  to	  combinations	  of	  glucose	  and	  glutamine.	  MDA-­‐MB-­‐231	  cells	  are	  very	  responsive	  to	  both	  glucose	  and	  glutamine	  in	  both	  HS-­‐5	  and	  HS-­‐27A	  co-­‐cultures	  (Fig.	  5.4A-­‐B).	  	  Conversely,	  their	  counterpart	  stromal	  cells	  were	  insensitive	  to	  glutamine	  but	  highly	  sensitive	  to	  glucose	  for	  HS-­‐5,	  and	  largely	  insensitive	  to	  both	  glucose	  and	  glutamine	  for	  HS-­‐27A.	  	  These	  data	  correspond	  with	  our	  NADH	  lifetime	  profiles	  suggesting	  that	  HS-­‐5	  stromal	  cells	  are	  highly	  glycolytic,	  but	  HS-­‐27A	  cells	  are	  more	  flexibly	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glycolytic.	  	  Warmer	  color-­‐coding	  for	  low	  glutamine	  and	  high	  glucose	  conditions	  highlights	  the	  selective	  response	  of	  MDA-­‐MB-­‐231	  cells	  towards	  glutamine	  depletion	  in	  HS-­‐5	  co-­‐cultures.	  	  The	  stromal	  cells’	  glucose-­‐glutamine	  response	  surface	  profile	  was	  independent	  of	  counterpart	  cancer	  cells	  (Fig.	  D.3),	  suggesting	  the	  larger	  fraction	  of	  stromal	  cells	  in	  each	  spheroid	  dominates	  their	  response.	  	  MDA-­‐MB-­‐468	  followed	  closely	  after	  response	  of	  MDA-­‐MB-­‐231	  cells	  in	  HS-­‐5	  co-­‐cultures	  (Fig.	  5.4C),	  showing	  higher	  sensitivity	  to	  both	  glucose	  and	  glutamine,	  which	  is	  reflected	  by	  warmer	  color-­‐coding.	  	  In	  HS-­‐27A	  co-­‐cultures	  MDA-­‐MB-­‐468	  cells	  were	  refractory	  to	  changes	  in	  glucose	  and	  glutamine,	  suggesting	  a	  metabolically	  protective	  environment	  (Fig.	  5.4D).	  	  T47D	  cells	  showed	  no	  sensitivity	  to	  glutamine	  but	  extremely	  high	  sensitivity	  to	  glucose	  withdrawal	  in	  HS-­‐5	  co-­‐cultures	  (Fig.	  5.4E),	  which	  may	  reflect	  dependence	  on	  glycolysis	  that	  is	  associated	  with	  ER+	  dependent	  signaling	  (44).	  	  In	  HS-­‐27A	  co-­‐cultures,	  T47D	  were	  moderately	  responsive	  to	  glucose	  and	  glutamine	  withdrawal.	  	  These	  data	  are	  summarized	  in	  Table	  5.1,	  which	  captures	  the	  qualitative	  responsiveness	  of	  these	  breast	  cancer	  subtypes	  at	  the	  four	  glucose-­‐glutamine	  extremes	  of	  each	  surface	  plot.	  	  Recreating	  pharmacologic	  sensing	  of	  glutamine	  and/or	  glucose	  deprivation	  may	  provide	  an	  avenue	  for	  selectively	  eliminating	  some	  subsets	  of	  breast	  cancer	  metastases.	  	  Additionally,	  these	  results	  suggest	  that	  independence	  of	  T47D	  to	  glutamine	  withdrawal	  and	  MDA-­‐MB-­‐468	  cells	  independence	  of	  glucose	  and	  glutamine,	  may	  suggest	  resistant	  phenotypes	  that	  contribute	  to	  late	  bone	  metastasis	  relapse.	  	  
5.4.4 Metabolic	  inhibition	  selectively	  eliminates	  cancer	  cells	  Using	  known	  inhibitors	  of	  glycolysis	  we	  tested	  whether	  we	  could	  selectively	  eliminate	  growing	  and	  quiescent	  cancer	  cells	  by	  inhibiting	  differential	  metabolic	  profiles.	  	  Using	  2-­‐deoxy-­‐glucose,	  which	  inhibits	  the	  first	  enzyme	  in	  glycolysis	  we	  confirmed	  that	  HS-­‐5	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cells	  are	  more	  dependent	  on	  glycolysis	  than	  HS-­‐27A	  and	  MDA-­‐MB-­‐231	  cells	  (Fig.	  5.5A-­‐B).	  Dose-­‐response	  curves	  for	  2-­‐deoxy-­‐glucose	  closely	  match	  the	  differential	  effects	  on	  cancer	  and	  stromal	  cells	  produced	  by	  glucose	  deprivation	  (Supplemental	  Fig.	  D.4).	  	  As	  compared	  to	  HS-­‐5	  cells,	  HS-­‐27A	  and	  MDA-­‐MB-­‐231	  cells	  grown	  with	  either	  stromal	  spheroids	  are	  similarly	  less	  sensitive	  to	  both	  2-­‐deoxy-­‐glucose	  and	  glucose	  deprivation.	  	  Using	  dichloroacetate,	  which	  inhibits	  pyruvate	  dehydrogenase	  kinase	  and	  forces	  pyruvate	  away	  from	  lactate	  production	  into	  mitochondria,	  we	  selectively	  eliminated	  cancer	  cells	  in	  both	  their	  quiescent	  and	  growing	  states	  in	  both	  HS-­‐5	  and	  HS-­‐27A	  spheroids	  (Fig.	  5.5C-­‐D).	  	  We	  also	  tested	  known	  inhibitors	  of	  oxidative	  metabolism	  via	  electron	  transport	  decoupling	  and	  inhibition	  of	  oxidative	  metabolism.	  	  As	  predicted	  by	  minimal	  responsiveness	  of	  HS-­‐5	  and	  HS-­‐27A	  to	  oligomycin	  in	  Seahorse	  assays,	  inhibition	  of	  Complexed	  I	  and	  V	  with	  rotenone	  and	  oligomycin,	  respectively,	  had	  minimal	  effect	  on	  stromal	  cells	  (Fig.	  5.5C-­‐D).	  	  MDA-­‐MB-­‐231	  cells	  were	  selectively	  eliminated	  in	  both	  HS-­‐5	  and	  HS-­‐27A	  spheroids,	  suggesting	  the	  role	  of	  oxidative	  metabolism	  role	  in	  both	  quiescent	  and	  growing	  situations.	  	  Inhibition	  of	  oxidative	  metabolism	  was	  most	  effective	  in	  the	  growth	  supporting	  HS-­‐27A	  microenvironment	  and	  less	  positively	  selective	  in	  HS-­‐5	  spheroids.	  	  Although	  positively	  selective	  for	  both,	  eliminating	  cancer	  cells	  via	  inhibition	  of	  oxidative	  metabolism	  was	  incomplete,	  with	  10-­‐20%	  and	  30-­‐50%	  CBGreen	  signal	  remaining	  at	  maximal	  levels	  of	  rotenone	  and	  oligomycin,	  for	  HS-­‐27A	  and	  HS-­‐5	  co-­‐cultures,	  respectively.	  The	  incomplete	  response	  to	  inhibition	  of	  oxidative	  metabolism	  and	  the	  cancer	  cell	  location	  within	  HS-­‐27A	  spheroids	  (Fig.	  5.3D)	  suggests	  there	  is	  a	  reservoir	  of	  glycolytic	  cancer	  cells	  housed	  in	  the	  center	  of	  the	  HS-­‐27A	  spheroid.	  	  Therefore,	  molecular	  intervention	  that	  suppressed	  both	  oxidative	  and	  glycolytic	  metabolism	  may	  better	  eliminate	  cancer	  cells	  in	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both	  metabolic	  states.	  	  Co-­‐inhibition	  of	  glycolysis	  and	  oxidative	  metabolism	  was	  a	  successful	  strategy	  in	  reversing	  lupus	  by	  deactivating	  CD4+	  T	  cells	  (51).	  Contact-­‐inhibition	  induced	  quiescence	  of	  stromal	  fibroblasts	  has	  previously	  been	  coupled	  with	  maintenance	  of	  glycolytic	  throughput,	  shuttling	  glucose	  into	  the	  pentose	  phosphate	  shunt,	  and	  backward	  flux	  of	  glutamine	  into	  the	  TCA	  cycle	  (52).	  	  To	  test	  whether	  flexible	  metabolism	  of	  HS-­‐27A	  and	  their	  support	  of	  MDA-­‐MB-­‐231	  cell	  growth	  is	  dependent	  on	  the	  pentose	  phosphate	  pathway,	  we	  measured	  their	  dose	  response	  to	  the	  steroid	  hormone,	  dehydroepiandrosterone	  (DHEA)	  (Fig.	  5.5E).	  	  Interestingly,	  the	  cancer	  cells	  were	  eliminated	  with	  positive	  selectively	  in	  both	  HS-­‐5	  and	  HS-­‐27A	  spheroids,	  suggesting	  the	  involvement	  of	  the	  pentose	  phosphate	  pathway	  for	  these	  cancer	  cells	  in	  both	  stromal	  environments.	  	  The	  IC50	  was	  reduced	  for	  both	  stromal	  and	  cancer	  cells	  in	  HS-­‐27A	  as	  compared	  to	  HS-­‐5	  co-­‐cultures.	  	  These	  data	  suggest	  that	  unlike	  HS-­‐5,	  HS-­‐27A	  produce	  compensatory	  shift	  towards	  the	  pentose	  phosphate	  pathway	  within	  spheroids.	  	  We	  previously	  suggested	  that	  selective	  elimination	  of	  quiescent	  and	  growing	  MDA-­‐MB-­‐231	  cells	  by	  inhibition	  of	  constitutively	  active	  KRas	  (MEK	  inhibitor,	  PD0325901)	  could	  be	  attributed	  to	  non-­‐proliferation-­‐based	  mechanisms	  (41)	  (Fig.	  5.5F).	  To	  test	  the	  metabolic	  effects	  of	  MEK	  inhibition,	  we	  pretreated	  MDA-­‐MB-­‐231	  cells	  overnight	  prior	  to	  measuring	  extracellular	  flux	  in	  the	  Seahorse	  system	  (Fig.	  5.6).	  	  Metabolic	  activity	  was	  suppressed	  for	  glutaminolysis,	  glycolysis,	  and	  maximal	  glycolytic	  capacity.	  	  These	  data	  further	  suggest	  that	  MEK	  inhibition	  functions	  in	  part	  through	  a	  non-­‐cell	  cycle-­‐based	  mechanism	  and	  suppresses	  both	  glycolytic	  and	  oxidative	  metabolism.	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5.5 Discussion	  and	  Future	  Goals	  Elimination	  of	  cancer	  cells	  with	  non-­‐cytotoxic	  therapies	  has	  two-­‐fold	  benefit.	  	  Firstly,	  targeting	  non-­‐cytotoxic	  can	  limit	  toxicity	  to	  other	  high	  turnover	  cells	  such	  as	  hematopoietic	  cells,	  bone	  marrow,	  mucosal	  membranes,	  etc.	  	  Secondly	  and	  our	  major	  focus	  here,	  targeting	  non-­‐cytotoxic	  phenotypes	  offers	  means	  to	  eliminate	  quiescent	  cancer	  cells	  that	  are	  refractory	  to	  standard	  chemotherapies	  therapies	  and	  contribute	  to	  relapse.	  	  Here	  we	  build	  upon	  our	  previous	  co-­‐culture	  model	  of	  bone	  marrow	  metastases	  in	  order	  to	  analyze	  metabolic	  phenotypes	  in	  quiescent	  and	  growing	  cancer	  cells.	  	  Using	  this	  system	  we	  identify	  the	  glycolytic	  HS-­‐5	  spheroids	  promote	  cancer	  cell	  quiescence	  and	  the	  basally	  less	  metabolically	  active,	  but	  more	  responsive	  HS-­‐27A	  spheroids	  promote	  cancer	  growth.	  	  Using	  our	  complementary	  strategies	  to	  measure	  and	  perturb	  metabolic	  status	  of	  growing	  and	  quiescent	  cells	  may	  provide	  a	  platform	  to	  screen	  therapies	  that	  limit	  quiescent	  cancer	  relapse.	  	  Despite	  derivation	  from	  the	  same	  mesenchymal	  stem	  cell	  population	  and	  corresponding	  with	  previous	  results	  (34),	  our	  results	  reveal	  that	  HS-­‐5	  and	  HS-­‐27A	  cells	  represent	  two	  metabolically	  distinct	  stromal	  populations.	  	  Our	  measured	  redox	  ratios,	  extracellular	  flux	  analysis,	  glucose	  consumption,	  basal	  NADH	  phase	  lifetimes,	  and	  radial	  NADH	  phase	  lifetime	  gradients	  describe	  HS-­‐5	  cells	  as	  more	  glycolytic	  and	  less	  metabolically	  responsive	  than	  HS-­‐27A	  cells.	  These	  results,	  previous	  results	  of	  HS-­‐27A	  cells	  expressing	  a	  marker	  of	  multi-­‐potency	  and	  of	  the	  hematopoietic	  niche	  (34),	  and	  description	  of	  metabolically	  flexible	  mesenchymal	  stem	  cells	  (15),	  suggests	  that	  HS-­‐27A	  are	  less	  differentiated	  and	  more	  common	  to	  the	  hematopoietic	  niche	  in	  vivo	  than	  HS-­‐5	  cells.	  	  Furthermore,	  our	  results	  suggest	  that	  HS-­‐5	  spheroids	  contain	  a	  larger	  reservoir	  of	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glycolytic	  cancer	  cells	  resistant	  to	  inhibition	  of	  oxidative	  metabolism	  as	  compared	  to	  HS-­‐27A	  co-­‐cultures.	  	  These	  data,	  the	  cancer	  cell	  location	  data,	  and	  the	  minimal	  NADH	  lifetime	  responsiveness	  suggests	  that	  HS-­‐5	  co-­‐cultures	  may	  model	  rigid	  hypoxic-­‐like,	  glycolytic	  phenotypes	  as	  compared	  to	  the	  metabolically	  responsive	  HS-­‐27A	  spheroids.	  Conversely	  in	  HS-­‐27A	  spheroids,	  cancer	  sensitivity	  to	  inhibition	  of	  oxidative	  metabolism,	  glycolysis,	  and	  the	  pentose	  phosphate	  pathway,	  taken	  with	  cancer	  cell	  distribution	  on	  NADH	  lifetime	  profile,	  all	  suggest	  these	  stromal	  cells	  to	  be	  more	  metabolically	  responsive.	  	  While	  it	  is	  difficult	  to	  assign	  cause-­‐effect	  with	  these	  outcomes,	  it	  is	  clear	  that	  the	  more	  metabolically	  responsive	  HS-­‐27A	  spheroids	  provide	  protection	  from	  glucose-­‐glutamine	  withdrawal	  for	  three	  breast	  cancer	  sub-­‐populations	  (MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐468,	  and	  T47D).	  	  Using	  this	  strategy,	  we	  reveal	  unique	  metabolic	  profiles	  for	  three	  breast	  cancer	  sub-­‐populations.	  Triple	  negative	  (ER-­‐/PR-­‐/Her2-­‐)	  MDA-­‐MB-­‐231	  cells	  were	  dependent	  on	  both	  glucose	  and	  glutamine	  in	  both	  stromal	  cell	  types,	  which	  may	  reflect	  a	  previous	  report	  of	  decoupled	  dependence	  of	  K-­‐Ras	  transformed	  cells	  on	  both	  glucose	  and	  glutamine	  (53).	  	  In	  this	  work	  they	  describe	  that	  K-­‐Ras	  transformed	  cells	  such	  as	  MDA-­‐MB-­‐231	  cells,	  rely	  on	  glycolysis	  for	  ATP	  and	  glutamine	  for	  anaplerosis.	  Additionally,	  we	  found	  inhibition	  of	  MEK	  within	  MDA-­‐MB-­‐231	  cells	  suppressed	  both	  oxidative	  metabolism	  and	  glycolysis	  resulting	  in	  selective	  cancer	  cell	  elimination	  in	  both	  spheroid	  environments.	  For	  these	  cancer	  cells,	  mimicking	  combined	  oxidative	  and	  glycolytic	  inhibition	  may	  provide	  a	  strategy	  for	  eliminating	  metastases	  similar	  to	  normalization	  of	  metabolism	  to	  reverse	  symptoms	  of	  lupus	  (51).	  Similarly,	  triple	  negative	  (ER-­‐/PR-­‐/Her2-­‐)	  MDA-­‐MB-­‐468	  cells	  showed	  high	  sensitivity	  to	  glucose	  and	  glutamine	  in	  HS-­‐5,	  but	  nearly	  undetectable	  response	  in	  HS-­‐27A	  co-­‐cultures,	  suggesting	  a	  supportive	  environment	  created	  by	  HS-­‐27A	  cells.	  	  Such	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Figure	  5.1.	  HS-­‐5	  and	  HS-­‐27A	  bone	  marrow	  spheroids	  support	  different	  levels	  of	  glucose	  consumption	  
and	  growth	  of	  MDA-­‐MB-­‐231	  cells.	  	  (A)	  Increasing	  proportion	  of	  HS-­‐5	  relative	  to	  HS-­‐27A	  stromal	  cells	  decrease	  the	  relative	  growth	  of	  MDA-­‐MB-­‐231	  cells.	  	  We	  measured	  growth	  by	  bioluminescent	  flux	  fold	  change	  from	  day	  2	  to	  day	  10	  and	  plotted	  it	  on	  the	  left	  axis	  (black	  bars).	  	  Fold	  change	  values	  are	  reported	  as	  mean	  +	  S.E.M.	  for	  N	  =	  28	  spheroids	  for	  each	  condition	  from	  one	  of	  three	  representative	  experiments.	  In	  a	  separate	  experiment	  without	  cancer	  cells	  but	  similar	  proportions	  of	  HS-­‐5	  and	  HS-­‐27A,	  we	  found	  glucose	  consumption	  to	  increase	  with	  larger	  proportion	  of	  HS-­‐5	  cells.	  	  We	  plotted	  the	  glucose	  consumption	  on	  the	  right	  axis	  (Gray	  bars)	  as	  percentage	  of	  25mM	  glucose	  in	  base	  media.	  Glucose	  values	  are	  reported	  as	  mean	  +	  S.E.M.	  for	  5	  measurements	  with	  a	  commercial	  glucose	  meter	  for	  supernatants	  pooled	  from	  4	  spheroids	  (20	  spheroids	  total)	  from	  two	  independent	  setups.	  (B)	  For	  both	  HS-­‐5	  (green)	  and	  HS-­‐27A	  (purple)	  stromal	  cells	  we	  plotted	  the	  oxygen	  consumption	  rate	  and	  extracellular	  acidification	  rate	  for	  sequential	  baseline	  (i)	  glutamine	  conditions,	  (ii)	  after	  injection	  of	  25mM	  glucose,	  or	  (ii)	  after	  injection	  of	  1μM	  oligomycin	  in	  the	  XFe96	  Seahorse	  Biosciences	  assay.	  	  Averages	  are	  pooled	  for	  N=6	  wells	  over	  three	  consecutive	  mixing-­‐measurement	  cycles.	  	  Assays	  were	  seeded	  overnight	  with	  15x103	  stromal	  cells	  per	  well.	  	  We	  incubated	  for	  1	  hour	  prior	  to	  measurement	  in	  un-­‐buffered	  media	  containing	  essential	  amino	  acids	  and	  glutamine,	  per	  manufacture	  recommendation	  for	  the	  XF	  Glycolysis	  Stress	  Test.	  Frequency	  distributions	  of	  (C)	  NADH,	  (D)	  FAD,	  and	  (E)	  NADH:FAD	  ratio	  for	  HS-­‐5,	  HS-­‐27A,	  and	  primary	  mesenchymal	  stem	  cells	  (MSCs).	  	  For	  each	  intensity-­‐	  or	  ratio-­‐level	  (x-­‐axes)	  of	  the	  frequency	  distribution,	  the	  maximum-­‐normalized	  values	  are	  plotted	  as	  the	  mean	  ±	  S.E.M.	  for	  four	  images,	  from	  one	  of	  three	  representative	  setups.	  	  Redox	  ratios	  are	  calculated	  in	  a	  pixel-­‐by-­‐pixel	  manner	  from	  four	  pictures	  from	  one	  of	  three	  representative	  setups.	  	  Intensity-­‐based	  NADH	  images	  were	  captured	  with	  a	  740	  nm	  excitation	  and	  420-­‐460nm	  emission	  filter	  and	  FAD	  is	  captured	  with	  890	  nm	  excitation	  and	  495-­‐540	  nm	  emission	  filter.	  (F)	  NADH	  phase	  lifetime	  plotted	  as	  mean	  ±	  S.E.M.	  for	  each	  of	  the	  same	  three	  stromal	  cell	  types	  from	  N	  =	  10	  measurements,	  from	  three	  independent	  setups.	  We	  pooled	  lifetime-­‐based	  data	  due	  to	  our	  ability	  to	  calibrate	  lifetime	  measurements	  between	  trials.	  Lifetime-­‐based	  measurements	  were	  captured	  with	  a	  740	  nm	  excitation	  and	  filtered	  with	  435	  (40)	  nm	  and	  530	  (11)	  nm	  band-­‐pass	  filters	  for	  NADH.	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Figure	  5.2.	  Lifetime-­‐based	  optical	  metabolic	  imaging	  reveals	  NADH	  lifetime	  gradients	  in	  different	  size	  
mesenchymal	  stem	  cell	  spheroids.	  	  (A)	  For	  MSC	  spheroids,	  increasing	  diameter	  from	  120μm,	  to	  160μm	  and	  200	  μm	  diameter	  changed	  the	  NADH	  phase	  lifetime	  profile	  (B).	  (A)	  Images	  of	  spheroids	  are	  depiction	  of	  the	  number	  of	  photon	  counts	  acquired	  across	  spheroids.	  	  Note	  that	  larger	  spheroids	  required	  longer	  acquisition	  time	  to	  provide	  above-­‐background	  counts	  on	  the	  interior	  of	  the	  spheroid,	  hence	  the	  high	  counts	  on	  the	  exterior.	  	  Increasing	  spheroid	  size	  corresponded	  with	  increasing	  NADH	  lifetime	  slope	  (C),	  which	  we	  attribute	  to	  decreasing	  nutrient	  concentrations	  for	  larger	  spheroids.	  	  See	  Supplemental	  Figure	  D.1	  for	  details	  of	  quantification.	  	  NADH	  phase	  lifetime	  profiles	  are	  averaged	  for	  four	  radial	  cross-­‐sections	  on	  four	  spheroids	  for	  each	  size	  spheroid.	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Figure	  5.3.	  Bone	  marrow	  stromal	  cell	  type	  produce	  different	  3D	  metabolic	  gradients	  in	  spheroids.	  	  (A)	  Similar	  to	  Figure	  5.2,	  NADH	  fluorescence	  lifetime	  profiles	  reveal	  rank-­‐order	  decrease	  of	  lifetime	  for	  the	  exterior	  of	  spheroids	  similar	  to	  in	  2D	  cultures	  (Fig.	  5.1F),	  with	  HS-­‐27A	  the	  highest,	  followed	  by	  HS-­‐5	  and	  MSCs.	  	  (B)	  The	  slope	  of	  the	  NADH	  phase	  lifetime	  measured	  by	  linear	  regression	  over	  the	  first	  60	  μm	  was	  highest	  for	  MSCs,	  closely	  followed	  by	  HS-­‐27A,	  and	  the	  lowest	  with	  HS-­‐5.	  	  NADH	  phase	  lifetime	  profiles	  are	  averaged	  for	  four	  radial	  cross-­‐sections	  on	  four	  spheroids	  for	  each	  size.	  	  Fluorescence	  imaging	  of	  cancer	  cells	  showed	  localization	  to	  the	  exterior	  of	  (C)	  HS-­‐5	  spheroids	  but	  to	  interior	  and	  exterior	  of	  (D)	  HS-­‐27A	  spheroids.	  	  These	  locations	  were	  also	  maintained	  at	  longer	  time	  points.	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Figure	  5.4.	  Interdependence	  on	  glucose	  and	  glutamine	  for	  cancer	  and	  stromal	  cells	  in	  bone	  marrow	  




Figure	  5.5.	  Molecular	  perturbation	  of	  glycolytic	  or	  oxidative	  metabolism	  reveals	  selective	  elimination	  
of	  cancer	  or	  stromal	  cells.	  	  We	  plot	  dose-­‐response	  curves	  for	  (A-­‐B)	  MDA-­‐MB-­‐231	  grown	  in	  (green	  curve)	  HS-­‐5	  or	  (purple	  curve)	  HS-­‐27A	  spheroids.	  	  We	  plot	  their	  fold	  change	  Treatment	  with	  (A)	  2-­‐deoxy-­‐D-­‐glucose,	  (B)	  dichloroacetate,	  (C)	  oligomycin,	  (D)	  rotenone,	  (E)	  DHEA,	  and	  (F)	  PD0325901	  result	  in	  typical	  sigmoidal	  dose-­‐response	  curves.	  	  The	  selectivity	  curves	  corresponding	  to	  (black	  curves)	  HS-­‐5	  and	  (gray)	  HS-­‐27A	  co-­‐cultures	  represent	  the	  log-­‐2-­‐scaled	  ratio	  of	  CBRed	  to	  CBGreen	  signal,	  both	  normalized	  to	  untreated	  conditions	  and	  plotted	  on	  the	  right	  y-­‐axis.	  	  Negative	  and	  positive	  values	  of	  selectivity	  denote	  relative	  loss	  of	  stromal	  or	  cancer	  signals.	  	  We	  omit	  selectivity	  values	  for	  dose	  levels	  with	  both	  CBGreen	  and	  CBRed	  signals	  less	  than	  1%	  of	  untreated.	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Figure	  5.6.	  	  Suppression	  of	  metabolism	  by	  PD0325901	  for	  MDA-­‐MB-­‐231	  cells.	  Similar	  to	  Figure	  5.1B,	  we	  plotted	  the	  oxygen	  consumption	  rate	  and	  extracellular	  acidification	  rate	  for	  MDA-­‐MB-­‐231	  cells	  after	  sequential	  baseline	  (i)	  glutamine	  conditions,	  (ii)	  after	  injection	  of	  25mM	  glucose,	  or	  (iii)	  after	  injection	  of	  1μM	  oligomycin	  in	  the	  XFe96	  Seahorse	  Biosciences	  assay.	  	  Averages	  are	  pooled	  for	  N=6	  wells	  over	  three	  consecutive	  mixing-­‐measurement	  cycles.	  	  Assays	  were	  seeded	  overnight	  with	  15x103	  cancer	  cells	  per	  well.	  	  After	  allowing	  cells	  to	  firmly	  adhere,	  we	  treated	  cancer	  cells	  with	  PD0325901	  for	  12	  hours	  prior	  to	  the	  assay.	  	  We	  incubated	  for	  1	  hour	  prior	  to	  measurement	  in	  un-­‐buffered	  media	  containing	  essential	  amino	  acids	  and	  glutamine,	  per	  manufacture	  recommendation	  for	  the	  XF	  Glycolysis	  Stress	  Test.	  	  	  	  
Table	  5.1.	  Summary	  of	  metabolic	  interdependence	  on	  glucose	  and	  glutamine	  
withdrawal.	  	  The	  qualitative	  characteristics	  designate	  positive	  or	  negative	  association	  with	  fraction	  of	  signal	  remaining	  as	  compared	  to	  the	  high	  glucose	  and	  high	  glutamine	  condition,	  for	  glucose	  and	  glutamine	  extremes	  (-­‐	  indicated	  >	  1.0,	  +/-­‐	  no	  change,	  +	  0.5-­‐1.0,	  ++	  0.2-­‐0.5	  fraction	  remaining,	  +++	  0.0-­‐0.2	  fraction	  remaining).	  	   Cell	  Type	  	  (Stromal	  Pair)	   Cell	  Characteristic	   Glucose	  Dependence	   Glutamine	  Dependence	  231	  (HS5)	   Triple	  Negative,	  Active	  MEK	   ++	   ++	  231	  (HS27A)	   ++	   ++	  468	  (HS5)	   Triple	  Negative	   +++	   +++	  468	  (HS27A)	   +/-­‐	   +/-­‐	  T47D	  (HS5)	   ER+	  	   +++	   +/-­‐	  T47D	  (HS27A)	   ++	   ++	  HS5*	   MSC-­‐derived	  Cell	  Line	   +++	   -­‐	  HS27A*	   MSC-­‐derived	  Cell	  Line	   +	   +	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6 Chapter Six: Future Goals and Directions 
6.1 Summary	  The	  primary	  goal	  of	  this	  dissertation	  was	  to	  develop	  systems	  that	  model	  compartments	  of	  the	  metastatic	  cascade	  that	  are	  difficult	  to	  analyze	  experimentally.	  	  By	  experimentally	  beginning	  to	  bridge	  the	  physical	  and	  biological	  dimensionality	  gap	  between	  standard	  in	  vitro	  conditions	  and	  in	  vivo	  physiology,	  this	  dissertation	  highlights	  that	  systems	  of	  interacting	  cellular	  components	  behave	  very	  differently	  than	  individual	  components	  alone.	  	  In	  the	  metastatic	  process,	  multiple	  cells	  interact	  to	  drive	  bulk	  phenomena	  and	  rare,	  single	  cell	  events	  that	  contribute	  to	  cell	  functions	  and	  treatment	  efficacy.	  	  By	  increasing	  the	  number	  of	  these	  interacting	  components	  and	  improving	  the	  scales	  of	  observation	  in	  our	  experimental	  systems	  (single	  and	  bulk	  events),	  we	  were	  able	  to	  observed	  how	  relatively	  few	  cells	  interact	  in	  primary	  and	  metastatic	  sites	  and	  may	  contribute	  to	  metastasis.	  	  	  We	  highlight	  the	  success	  of	  using	  our	  in	  vitro	  models	  to	  increase	  dimensionality	  (physical	  and	  biological),	  to	  integrate	  the	  entire	  microenvironment	  (biochemical,	  biomechanical,	  metabolic),	  and	  create	  insights	  that	  predict	  in	  vivo	  responses.	  	  Firstly,	  in	  our	  source	  sink	  model	  we	  found	  a	  high-­‐matrix-­‐binding	  chemokine	  isoform	  to	  drive	  high	  sensitivity	  migration,	  be	  more	  refractory	  towards	  molecular	  inhibition	  even	  at	  low	  secretion	  rates,	  to	  work	  independently	  of	  receptor-­‐based	  scavenging,	  and	  to	  have	  increased	  expression	  in	  advanced	  breast	  cancer	  as	  compared	  to	  other	  isoforms	  of	  this	  chemokines.	  	  The	  second	  in	  vivo	  insight	  we	  found	  was	  using	  our	  bone	  marrow	  spheroid	  model	  to	  identify	  
	  136	  
therapy	  combinations	  that	  predicted	  complete	  elimination	  of	  breast	  cancer	  cells	  from	  mouse	  bone	  marrow.	  	  These	  two	  examples	  highlight	  the	  benefits	  of	  	  developing	  robust	  and	  practical	  experimental	  systems	  that	  better	  capture	  in	  vivo	  physiology	  of	  metastasis.	  By	  studying	  processes	  underlying	  metastasis,	  we	  hope	  to	  screen	  for	  prognostic	  markers	  and	  therapies	  that	  prevent	  and/or	  eliminate	  metastatic	  disease.	  	  In	  order	  to	  meet	  these	  challenges,	  we	  developed	  multiple	  tissue	  engineering	  and	  imaging	  systems	  to	  bridge	  the	  dimensionality	  gap	  between	  standard	  in	  vitro	  assays	  and	  in	  vivo	  physiology.	  	  Further	  development	  of	  the	  systems	  utilized	  in	  this	  dissertation	  will	  advance	  our	  understanding	  of	  metastatic	  disease.	  	  In	  particular,	  leveraging	  these	  systems	  in	  combination	  with	  three	  specific	  avenues	  will	  provide	  substantial	  advances	  towards	  improving	  clinical	  medicine,	  including	  further	  increasing	  dimensionality,	  computational	  modeling,	  and	  patient-­‐specific	  models.	  
6.2 Increasing	  Dimensionality	  
In	  vivo	  physiology	  is	  inherently	  multi-­‐dimensional,	  involving	  multiple	  cell	  types,	  time	  scales,	  and	  3D	  physical	  interactions.	  	  Further	  development	  of	  practical	  and	  robust	  in	  
vitro	  models	  that	  capture	  in	  vivo	  characteristics	  will	  improve	  our	  ability	  to	  model,	  screen	  for	  markers,	  and	  design	  therapies	  against	  metastatic	  disease.	  	  Shifting	  from	  simple,	  relatively	  amorphous	  3D	  models	  (spheroids,	  hydrogels),	  towards	  highly	  controlled,	  organoid	  systems	  is	  one	  such	  improvement	  in	  dimensionality	  (1).	  Interfacing	  organoid	  cultures	  with	  microfluidic	  control,	  reagent	  delivery	  and	  mechanical	  stimulation	  will	  further	  our	  ability	  to	  model	  physiology	  with	  “organ-­‐on-­‐chip”	  technology”	  (2).	  	  For	  instance,	  encapsulating	  skin,	  hair,	  (3),	  brain	  (4),	  bone	  marrow	  (5),	  intestines,	  and/or	  liver	  (6)	  on	  microfluidic	  chips	  allows	  perfusion,	  extended	  observation,	  fine-­‐tuned	  delivery	  of	  reagents,	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and/or	  pharmacokinetic-­‐pharmacodynamic	  studies.	  	  In	  addition	  to	  increasing	  the	  biological	  and	  physical	  dimensionality	  of	  tissue	  engineering	  tools,	  improving	  the	  time-­‐	  and	  spatial-­‐	  resolution	  of	  analysis	  will	  further	  advance	  our	  understanding	  of	  metastasis.	  Such	  advances	  also	  require	  integration	  of	  novel	  optical	  and	  molecular	  imaging	  tools	  to	  improve	  spatial	  and	  temporal	  scales	  of	  observation.	  	  From	  a	  practical	  standpoint,	  simple	  tools	  that	  increase	  physiological	  dimensionality	  are	  most	  critical	  to	  near	  term	  advances.	  	  For	  instance	  we	  used	  surface-­‐templated	  3D	  hydrogels	  to	  recreate	  source-­‐sink	  migration	  (7).	  	  In	  this	  study,	  proteoglycans	  in	  the	  patterned	  extracellular	  matrix	  were	  critical	  for	  shaping,	  presentation,	  and/or	  sensing	  of	  chemotactic	  gradients.	  	  Similarly,	  we	  used	  a	  similar	  3D	  cell-­‐laden	  hydrogel	  system	  to	  adapt	  standard	  384	  well	  2D	  assays	  to	  recreate	  decreased	  sensitivity	  to	  therapies	  within	  3D	  culture	  (8).	  	  Building	  upon	  these	  systems,	  adding	  physical	  and	  biological	  dimensionality,	  and	  improving	  our	  observation	  scales	  will	  improve	  our	  knowledge	  of	  how	  to	  impede/eliminate	  the	  few	  cells	  that	  interact	  with	  their	  microenvironment	  to	  metastasize.	  
6.3 Computational	  Modeling	  Computational	  modeling	  will	  aid	  the	  development	  and	  analysis	  of	  increased	  dimensionality	  within	  in	  vitro	  and	  in	  vivo	  models	  (9)	  (10)	  (11).	  	  With	  increasing	  dimensionality	  of	  in	  vitro	  assays,	  experiments	  become	  more	  costly,	  more	  multivariate	  and	  complicated	  to	  analyze,	  and	  collectively	  more	  difficult	  to	  interpret.	  	  Computational	  models	  provide	  three	  avenues	  for	  improvement	  to	  experimental	  models:	  1)	  preemptive	  sensitivity	  analysis	  to	  define/reduce	  the	  number	  of	  minimally	  necessary	  experiments,	  2)	  integration	  of	  multiple	  scales	  of	  data	  (DNA/RNA	  sequencing,	  proteomic,	  signaling,	  phenotypic	  outcomes,	  and	  response	  to	  therapy),	  and	  3)	  improving	  data	  interpretation	  at	  scales	  by	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typical	  sampling.	  	  One	  example	  is	  our	  use	  of	  agent-­‐based	  models	  to	  visualize	  the	  magnitude	  and	  shape	  of	  chemokine	  gradients,	  which	  were	  impossible	  to	  observe	  in	  our	  in	  vitro	  model	  of	  source-­‐sink	  migration	  (Chang,	  2015,	  work	  in	  progress).	  	  By	  fitting	  experimental	  cell	  migration	  data	  to	  ODE	  models	  that	  recreate	  intracellular	  receptor-­‐ligand	  dynamics,	  extracellular	  ligand	  kinetics	  (mass	  transfer,	  surface	  binding,	  etc),	  and	  agent-­‐based	  cell	  movement,	  we	  extended	  our	  2D	  microfluidic	  source-­‐sink	  model	  to	  predictions	  of	  gradient	  formation	  and	  migration	  in	  vivo.	  	  More	  so,	  we	  modeled	  the	  limited	  efficacy	  of	  receptor-­‐ligand	  inhibitors	  based	  on	  high	  local	  concentration	  of	  high	  binding	  ligand	  isoforms.	  	  We	  expect	  that	  combining	  similar	  modeling	  approaches	  with	  large	  cohorts	  of	  gene	  expression	  data	  and	  metastatic	  outcomes	  will	  further	  link	  clinical	  and	  experimental	  data	  to	  provide	  prognostic	  markers	  and	  therapeutic	  opportunities.	  
6.4 Patient-­‐specific	  Models	  Improved	  culture	  techniques,	  tools	  to	  induce	  cell	  differentiation,	  and	  improved	  tissue	  sampling/expansion	  techniques	  make	  working	  with	  primary	  patient	  tissues	  increasingly	  feasible	  (1).	  	  Combining	  tissue	  engineering	  and	  molecular	  imaging	  techniques	  described	  in	  this	  dissertation	  with	  primary	  patient	  samples	  will	  allow	  direct	  drug	  screening	  against	  patient-­‐specific	  phenotypes.	  	  For	  example,	  routine	  bone	  marrow	  biopsies	  for	  breast	  cancer	  patients	  enable	  growth	  and	  expansion	  of	  primary	  bone	  marrow	  stromal	  cells	  that	  form	  3D	  spheroids	  (12).	  	  Culturing	  of	  patient-­‐matched	  circulating	  and	  resected	  primary	  tumor	  cells	  and	  within	  these	  patient	  bone	  marrow	  spheroids	  would	  allow	  screening	  against	  refractory	  cancer	  cells	  in	  this	  microenvironent.	  	  Multi-­‐modal	  imaging	  tools	  have	  been	  described	  to	  work	  with	  primary	  samples,	  which	  would	  enable	  the	  many	  strategies	  contained	  in	  this	  dissertation.	  	  Using	  primary	  patient	  samples	  within	  these	  experimental	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models	  may	  provide	  avenues	  to	  experimentally	  predict	  therapies	  that	  will	  limit	  metastatic	  disease	  and	  relapse	  for	  patients.	  	  These	  combined	  strategies	  may	  begin	  to	  allow	  drug	  development	  that	  accounts	  for	  intra-­‐	  and	  inter-­‐patient	  disease	  heterogeneity,	  which	  is	  a	  major	  challenge	  to	  successful	  treatment	  of	  all	  diseased	  cells.	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Figure	  A.2.	  	  Increased	  chemotaxis	  of	  CXCR4+	  cells	  toward	  CXCL12-­‐γ.	  	  (A-­‐D)	  Position	  frequency	  distribution	  of	  CXCR4+	  cells	  relative	  to	  the	  starting	  point	  (channel	  boundaries).	  Frequencies	  are	  normalized	  to	  the	  number	  of	  cells	  per	  view.	  	  These	  data	  are	  composite	  distributions	  for	  each	  CXCL12-­‐isoform	  representing	  10-­‐11	  devices	  with	  6	  view	  fields	  each	  (~15x103	  cells	  total	  per	  histogram).	  	  The	  black	  distribution	  represents	  the	  pooled	  initial	  distribution.	  	  Graphs	  depict	  chemotaxis	  toward	  CXCL12	  as	  a	  shift	  to	  positive	  positions	  with	  higher	  values	  denoting	  greater	  distances	  traveled	  by	  cells.	  (E)	  Production	  of	  CXCL12	  isoforms	  after	  24	  hours	  based	  on	  corresponding	  Gaussia	  luciferase	  activity	  and	  CXCL12-­‐α	  ELISA	  equivalent	  measurements.	  	  We	  measured	  CXCL12-­‐isoform	  content	  in	  supernatants	  from	  106	  231	  cells	  secreting	  individual	  CXCL12-­‐isoforms.	  	  We	  measured	  Gaussia	  luciferase	  activity	  with	  1:5	  final	  dilution	  of	  supernatants	  in	  a	  1:100	  dilution	  in	  PBS	  of	  1	  mg	  per	  ml	  coelenterazine	  (50	  μl	  total).	  	  Data	  are	  reported	  as	  mean	  ±	  S.E.M.	  for	  6	  measurements	  each	  in	  two	  independent	  setups	  with	  paired	  ELISA	  and	  bioluminescence	  measurements	  (n	  =	  12	  total).	  	  Each	  ELISA	  well	  was	  measured	  in	  quadruplicate.	  	  (F)	  Relative	  qRT-­‐PCR	  amplification	  cycle	  number	  (ΔCT)	  as	  compared	  to	  GAPDH.	  	  We	  measured	  comparable	  mRNA	  levels	  of	  CXCL12-­‐isoforms	  in	  our	  transduced	  cells.	  CXCL12	  was	  not	  detectable	  in	  the	  parental	  cells.	  	  (G)	  Transwell	  migration	  towards	  100	  ng/ml	  CXCL12-­‐isoforms	  in	  the	  absence	  or	  presence	  of	  CXCR4	  inhibitor	  AMD3100	  (1	  µM).	  	  Cells	  migrating	  through	  the	  membrane	  in	  response	  to	  equal	  amounts	  of	  cell-­‐secreted	  CXCL12	  isoforms	  based	  on	  Gaussia	  luciferase	  activity	  were	  detected	  by	  staining	  with	  crystal	  violet.	  	  Darker	  staining	  shows	  relatively	  greater	  cell	  migration.	  	  10%	  fetal	  bovine	  serum	  (FBS)	  was	  used	  as	  a	  positive	  control.	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Figure	  A.3.	  	  CXCL12-­‐isoform	  vector	  construction.	  	  	  We	  used	  two	  viral	  constructs	  to	  express	  CXCL12-­‐isoforms	  in	  mammalian	  cells.	  	  (A)	  Schematic	  representation	  of	  the	  two-­‐part	  construct	  with	  CXCL12-­‐isoforms	  fused	  to	  Gaussia	  luciferase	  under	  one	  the	  CMV	  promoter	  and	  the	  far-­‐red	  fluorescent	  protein	  under	  the	  Ubi	  promoter.	  	  This	  strategy	  forgoes	  the	  ability	  to	  express	  and	  sort	  for	  Gaussia	  luciferase-­‐unfused	  CXCL12.	  	  We	  used	  this	  construction	  for	  most	  data	  represented	  in	  this	  paper.	  	  (B)	  Schematic	  representations	  of	  the	  one-­‐transcript	  expression	  system	  using	  and	  internal	  ribosomal	  entry	  site	  (IRES)	  separating	  two	  genes	  of	  interest	  under	  a	  single	  EF1α	  promoter.	  	  This	  strategy	  enabled	  more	  quantitative	  control	  of	  CXCL12	  abundance	  based	  on	  proportional	  expression	  with	  mCherry.	  	  The	  IRES	  construct	  also	  enabled	  flow	  cytometry	  sorting	  for	  CXCL12	  with	  a	  stop	  codon	  rather	  than	  linked	  to	  Gaussia	  luciferase.	  	  We	  used	  the	  IRES	  construct	  for	  comparison	  of	  the	  biological	  effect	  of	  recombinant	  Gaussia	  luciferase	  fusions	  in	  Figure	  A.2.	   	  
CXCL12-Isoform Linker GLuc FP650
CMV







A   Two-promoter, two-transcript system:
B    Single-promoter, single-transcript system:
Secreted Gaussia Luciferase (Negative Control) + mCherry
CXCL12-Isoforms Fused to Gaussia Luciferase (Fused)  + FP650
CXCL12-Isoforms not fused to Gaussia Luciferase (Unfused) + mCherry
CXCL12-Isoforms Fused to Gaussia Luciferase (Fused)  + mCherry
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Figure	  A.4.	  Characterization	  to	  recombinant	  CXCL12-­‐isoforms	  with	  and	  without	  Gaussia	  luciferase	  
fusions.	  	  (A)	  Average	  position	  of	  CXCR4+	  cells	  after	  24	  hours	  of	  migration	  toward	  cells	  expressing	  IRES	  constructs	  for	  CXCL12-­‐α,	  β,	  or	  γ	  with	  (+)	  and	  without	  (-­‐)	  recombinant	  Gaussia	  luciferase	  fusion,	  as	  described	  in	  Figure	  A.2	  part	  B.	  	  The	  negative	  control	  cells	  secrete	  Gaussia	  luciferase	  without	  CXCL12.	  	  Data	  are	  shown	  as	  mean	  values	  ±	  S.E.M.	  (n=6	  view	  fields	  for	  4-­‐6	  devices	  per	  condition,	  similar	  to	  described	  in	  Fig.	  2.1).	  	  The	  bars	  represent	  the	  statistical	  comparison	  of	  all	  fractions	  to	  the	  non-­‐secreting	  control	  (0%).	  	  Statistical	  demarcations	  directly	  above	  data	  are	  comparisons	  to	  the	  100%	  secreting	  fraction	  (*	  p<0.005).	  	  Matched	  conditions	  were	  performed	  in	  parallel.	  	  We	  measured	  secretion	  of	  IRES	  CXCL12	  constructs	  based	  on	  corresponding	  equivalent	  ELISA	  reactivity,	  which	  was	  developed	  and	  calibrated	  towards	  CXCL12-­‐α	  (B)	  and	  




Figure	  A.5.	  	  CXCL12-­‐isoform	  induction	  of	  AKT	  phosphorylation.	  	  (A-­‐C)	  Western	  blot	  analysis	  of	  AKT	  phosphorylation	  downstream	  of	  CXCR4	  in	  MDA-­‐MB-­‐231	  cells	  for	  CXCL12-­‐α,	  -­‐β,	  and	  -­‐γ,	  respectively.	  	  We	  measured	  total	  AKT	  and	  GAPDH	  as	  loading	  controls.	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Figure	  A.6.	  	  Representative	  bioluminescence	  images	  of	  β-­‐arrestin	  2	  recruitment	  to	  CXCR4	  in	  response	  
to	  CXCL12	  isoforms.	  	  Dilutions	  of	  equimolar	  concentrations	  of	  recombinant	  CXCL12	  isoforms	  were	  applied	  simultaneously	  to	  cells.	  	  This	  image	  was	  taken	  at	  t=40	  minutes	  of	  a	  1	  hour	  time	  course.	  	  Scale	  bar	  depicts	  range	  of	  photon	  flux	  (p/s/cm2)	  values	  with	  the	  pseudocolor	  dislay	  scale	  showing	  red	  and	  blue	  as	  highest	  and	  lowest	  values,	  respectively.	  	  The	  image	  depicted	  is	  representative	  two	  experimental	  runs.	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Figure	  A.7.	  	  Representative	  bioluminescence	  images	  of	  β-­‐arrestin	  2	  recruitment	  to	  CXCR7	  in	  response	  
to	  CXCL12	  isoforms.	  Cells	  expressing	  a	  luciferase	  complementation	  reporter	  for	  association	  of	  CXCR7	  and	  β-­‐arrestin	  2	  were	  incubated	  with	  increasing	  equimolar	  concentrations	  of	  synthetic	  CXCL12-­‐α,	  β,	  or	  γ.	  	  Representative	  bioluminescence	  image	  from	  t=40	  minutes	  from	  a	  one	  hour	  time	  course.	  	  Scale	  bar	  depicts	  range	  of	  photon	  flux	  (p/s/cm2)	  values	  with	  pseudocolor	  display.	  	  The	  image	  depicted	  is	  representative	  two	  experimental	  runs.	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Figure	  A.8.	  Mouse	  expression	  of	  CXCL12-­‐isoforms	  in	  primary	  breast	  tumors.	  	  Quantitative	  RT-­‐PCR	  cycle	  numbers	  are	  reported	  for	  orthotopic	  implants	  of	  (A)	  syngenic	  implants	  of	  E0771	  breast	  cancer	  cells	  in	  C57BL/6mice	  and	  (D)	  human	  xenograft	  of	  MDA-­‐MB-­‐231	  cells	  in	  NSG	  mice.	  	  Tissues	  homogenates	  were	  analyzed	  from	  primary	  tumors.	  	  Numerals	  above	  data	  represent	  the	  fraction	  of	  samples	  positive	  for	  each	  transcript.	  Transcripts	  amplified	  below	  40	  qRT-­‐PCR	  cycles	  we	  denoted	  as	  positive.	  	  Amplified	  gene	  product	  purity	  was	  also	  confirmed	  via	  gel	  electrophoresis.	  
	  
7.2 Supplemental	  Results	  
Characterization	  of	  secreted	  Gaussia	  luciferase	  CXCL12-­‐isoform-­‐fusions	  	  	  	  The	  single	  promoter,	  IRES-­‐linked	  CXCL12	  and	  mCherry	  construct	  facilitates	  characterization	  of	  CXCL12-­‐isoforms	  fused	  or	  not	  fused	  with	  Gaussia	  luciferase.	  	  The	  internal	  ribosomal	  entry	  site	  (IRES)-­‐linkage	  promotes	  proportional	  expression	  of	  both	  proteins,	  but	  limits	  translational	  efficiency	  and	  total	  protein	  levels	  as	  compared	  to	  single	  protein	  transcripts.	  	  For	  this	  reason,	  we	  also	  developed	  a	  vector	  to	  co-­‐express	  CXCL12-­‐isoforms	  fused	  to	  Gaussia	  luciferase	  and	  a	  far-­‐red	  fluorescent	  protein	  (FP650)	  from	  two	  different	  promoters.	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We	  used	  the	  IRES	  system	  to	  evaluate	  effects	  of	  the	  Gaussia	  luciferase	  fusion	  on	  biological	  activity	  of	  CXCL12-­‐isoforms	  (Fig.	  S4).	  	  To	  characterize	  levels	  of	  secreted	  CXCL12	  
Gaussia	  luciferase	  fusions,	  we	  complemented	  ELISA	  reactivity	  with	  bioluminescence	  imaging.	  	  Although	  polyclonal	  ELISA	  antibodies	  were	  developed	  towards	  CXCL12-­‐α,	  we	  measured	  the	  relative	  ELISA	  ng	  per	  bioluminescence	  flux	  to	  be	  on	  the	  same	  order	  of	  magnitude	  for	  all	  isoforms.	  	  All	  CXCL12-­‐isoforms	  elicited	  chemotaxis	  of	  CXCR4+	  cells	  independent	  of	  fusion	  to	  Gaussia	  luciferase.	  	  To	  measure	  the	  biological	  effect	  of	  recombinant	  Gaussia	  luciferase	  fusions,	  we	  measured	  phosphorylation	  of	  AKT,	  a	  known	  downstream	  target	  of	  CXCL12-­‐CXCR4	  signaling	  (Fig.	  S5).	  	  As	  compared	  with	  recombinant	  CXCL12-­‐isoforms,	  CXCL12	  secreted	  by	  231	  cells	  stimulated	  levels	  of	  AKT	  phosphorylation	  corresponding	  to	  the	  measured	  ELISA-­‐based	  concentrations	  for	  each	  isoform,	  independent	  of	  fusion	  to	  Gaussia	  luciferase.	  	  For	  the	  Gaussia	  luciferase	  fusions,	  our	  bioluminescence-­‐based	  measurement	  of	  chemokine	  concentration	  corresponded	  with	  the	  Western	  blot	  phosphorylation	  of	  AKT	  as	  compared	  with	  recombinant	  CXCL12-­‐isoforms.	  	  In	  combination	  with	  our	  prior	  studies	  of	  CXCL12-­‐α,	  these	  data	  show	  that	  CXCL12	  isoforms	  retain	  expected	  biological	  activity	  when	  fused	  to	  Gaussia	  luciferase	  (Fig.	  S4-­‐5)(1).	  Since	  IRES-­‐linkage	  may	  limit	  translational	  efficiency	  of	  both	  products,	  we	  used	  a	  two-­‐promoter	  system	  to	  express	  higher	  levels	  of	  CXCL12-­‐isoform	  fusions	  with	  Gaussia	  luciferase	  for	  subsequent	  studies	  (Fig.	  S2A).	  	  Similar	  to	  the	  IRES-­‐linked	  expression	  system,	  ELISA	  and	  bioluminescence	  imaging	  provided	  complementary	  measures	  of	  chemokine	  production	  (Fig.	  2F	  and	  S2B-­‐D).	  	  We	  sorted	  cells	  for	  equal	  expression	  of	  co-­‐expressed	  FP650	  fluorescent	  protein,	  yielding	  comparable	  levels	  of	  mRNA	  for	  CXCL12	  α	  and	  β	  with	  slightly	  lower	  levels	  of	  CXCL12-­‐γ	  (Fig	  2G).	  	  We	  note	  that	  CXCL12	  transcripts	  were	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undetectable	  in	  parental	  231	  cells,	  so	  source	  cells	  secreted	  only	  the	  desired	  isoform	  (data	  not	  shown).	  	  	  
7.3 Supplemental	  Discussion	  For	  the	  simplest	  semi-­‐quantitative	  conceptualization	  of	  increased	  CXCL12-­‐γ	  potency,	  we	  posit	  that	  CXCL12	  is	  a	  bivalent	  ligand	  between	  CXCR4	  and	  heparan	  sulfate,	  a	  major	  component	  of	  cell	  surfaces	  and	  the	  extracellular	  compartment.	  	  Previous	  studies	  have	  shown	  that	  co-­‐localization	  of	  heparan	  sulfate	  with	  CXCR4	  cooperatively	  increases	  local	  concentrations	  of	  CXCL12,	  thus	  promoting	  signaling(2).	  	  To	  estimate	  the	  overall	  affinity	  of	  CXCL12-­‐isoforms	  to	  CXCR4	  and	  heparan	  sulfate,	  we	  extend	  a	  model	  developed	  to	  calculate	  the	  bivalent	  affinity	  of	  polymer-­‐linked	  ligands(3,	  4).	  	  The	  bivalent	  affinity	  is	  a	  multiplicative	  function	  of	  the	  two	  monovalent	  affinities	  of	  CXCL12	  for	  CXCR4	  and	  heparan	  sulfate	  (KR4	  and	  KHS)	  with	  the	  effective	  concentration	  of	  the	  multiple-­‐binding	  ligand	  (CEff).	  	  The	  parameter	  CEff	  is	  based	  on	  molecular	  size,	  shape,	  and	  rigidity	  of	  the	  multiple-­‐binding	  ligand,	  which	  we	  assume	  to	  be	  the	  same	  between	  CXCL12	  isoforms	  and	  therefore	  we	  leave	  this	  as	  a	  constant.	  	  We	  also	  assume	  the	  distance	  between	  heparan	  sulfates	  and	  CXCR4	  not	  to	  be	  limiting	  based	  on	  the	  high	  abundance	  and	  flexibility	  of	  heparan	  sulfates(5).	  	  Multiplication	  of	  the	  binding	  constant	  for	  CXCL12-­‐isoforms	  to	  CXCR4	  or	  heparan	  sulfate	  reveals	  ~6	  fold	  greater	  apparent	  affinity	  for	  CXCL12-­‐γ	  as	  compared	  to	  the	  α-­‐isoform	  (Table	  S1).	  	  Although	  only	  semi-­‐quantitative,	  this	  conceptual	  framework	  provides	  a	  potential	  mechanism	  for	  increased	  chemotactic	  potency	  of	  CXCL12-­‐γ.	  	  	  	  
Table	  A.1.	  Affinities	  for	  CXCL12	  isoforms	  towards	  CXCR4,	  heparan	  
sulfate,	  and	  divalent	  CXCR4-­‐HS	  complex.	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7.4 Supplemental	  Methods	  
Text	  S1.	  ImageJ	  Script	  for	  Cell	  Position.	  	  The	  following	  imageJ	  script	  takes	  corresponding	  8-­‐bit	  phase	  contrast	  and	  fluorescent	  images	  and	  maps	  the	  coordinate	  of	  every	  cell.	  	  The	  script	  converts	  fluorescent	  images	  to	  binary	  images	  for	  a	  range	  of	  threshold	  values	  to	  identify	  both	  bright	  and	  dim	  cells.	  	  The	  threshold	  scan	  also	  identifies	  duplicate	  counts,	  which	  we	  exclude	  using	  an	  embedded	  loop	  comparison.	  	  The	  output	  coordinates	  were	  analyzed	  in	  Microsoft	  Excel.	  macro	  "automated	  migration"	  {	  waitForUser("Open	  Phase	  Contrast	  and	  Draw	  Rectangle");	  run("Set	  Measurements...",	  "area	  center	  limit	  redirect=None	  decimal=3");	  run("Clear	  Results");	  myImageID	  =	  getImageID();	  //get	  Image	  information	  	  //Make	  Rectangle	  Manually,	  Delay,	  Check	  the	  Channel	  Position	  setTool(0);	  if(selectionType()	  !=	  0)	  	   exit("Sorry,	  no	  rectangle");	  run("Measure");	  area=getResult("Area",0);	  xm=getResult("XM",0);	  ym=getResult("YM",0);	  	  run("Close	  All");	  waitForUser("Open	  Fluorescence	  IMG");	  myImageID2	  =	  getImageID();	  selectImage(myImageID2);	  direct	  =	  getInfo("image.directory");	  filename	  =	  getInfo("image.filename");	  	  setThreshold(20,	  255);	  run("Convert	  to	  Mask");	  run("Open");	  run("Watershed");	  run("Analyze	  Particles...",	  "size=30-­‐300	  circularity=0.00-­‐1.00	  show=Ellipses	  display	  clear");	  	  for(i=nResults;	  i>0;	  i-­‐-­‐)	  {	  
	   CXCL12-­‐Isoforms	  Tumor	  Grade:	   α	   β	   γ	  CXCR4	  (IC50	  ~	  KR4)(	  6)	   15	  nM	   -­‐-­‐	   350	  nM	  Heparan	  Sulfate	  (KHS)(	  7)	   200	  nM	   53	  nM	   1.5	  nM	  CEff*KR4*KHS	  	   CEff*3000	   -­‐-­‐	   CEff*525	  Note:	  IC50	  is	  proportional	  between	  α	  and	  γ	  for	  CXCR4	  so	  we	  use	  it	  as	  a	  surrogate	  for	  Kd	  for	  CXCL12-­‐γ.	  	  We	  assume	  CEff	  to	  be	  equal	  for	  both	  isoforms	  based	  on	  structural	  similarities.	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areai=getResult("Area",i-­‐1);	  xmi=getResult("XM",i-­‐1);	  ymi=getResult("YM",i-­‐1);	  setResult("Area",i,areai);	  setResult("XM",i,xmi);	  	  setResult("YM",i,ymi);}	  setResult("Area",0,area);	  setResult("XM",0,xm);	  setResult("YM",0,ym);	  updateResults();	  run("Close	  All");	  	  //Loop	  through	  thresholds,	  5	  threhold	  incraments	  	  i=25;	  while(i<75){open(direct+"/"+filename);	  setThreshold(i,	  255);	  run("Convert	  to	  Mask");	  run("Open");	  run("Watershed");	  run("Analyze	  Particles...",	  "size=30-­‐300	  circularity=0.00-­‐1.00	  show=Ellipses	  display");	  run("Close	  All");	  i=i+5;}	  	  //Loop	  through	  thresholds,	  20	  threshold	  increments	  	  i=75;	  while(i<250){open(direct+"/"+filename);	  setThreshold(i,	  255);	  run("Convert	  to	  Mask");	  run("Open");	  run("Watershed");	  run("Analyze	  Particles...",	  "size=30-­‐300	  circularity=0.00-­‐1.00	  show=Ellipses	  display");	  run("Close	  All");	  i=i+20;}	  	  //Remove	  Data	  with	  Duplicates,	  run("Close	  All");	  	  for(i=1;	  i<=nResults;	  i++)	  {	  	   for(j=i+1;	  j<nResults;	  j++)	  	  {	  	  //Speeds	  up	  program	  by	  not	  Processing	  NaNs	  as	  duplicates	  	   	   if(getResult("XM",j)==NaN)	  	   	  	   	   	   j=nResults;	  	   	   if(	  abs(getResult("XM",i)-­‐getResult("XM",j))	  <	  5	  &&	  abs(getResult("YM",i)-­‐getResult("YM",j))	  <	  5)	  {	   for(k=j+1;k<nResults;k++){	  	   	   	   	   areak=getResult("Area",k);	  	   	   	   	   xmk=getResult("XM",k);	  	   	   	   	   ymk=getResult("YM",k);	  	   	   	   	   setResult("Area",k-­‐1,areak);	  	   	   	   	   setResult("XM",k-­‐1,xmk);	  	   	   	   	   setResult("YM",k-­‐1,ymk);	  	   	   	   	   setResult("Area",k,NaN);	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   setResult("XM",k,NaN);	  	   	   	   	   setResult("YM",k,NaN);	  	   	   	   }}}}	  	  setResult("Area",0,area);	  setResult("XM",0,xm);	  setResult("YM",0,ym);	  updateResults();	  	  //Starts	  over	  for	  a	  new	  image	  run("automated	  migration");	  }	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Table	  A.2	  Cloning	  strategy	  for	  CXCL12	  isoforms	  and	  Gaussia	  
luciferase	  fusions.	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8 Appendix B: Chapter 3 Supporting Information 
8.1 Supplemental	  Figures	  
	  




Figure	  B.2.	  	  Multi-­‐radius	  well	  curvature	  and	  dimensions.	  	  Each	  well	  is	  4	  mm	  in	  diameter	  with	  a	  multi-­‐radial	  (radii	  are	  noted)	  contour	  and	  a	  total	  depth	  of	  1.75	  mm.	  	  The	  radii	  are	  labeled	  adjacent	  to	  corresponding	  dashed	  circles.	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9 Appendix C: Chapter 4 Supporting Information 
9.1 Supplemental	  Figures	  
	  
Figure	  C.1.	  Human	  mammary	  fibroblast	  induced	  growth	  differences	  change	  responsiveness	  to	  




Figure	  C.2.	  Flow	  cytometry-­‐based	  measure	  of	  FUCCI	  status	  of	  MDA-­‐MB-­‐231	  cells	  in	  HS5	  or	  HS27A	  









Figure	  C.4.	  Response	  of	  T47D	  and	  stromal	  cells	  to	  cytotoxic	  drugs.	  Dose-­‐response	  cytotoxicity	  curves	  for	  T47D	  cells	  treated	  for	  eight	  days	  with	  cisplatin,	  doxorubicin,	  or	  paclitaxel	  in	  HS5	  spheroids.	  Red	  curves	  designate	  CBRed	  HS5	  signal,	  and	  green	  curves	  designate	  the	  CBGreen	  cancer	  cell	  signal,	  respectively.	  After	  background	  subtraction,	  we	  normalized	  photon	  flux	  values	  for	  both	  CBGreen	  and	  CBRed	  luciferases	  in	  cancer	  and	  stromal	  cells,	  respectively,	  to	  their	  respective	  untreated	  control.	  We	  calculate	  selective	  toxicity	  for	  cancer	  cells	  based	  on	  the	  log-­‐2-­‐scale	  ratio	  of	  CBRed	  to	  CBGreen	  signal	  adjusted	  to	  center	  around	  the	  untreated	  control	  (black	  curve).	  Positive	  values	  for	  selectivity	  (black	  curve)	  that	  lie	  above	  the	  horizontal	  dotted	  line	  denote	  selective	  loss	  of	  bioluminescence	  from	  cancer	  cells.	  We	  omit	  selectivity	  data	  points	  for	  conditions	  where	  CBRed	  and/or	  CBGreen	  signal	  is	  below	  1%	  of	  untreated	  control	  since	  instrument	  noise	  generates	  most	  of	  the	  signal.	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Figure	  C.5.	  Serum	  concentrations	  modulate,	  growth,	  drug	  efficacy,	  and	  selectivity	  of	  eliminating	  MDA-­‐





Figure	  C.6.	  Combinatorial	  treatment	  with	  doxorubicin	  and	  Jak2	  kinase	  inhibitor	  to	  target	  cytokines	  




Figure	  C.7.	  Representative	  cytotoxicity	  curves	  for	  selective	  inhibitors	  of	  Jak2	  (AG-­‐490),	  PI3-­‐kinase	  
(GDC-­‐0941),	  AKT	  (MK-­‐2206),	  and	  β2-­‐adrenergic	  receptor	  (propranolol)	  with	  MDA-­‐MB-­‐231	  cells	  in	  
HS5	  spheroids.	  Graph	  shows	  mean	  values	  +	  SEM	  (n	  =	  8	  per	  condition)	  for	  fold	  change	  in	  bioluminescence	  from	  MDA-­‐MB-­‐231	  cells	  (green	  curves)	  and	  HS5	  cells	  (red	  curves).	  We	  calculated	  selectivity	  of	  compounds	  for	  cancer	  versus	  stromal	  cells	  as	  described	  in	  Fig	  C.4	  (black	  curves)	  with	  positive	  values	  representing	  greater	  killing	  of	  cancer	  cells	  and	  negative	  selectivity	  values	  for	  greater	  killing	  of	  HS5	  stromal	  cells.	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Figure	  C.8.	  Representative	  cytotoxicity	  curves	  for	  selective	  inhibitors	  of	  Jak2	  (AG-­‐490),	  PI3-­‐kinase	  
(GDC-­‐0941),	  AKT	  (MK-­‐2206),	  and	  β2-­‐adrenergic	  receptor	  (propranolol)	  with	  T47D	  cells	  in	  HS5	  
spheroids.	  Graph	  shows	  mean	  values	  +	  SEM	  (n	  =	  8	  per	  condition)	  for	  fold	  change	  in	  bioluminescence	  from	  MDA-­‐MB-­‐231	  cells	  (green	  curves)	  and	  HS5	  cells	  (red	  curves).	  We	  calculated	  selectivity	  of	  drugs	  for	  cancer	  versus	  stromal	  cells	  as	  described	  in	  Fig	  C.4	  (black	  curves)	  with	  positive	  values	  representing	  greater	  killing	  of	  cancer	  cells	  and	  negative	  selectivity	  values	  for	  greater	  killing	  of	  stromal	  cells.	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Figure	  C.9.	  Flow	  cytometry-­‐based	  measure	  of	  FUCCI	  status	  of	  MDA-­‐MB-­‐231	  cells	  in	  bone	  marrow	  of	  
mice.	  Figure	  4.5D	  represents	  flow	  cytometry	  data	  from	  mouse	  bone	  marrow.	  Representative	  negative	  control	  flow	  cytometry	  plots	  from	  unmarked	  (negative)	  MDA-­‐MB-­‐231	  cells	  in	  2D	  culture	  (A)	  and	  mouse	  bone	  marrow	  (B).	  (C)	  Representative	  flow	  cytometry	  plot	  of	  MDA-­‐MB-­‐231	  FUCCI	  cells	  plated	  24	  hours	  prior	  and	  harvested	  at	  80%	  confluence	  to	  give	  a	  benchmark	  of	  cell	  cycle	  status.	  Representative	  plots	  of	  bone	  marrow	  from	  vehicle	  treated	  (D)	  and	  trametinib	  treated	  (E)	  mice.	  In	  figure	  4.5D,	  we	  calculated	  the	  fraction	  of	  dividing	  cells	  as	  G/(G+R),	  where	  G	  is	  number	  of	  cells	  in	  P4	  (top	  left	  ROI),	  and	  R	  is	  the	  number	  of	  cells	  in	  P5	  (bottom	  right	  ROI).	  We	  analyzed	  5	  x105	  cell	  events	  for	  bone	  marrow	  samples.	  X	  and	  Y	  axes	  denote	  fluorescence	  from	  mKO	  (582/15	  (561))	  and	  AcGFP	  (530/30	  (488)),	  respectively.	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Figure	  C.11.	  Bioluminescence	  reveals	  improved	  treatment	  of	  breast	  cancer	  cells	  in	  bone	  marrow	  with	  
combination	  doxorubicin	  and	  trametinib	  treatment.	  After	  visualizing	  experimental	  MDA-­‐MB-­‐231	  bone	  metastases	  by	  bioluminescence	  imaging,	  we	  treated	  mice	  with	  a	  single	  dose	  of	  doxorubicin,	  5	  days	  of	  daily	  trametinib	  initiated	  on	  the	  same	  day	  as	  doxorubicin,	  both	  doxorubicin	  and	  trametinib,	  or	  vehicle	  controls.	  (A-­‐B)	  Representative	  pseudo-­‐colored	  bioluminescence	  images	  reveal	  the	  increased	  signal	  from	  the	  same	  bone	  regions	  at	  day	  7	  (left)	  and	  day	  12	  (right)	  for	  both	  vehicle	  (A)	  and	  (B)	  trametinib	  treated	  animals.	  The	  top	  and	  bottom	  pairs	  of	  images	  in	  panel	  B	  represent	  metastases	  responding	  or	  not-­‐responding	  to	  treatment,	  respectively.	  Note	  that	  for	  each	  pair	  of	  images	  we	  changed	  the	  lower	  end	  of	  the	  log-­‐scale	  to	  visualize	  the	  metastases	  similarly.	  (C)	  Bioluminescence	  measurements	  from	  matched	  femurs	  and	  tibias	  were	  compared	  between	  day	  12	  and	  the	  treatment	  day	  7.	  Paired	  t-­‐tests	  depict	  that	  only	  combination	  treatment	  with	  doxorubicin	  and	  trametinib	  caused	  a	  statistically	  significant	  decrease	  relative	  to	  the	  vehicle	  (*	  p<0.05).	  Dotted	  line	  demarcates	  lesions	  with	  <	  10-­‐fold	  change	  in	  signal	  over	  time,	  which	  occurred	  only	  in	  the	  combination	  doxorubicin	  and	  trametinib	  group.	  Individual	  data	  points	  are	  plotted	  with	  median	  for	  n	  =	  12,	  16,	  16,	  16	  lower	  extremity	  segments	  (femur	  and	  tibia	  from	  each	  lower	  extremity	  per	  mouse),	  for	  trametinib,	  trametinib	  +	  doxorubicin,	  doxorubicin,	  and	  vehicle,	  respectively,	  with	  four	  lower	  extremity	  segments	  from	  each	  animal.	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9.2 Supplemental	  Tables	  
Tables	  C.1-­‐C.4	  summarize	  effects	  of	  several	  different	  molecularly-­‐targeted	  
compounds	  for	  selective	  toxicity	  to	  MDA-­‐MB-­‐231	  (C.1,	  C.3)	  or	  T47D	  cells	  (C.2,	  C.4)	  in	  
HS5	  bone	  marrow	  spheroids.	  We	  determined	  selectivity	  for	  toxicity	  to	  cancer	  versus	  stromal	  cells	  based	  on	  CBGreen	  and	  CBRed	  bioluminescence,	  respectively,	  as	  detailed	  in	  Figures	  4.2	  and	  C.6	  after	  8	  days	  of	  treatment.	  Tables	  C.1-­‐C.2	  list	  compounds	  with	  minimal	  effects	  on	  either	  cancer	  or	  stromal	  cells	  at	  peak	  concentrations	  of	  at	  least	  1	  µM).	  Tables	  C.3-­‐C.4	  list	  compounds	  showing	  non-­‐selective	  toxicity	  to	  both	  cancer	  and	  stromal	  cells	  or	  greater	  toxicity	  to	  stromal	  cells.	  Each	  table	  lists	  the	  compound	  and	  its	  molecular	  target.	  	  	  
Table	  C.1.	  Compounds	  with	  limited	  effect	  on	  MDA-­‐MB-­‐231	  cells	  in	  HS5	  
spheroids	  (up	  to	  1uM)	  Compound	   Target	  Bazedoxifene	   Estrogen	  receptor	  Fulvestrant	   Estrogen	  receptor	  Tamoxifen	   Estrogen	  receptor	  MK-­‐8669	   mTOR	  SB-­‐431542	   TGF-­‐β	  CP-­‐724,714	   Her2	  AMD3100	   CXCR4	  	   	  	  
Table	  C.2.	  Compounds	  with	  limited	  effect	  on	  T47D	  cells	  in	  HS5	  spheroids	  
(>1uM)	  Compound	   Target	  Bazedoxifene	   Estrogen	  receptor	  Fulvestrant	   Estrogen	  receptor	  Tamoxifen	   Estrogen	  receptor	  PD0325901	   MEK	  MK-­‐8669	   mTOR	  SB-­‐431542	   TGF-­‐β	  CP-­‐724,714	   Her2	  AMD3100	   CXCR4	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Table	  C.3.	  Compounds	  with	  non-­‐selective	  or	  negatively	  selective	  effects	  for	  MDA-­‐MB-­‐
231	  cells	  versus	  HS5	  cells	  Compound	   Target	   CBGReen	   CBRed	  AG-­‐490	   JAK2	   >1uM	   >1uM	  GDC-­‐0941	   PI3-­‐kinase	   Limited	   ~100nM	  MK-­‐2206	   AKT	   >1uM	   >1uM	  Propanolol	   Β2	  adrenergic	  receptors	   >10uM	   >10uM	  	  	  
Table	  C.4.	  Compounds	  with	  non-­‐selective	  or	  negatively	  selective	  effects	  for	  T47D	  cells	  
versus	  HS5	  cells	  	   Compound	   Target	   CBGReen	   CBRed	  AG-­‐490	   JAK2	   >1uM	   >1uM	  GDC-­‐0941	   PI3-­‐kinase	   Limited	   ~100nM	  MK-­‐2206	   AKT	   >1uM	   >1uM	  Propanolol	   Β2	  adrenergic	  receptors	   >10uM	   >10uM	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10.1 Supplemental	  Figures	  
	  
Figure	  D.1.	  Quantification	  of	  NADH	  phase	  lifetime	  through	  spheroid	  cross-­‐sections.	  	  Representative	  spheroid	  profiles	  of	  color-­‐coded	  (A)	  NADH	  phase	  lifetime	  and	  (B)	  photon	  counts.	  	  The	  black	  boxes	  represent	  one	  horizontal	  and	  vertical	  radial	  cross-­‐section	  from	  this	  spheroid.	  	  For	  a	  given	  radial	  position,	  the	  blue	  and	  purple	  lines	  designate	  a	  50	  pixel	  vector	  of	  lifetimes	  and	  counts	  which	  we	  use	  to	  calculate	  a	  weighted	  average.	  	  For	  each	  radial	  position	  (R)	  the	  weighted	  average	  is	  calculated	  using	  the	  inset	  equation,	  for	  pixel	  numbers	  i=1	  to	  50.	  	  We	  then	  align	  spheroid	  edge	  positions	  and	  average	  the	  radial	  profiles	  from	  four	  locations	  on	  the	  spheroid	  for	  four	  spheroids	  to	  generate	  the	  radial	  lifetime	  profiles	  in	  Figures	  5.2-­‐5.3.	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Figure	  D.2.	  Characterization	  of	  the	  lifetime-­‐based	  metabolic	  imaging	  throughout	  depth	  of	  small	  
mesenchymal	  stem	  cell	  spheroid.	  	  (A)	  Similar	  to	  Figure	  5.2,	  we	  depict	  images	  of	  photon	  counts	  at	  20,	  40,	  60,	  80,	  and	  100	  μm	  depth	  for	  small,	  non-­‐nutrient-­‐limited	  MSC	  spheroids.	  (B)	  The	  average	  NADH	  phase	  lifetime	  was	  constant	  throughout	  the	  depth	  of	  the	  spheroids.	  	  NADH	  phase	  lifetimes	  are	  plotted	  as	  mean	  ±	  S.E.M.	  for	  a	  single	  cross-­‐sections	  from	  four	  spheroids.	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Figure	  D.3.	  Interdependence	  on	  glucose	  and	  glutamine	  for	  cancer	  and	  stromal	  cells	  in	  bone	  marrow	  
spheroids.	  	  Similar	  to	  Figure	  5.4,	  but	  for	  the	  CBRed	  component,	  We	  plotted	  combination	  dose-­‐response	  surface	  plots	  of	  glucose	  and	  glutamine	  concentrations	  for	  CBRed	  signal	  from	  (A-­‐B)	  MDA-­‐MB-­‐231,	  (C-­‐D)	  MDA-­‐MB-­‐468,	  and	  (E-­‐F)	  T47D	  cells	  grown	  in	  (A,	  C,	  E)	  HS-­‐5	  or	  (B,	  D,	  F)	  HS-­‐27A	  spheroids.	  	  We	  plotted	  the	  CBRed	  fold	  change	  as	  compared	  to	  the	  high	  glucose	  and	  high	  glutamine	  concentration	  for	  both	  cancer	  and	  stromal	  cells.	  	  The	  plots	  are	  color-­‐coded	  for	  log-­‐2-­‐scaled	  ratio	  of	  CBRed	  to	  CBGreen	  signal,	  both	  normalized	  to	  high	  glucose	  and	  high	  glutamine.	  	  Hot	  colors	  designate	  relatively	  lower	  cancer	  signal.	  	  In	  the	  dose-­‐response	  surfaces,	  values	  are	  plotted	  as	  mean	  for	  4	  spheroids	  from	  one	  of	  two	  representative	  independent	  trials.	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Figure	  D.4.	  Glucose	  and	  glutamine	  dependence	  of	  cancer	  and	  stromal	  cells.	  	  For	  direct	  comparison	  of	  glucose	  dose-­‐response	  in	  HS-­‐5	  and	  HS-­‐27A	  with	  maximal	  levels	  of	  glutamine,	  we	  plotted	  these	  curves	  together	  for	  CBGreen	  cancer	  and	  CBRed	  stromal	  signals	  for	  (A)	  HS-­‐5	  and	  (B)	  HS-­‐27A	  co-­‐cultures.	  	  Values	  are	  plotted	  as	  mean	  ±	  S.E.M.	  for	  4	  spheroids	  from	  one	  of	  two	  representative	  independent	  trials.	  	  	  
